Clinical Trial Protocol Version 4.0, Final  [ADDRESS_240980] Research Organization 
(CRO):  Syneos Health‚Ñ¢ group company  
including INC Research, LLC, together with INC 
Research [LOCATION_006] Limited  
[ADDRESS_240981]  
Raleigh, North Carolina [ZIP_CODE] -1547 
[LOCATION_003]  
Phone: +[PHONE_4340] 
The following additional numbers ar e also available for urgent contact  
24-Hour Urgent Medical Helpline 
Number: +[PHONE_4341] 
For drug-safety reporting, contact [CONTACT_202003]/Fax: Email: [EMAIL_3971]  
Fax: +[PHONE_4342] 
Confidentiality Statement  
This confidential information in this document is provided to you as an investigator or consultant 
for review by [CONTACT_10825], your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written authorization from the sponsor. 
  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 4 SIGNATURE [CONTACT_163604]:  A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-
on Trial of ARGX-113-1704 to Evaluate  the Safety and Tolerability of 
ARGX-113 in Patients With Myasth enia Gravis Having Generalized 
Muscle Weakness 
PROTOCOL NO:  ARGX-113-1705 (ADAPT+) 
This protocol is a confidential communication of argenx BVBA. I confirm that I have read this 
protocol, I understand it, and I will work according to this protocol. I will also work consistently 
with the ethical principles that have their origin in the Declaration of Helsinki and that are 
consistent with good clinical practices and the applicable laws and regu lations. Acceptance of 
this document constitutes my agreement that no unpublished information contained herein will 
be published or disclosed without prior written approval from argenx BVBA. 
 
Instructions to the investigator: Please SIGN and DATE this signature [CONTACT_3264]. PRINT you r 
name, title, and the name [CONTACT_202093]. Return the signed 
original copy to the local representative of your sponsor‚Äôs designated CRO.  
 
I have read this protocol in its entirety and agree to conduct the trial accordingly: 
Signature [CONTACT_7919]:  Date:  
Printed Name:     
[CONTACT_202094]:     
Name/Address of Site:     
   
  
    
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_240982] 2019  
Protocol Version 3.0  18 December 2019  
Protocol Version 3.1  15 April 2020  
Protocol Version 3.2  30 June 2020  
Protocol Version 4.0  19 January  2021 
SUMMARY OF CHANGES 
Changes from Protocol Version 3.2 compared to  Protocol Version 4.0 are summarized below. 
Note: updates to headers/footers and the tables of contents and editorial changes to layout, font, 
format, and style guide conventions are not captured in this summary. 
Section Change Rationale 
Safety Mailbox/Fax:  Email: [EMAIL_2212]  
Fax: +32 (0)15 29 93 94  
changed to  
Email: [EMAIL_3971]  
Fax: [PHONE_4344] -[ADDRESS_240983] 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 6 Section Change Rationale 
Billerica MA [ZIP_CODE] 
[LOCATION_002]  
Throughout document  ARGX -113 
changed to  
efgartigimod  ARGX -113 has been changed 
to efgartigimod throughout the 
document to be current with 
the clinical development program.
 
1.4. Benefit -Risk Assessment The section has been revised.  Updated  benefit-risk 
assessment based on emerging 
data and consistency with IB 
v9.0 
4.1. Summary of Trial Design 
Other sections impacted by 
[CONTACT_202004]:  
x Synopsis 
x Table 2 General Schedule 
of Assessments for Part B 
x Figure 2 ARGX-113- 1705 
Trial Design for Part B  
x Section 1.4 Benefit- Risk 
Assessment 
x 4.2. Discussion of Trial 
Design Added text:  
Patients who have completed at least [ADDRESS_240984] complete the early 
discontinuation (ED) visit assessments 
specified in Table 2. The previous 
efgartigimod IV dose must have been received 
at least 30 days before entry into ARGX -113-
2002.  
Patients can enroll in ARGX -113- 2002 until 
recruitment for this study is closed. Patients 
who enroll in ARGX -113- 2002 will not return 
to ARGX -113-1705. To allow patients to enroll in 
the safety stu dy ARGX- 113-
2002  
4.4. Early Discontinuation 
Other sections impacted by 
[CONTACT_202005]:  
x 5.4 End of Part A, End of 
Study and Early 
Discontinuation Visit ‚Ä¶contact [CONTACT_202006].
 
The reason for early discontinuation from the trial will be clearly documented by [CONTACT_3786].
 
Changed to  
‚Ä¶contact [CONTACT_202006].
 
Patients enrolling in ARGX -113- [ADDRESS_240985] complete the ED visit assessments from ARGX
-113-1705 (see T able 
2). Patients who enroll in ARGX -113- 2002 
will not return to ARGX -113-1705. To provide end of trial 
instruction for patients who 
enroll in study ARGX -113-
2002  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_240986] be documented by [CONTACT_202007].
 
5.2.1. Treatment Period 
Part A  
Other sections impacted by 
[CONTACT_202005]:  
x Synopsis 
x Table 1 General Schedule 
of Assessments for Part A 
(footnote c) 
x 4.1. Summary of Trial 
Design 
 If a patient becomes eligible for (re-)treatment 
with efgartigimod per total MG -ADL score 
but cannot complete the entire treatment 
period within the duration of Part A of the trial (re
-treatment in Part A can start at the latest by 
[CONTACT_4475] 336) the patient can be transitioned to Part 
B after completing the end of Part A (EoA) 
visit. If the patient is not willing or able to continue to Part B then he/she should continue to the EoA visit.
 
changed to  
If a patient becomes eligible for (re -)treatment 
with efgartigimod by [CONTACT_202008]- ADL score as stated in Section 
4.1, but cannot complete the entire treatment 
period within Part A (ie, after day 336) then the patient can be transitioned to Part
 B after 
completing the EoA visit assessments (Table 
1). These assessments should be  completed 
even if the patient is unwilling or unable to 
continue to Part  B (see Section 5.1). Revised for clarity  
4.3.2. Exclusion Criteria  
Other sections impacted by 
[CONTACT_202009]:  
x Synopsis Instruction on contraception requirements 
moved to Appendix 9.   Contraceptive requirements 
were removed from the Exclusion Criterion section for logical reasons.
 
Appendix 9: Contraceptive 
and Barrier Guidance  Updated contraception requirements to allow 
for ‚Äúacceptable‚Äù contraception methods per 
CTFG guidelines.  Guidance on contraception has 
been updated following results of nonclinical reproductive toxicity studies.
 
6. TRIAL TREATMENT  
6.8. Prior Treatments and 
Concomitant Medications 
Other sections impacted by 
[CONTACT_202004]:  
x Table 1 General Schedule 
of Assessments for Part A (footnote s) Added text: 
Any vaccination received within [ADDRESS_240987] vaccina tion history.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 8 Section Change Rationale 
x Figure 1: ARGX-113-
1705 Trial Design for Part 
A 
x Table 2 General Schedule 
of Assessments for Part B 
(footnote q) 
x Figure 2: ARGX-113-
1705 Trial Design for Part 
B 
7.2.3. Vital Signs, Physical 
Examination, and ECG  
Other sections impacted by 
[CONTACT_202010]:  
x Table 2 General Schedule 
of Assessments for Part B 
(footnote k) 
x 5.2.2. Trial Period Part B 
and 5.3. Inter Treatment 
Period 
x 5.4. End of Part A, End of 
Study and Early 
Discontinuation Visit 
x 7.2 Safety ECG assessment added to Part  B The ECG assessment was 
added to Part  B to comply 
with the DSMB 
recommendation to monitor QTcF abnormalities that could arise due to the accumulation of efgartigimod.
 
9.3 Monitoring  Added text: 
Monitoring details describing strategy (eg, 
risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk
-Based 
Monitoring), methods, responsibilities and 
requirements, inc luding handling of 
noncompliance issues and monitoring 
techniques (central, remote, or on -site 
monitoring) are provided in the monitoring 
plan.  Clarification  
An additional change was made to allow for testing in patients exhibiting symptoms of COVID-
19 infection. 
Even in countries where COVID-19 safety measures are stopped according to local regulations, 
COVID-19 testing should continue and the results sent to the sponsor for filing. 
  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 9  
Section  Change  Rationale  
Table 1  General Schedule of 
Assessments for Part A 
and 
Table 2  General Schedule of 
Assessments for Part B  Bold italics added to Table 1 and Table 2. The assessments identified for 
telephone assessment visits are highlighted in bold italics in the existing Schedule of Assessments for Part A in Table 1 and for Part
 B in Table 2. Footnote added:  
Assessments highlighted by [CONTACT_202011] a telephone assessment visit under the conditions outlined in Appendix
 8. 
Appendices  Appendix [ADDRESS_240988] been moved to 
Appendix 7. 
For the global amendment of the ARGX-113-1705 protocol from version 2.0 to 3.0 an additional 
part (Part B) has been added to the trial in order to provide the patients with the chance to have 
access to efgartigimod while it is not yet comm ercially available or available through another 
patient program. This extension to Part A of the trial will be a maximum of 2 years and will also 
enable additional long-term safety and tolerability  data to be collected. Below is a comparison of 
the differences between Part A and Part B of the trial: 
Subject  Part  A (1 year)  Part  B (max 2 years)  
Intertreatment  period visits 30 days after the previous visit  90 days after the previous visit  
Disease severity assessments  MG-ADL and QMG MG-ADL only 
Other assessments  As per Table 1 . 
 As per Table 2 : Fewer assessments 
to reduce burden for the patient:  
No suicidality assessments, ECG, 
anti-AChR/anti- MuSK antibodies 
and total IgG and its subtypes  
Laboratory testing  Central laboratory for clinical 
laboratory tests (hematology, clinical chemistry)
 Local laboratory for clinical 
laboratory tests (hematology, clinical chemis
try)  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_240989]  Part  A (1 year)  Part  B (max 2 years)  
Standard of care (SoC)  From [ADDRESS_240990] of prohibited medications  No prohibited medications  
Safety and disease severity follow-
up period  Has been removed from the current 
protocol amendment  Not applicable  
AChR=acetylcholine receptor; ECG= electrocardiogram; IgG=immunoglobulin gamma; MG-ADL=Myasthenia 
Gravis Activities of Daily Living; MuSK=Muscle-Specific Kinase; QMG=Quantitative Myasthenia Gravis score; 
SoC=Standard of Care 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 11 SYNOPSIS 
Name [CONTACT_790]:  argenx  
Name [CONTACT_202095] (IMP):  Efgartigimod (ARGX-113)  
Name [CONTACT_3261]:  A human anti-neonatal crystallizable fragment (Fc) receptor (FcRn) 
immunoglobulin G1 (IgG1) Fc fragment  
Indication:  Treatment of patients with generalized myasthenia gravis (gMG)  
Title of Trial:  A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 
Follow -on Trial of ARGX-113-1704 to Evaluate the Safety and 
Tolerability of ARGX -113 in Patients With Myasthenia Gravis 
Having Generalized Muscle Weakness 
Protocol No:  ARGX-113-1705 (ADAPT+) 
Trial Sites:  This trial is an extension of trial ARGX-113-1704 and will be 
conducted in the sites that participated in the ARGX -113- 1704 trial 
Trial Duration: The trial duration will be up to maximum 3 years. The 
trial consists of 2 parts: Part A (1 year) and Part B (up to maximum 
[ADDRESS_240991]). 
Patients who have completed at least [ADDRESS_240992] started Part B are eligible to 
enroll in the open -label trial ARGX-113-2002 to receive efgartigimod by 
[CONTACT_202012].  Phase: 3 
Objectives:  
Primary Objective : 
x To evaluate the long- term safety and tolerability of efgartigimod in acetylcholine receptor 
antibody (AChR-Ab) seropositive patients 
Secondary Objective : 
x To evaluate the long-term safety and tolerability of efgartigimod in the overall population 
(AChR-Ab seropositive and AChR-Ab seronegative patients) 
Tertiary Objectives : 
Part A only:  
x To evaluate the disease severity as assessed by  [CONTACT_202013] (MG-ADL) score changes in AChR-Ab seropositive patients. 
x To evaluate the disease severity as assessed by [CONTACT_202014]- ADL score changes in the overall 
population (AChR-Ab seropositive patients and AChR-Ab seronegative patients). 
x To evaluate disease severity as assess ed by [CONTACT_202015] (QMG) 
score changes in AChR-Ab seropositive patients. 
x To evaluate disease severity as assessed by [CONTACT_202016] (AChR-Ab seropositive patients and AChR-Ab seronegative patients). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_240993] of efgartigimod on pharmacodynamics (PD) (total immunoglobulin 
gamma [IgG], IgG subtypes, autoantibodies [anti-AChR antibodies and anti-muscle-
specific kinase (MuSK) antibodies]). 
Part A and B:  
x To evaluate the immunogenicity of efgartigimod.  
Methodology:  
DESCRIPTION  
This is a 3 -year (maximum), single-arm, open-label, multicenter, phase 3 follow-on trial of 
ARGX -113-1704 to evaluate the long-term safety and tolerability of efgartigimod in patients with 
gMG. The trial consists of 2 parts: Part A (1 year) and Part B (up  to maximum [ADDRESS_240994]). The additional part (Part  B) was added to ARGX-113- [ADDRESS_240995] access to efgartigimod while it is not yet commercially 
available or available through another patient program. This extension will also enable additional long-
term safety and tolerability data to be collected.  
A variable number of treatmen t periods consisting of 4 weekly infusions of efgartigimod (10 mg/kg of 
body weight) infused over a period of 3 weeks will be administered to eligible patients on an ‚Äúas 
needed basis‚Äù on top of their standard of care (SoC). The time between treatment perio ds is based on 
the duration of the treatment effect and may vary from patient to patient and within each patient from period to period (patient
-tailored approach). 
The first visit of trial ARGX -113-[ADDRESS_240996] visit of trial ARGX-113- 1704 for 
each patient.  
The study entry baseline (SEB) will be set at the first trial visit, while the baseline of each subsequent 
treatment period (TP nB for Part A or TPE nB for Part B) will be set at visit 1 of each corresponding 
treatment period.  
ROLL -OVER 
At the end of study (EoS) visit of trial ARGX -113- 1704, eligible patients will be offered the option to 
roll over into this trial. Patients in need of (re -)treatment in trial ARGX-113-1704 but who cannot 
complete a Treatment Cycle within the time frame of th at trial, may immediately roll over to this trial 
to receive treatment with efgartigimod.  
Patients who discontinued early from trial ARGX -113-1704 or discontin ued early from randomized 
treatment for rescue or pregnancy reasons or for a seri ous adverse event (SAE) that is likely to result in 
a life -threatening situation or pose a serious safety risk in that trial will not be offered the option to roll 
over into t his trial. 
Patients who discontinued early from randomized treatment for other reasons and patients who had a 
temporary interruption from randomized treatment in trial ARGX -113- [ADDRESS_240997] complete the early discontinuation (ED) 
visit assessments specified in Table 2. The previous ef gartigimod IV dose must have been received at least 30 
days before entry into ARGX -113-2002. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 13 Patients can enroll in ARGX-113-2002 until its recruitment has closed. Patients who enroll in 
ARGX -113-2002 will not return to ARGX-113-1705. 
(RE-)TREATMENT (Part A) 
Each patient will start a (new) treatment period with efgartigimod when all the following criteria apply:  
x The patient has completed the previous treatment period (ie, after visit 4) 
x The patient has a total MG- ADL score of ‚â•5 points with more than 50% of the total score 
due to non-ocular symptoms 
x The patient has a reduction in the MG- ADL total score of <2 points compared to the score 
at: 
1. The last treatment cycle baseline (TCB) in trial ARGX-113- [ADDRESS_240998] treatment 
period (TP 1) in trial ARGX-113-[ADDRESS_240999] treatment period baseline (TP nB) for all subsequent treatment periods (TP n+1) 
in trial ARGX-113-1705 
However, patients may  not receive (re-)treatment with efgartigimod if, at the time of (re- )treatment, 
they have clinical evidence of bacterial, viral or fungal disease, or any other significant disease which 
could confound the results of the trial or put patients at undue risk . Patients who are in need of an 
additional treatment but who ar e not eligible to receive (re -)treatment for reasons listed here will 
remain in the trial to receive appropriate alternative MG treatment  (see Appendix 5 and Appendix 6 ). 
Patients who show a treatment failure to efgartigimod for [ADDRESS_241000] 50% of the assessments (ie, 
TPnV2, TP nV3, TP nV4 and the first posttreatment period visit).  
If a patient becomes eligible for (re -)treatment with efgartigimod by [CONTACT_202017]-ADL score as stated in Section 4.1, but cannot complete the entire treatment period during Part A 
(ie, after day  336) then the patient can be transitioned to Part B after completing the end of Part A 
(EoA) visit assessments ( Table 1 ). These assessments should be completed even if the patient is 
unwilling or unable to continue to Part  B (see Section 5.1). 
The transition to Part  B can be either at ITPE 0V1 or TPE 1V1, depending on the patient‚Äôs status 
regarding the need for (re -)treatment upon transition from Part A. The first visit in Part B will always 
coincide with the EoA visit in Part  A. The assessments done for the last visit in Part A should not be 
repeated in Part  B. 
(RE-)TREATMENT (Part B) 
If the patient feels that his/her condition has deteriorated, then the investigator may start a new 
treatment period at an intertreatment period (ITPE) visit or the patient may contact [CONTACT_202018].  
A patient can start the next treatment period and receive efgartigimod if all of the followin g criteria are 
met:  
x The patient has completed the previous tr eatment period (ie, after visit 4)* 
x The investigator determines that the patient will benefit from re-treatment 
x There is at least 1 calendar month (minimum 4 we eks) between treatment periods (ie, between 
TPE nV4 and TPE n+1V1) 
*A patient who has had a temporary interruption of trial treatment in Part A may also continue into Part 
B of the trial and receive (re -)treatment if the conditions in Section 4.4.1 are met. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 14 However, patients may not receive (re-)treatment wi th efgartigimod if, at the time of (re-)treatment, 
they have clinical evidence of bacterial, viral or fungal disease, or any other significant disease which 
could confound the results of the trial or put patients at undue risk.  
If a patient becomes eligible for (re -)treatment with efgartigimod but cannot complete the entire 
treatment period within the  duration of the trial, the patient should continue to the EoS visit. 
If the investigator considers that the patient will not have a clinical benefit from (re -)treatment then the 
patient cannot start a new treatment period. The patient should then continue to the EoS visit.  
STANDARD OF CARE (SoC) 
In Part A:  
Permitted SoC for MG treatment under this protocol include NSIDs (eg, azathioprine, methotrexate, 
cyclosporine, tacrolimus, mycophenolate mofetil, and cyclophosphamide), steroids, as well as 
acetylcholinesterase (AChE) inhibitors.  
A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment of the 
SoC dose and/or frequency) is not allowed:  
x From trial entry until [ADDRESS_241001] 12 hours prior to performing the QMG 
assessment. Following this requirement, this possible temporary change in dosing regimen of AChE 
inhibitors will not be considered as a change in SoC.  
In Part B:  
A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment of the 
SoC dose and/or fr equency) is allowed, without restrictions, following current medical practice. 
Plasma exchange (PLEX), intravenous immunoglobulin (IVIg), immunoadsorption or use of a new 
type of corticosteroid or an increased dose of the current corticosteroids used as st and-alone therapy or 
in combination is also allowed in Part  B. 
TIME BETWEEN TREATMENT PERIODS  
At the end of each treatment period, patients will enter a variable intertreatment period  during which 
they will be treated with their SoC only. The length of the  intertreatment period may vary from patient 
to patient and for each patient from period to period (patient -tailored approach). For Part A, the visit 
frequency in the intertreatment period is every 30 days (¬± 2 days) after the previous visit. For Part B, 
the visit frequency in the intertreatment period is every 90 days (¬± 7 days) after the previous visit. If an 
inter-treatment period (ITP) visit for Part A is scheduled within 14 days of the EoA visit, then the EoA 
visit should be performed instead.  
RESCUE THERAPY (Part  A only) 
Rescue therapy will be limited to PLEX, IVIg, immunoadsorption or use of a new type of 
corticosteroid or an increased dose of the current corticosteroids used as stand -alone therapy or in 
combination.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 15 Rescue therapy is permitted for patients experiencing protocol-defined MG clinical deterioration AND 
if in addition the treating physician believes that the patient‚Äôs health is in jeopardy if rescue therapy is 
not given. An  MG clinical deterioration permitting rescue therapy to be given is defined as a patient 
experiencing at least 1 of the following: (1) new or worsening of respi[INVESTIGATOR_696] / bulbar symptoms or (2) 
at least 2 -point increase of individual non-ocular MG-ADL items. Whenever possible, prior to giving 
rescue therapy to a patient, the Medical Director  at the sponsor and the Medical Monitor at the 
sponsor‚Äôs designated Contract Research Organization (CRO) should be informed.  
In situations where the treatments as listed a bove are given under the protocol- defined rescue criteria, 
patients will be discontinued early from the trial.  
EARLY DISCONTINUATION  
For patients who discontinue early from the trial, the assessments will depend on the visit at which it 
was decided that th e patient had to discontinue (see Section 5.4, Figure 1,  and Figure 2). 
Patients who discontinue early from the trial within a treatment period should perform the planned 
assessments of the corresponding treatment period visit. These patients will not receive any further 
administration of efgartigimod during the trial and wi ll return for the ED visit 1 month (30 ¬± 2 days) 
after the last dose administration. An unscheduled vi sit can be organized if deemed necessary by [CONTACT_1275].  
Patients who discontinue ear ly from the trial between the last visit of a treatment period (TP nV4 or 
TPE nV4) and the next intertreatment period visit (ITP nVn or ITPE nVn) should perform the ED 
assessments 1 month (30 ¬± 2 days) after the last dose administration.  
Patients who discontin ue early from the trial at the ITP (Part A) or ITPE (Part B) visit should perform 
the ED assessments, instead of the ITP nVn (Part A) or ITPE nVn  (Part B) assessments.  
Patients who discontinue early from the trial after the ITP (Part  A) or ITPE (Part B) visit should 
perform the ED assessments.  
Any patient prematurely discontinuing the trial during Part A should perform the EoA/ED assessments 
according to the General Schedule of Assessments for Part A ( Table 1 ). Any patient prematurely 
discontinuing the trial during Part B should perform the EoS/ED assessments according to the General 
Schedule of Assessments for Part  B (Table 2 ). 
Before enrolling in ARGX -113-[ADDRESS_241002] complete the early discontinuation (ED) 
visit assessments specified in Table [ADDRESS_241003] a temporary 
interruption from trial treatment which is defined as a discontinuation only from the current treatment 
period. Therefore, these patients might still be elig ible for further additio nal treatments with 
efgartigimod within this trial.  
Patients for whom treatment is interrupted will ha ve to complete the current treatment period and will 
continue the trial as per the Ge neral Schedule of Assessments for Part A ( Table 1 ) or for Part B 
(Table  2) but without drug administration. A patient who has had a temporary interruption of trial 
treatment in Part A may also continue into Part B of the trial and receive (re -)treatment if the 
conditions mentioned above are met.  
Planned Number of Patients:  The maximum number of patients in this trial will be the number of 
patients who participated in trial ARGX -113-1704. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 16 Criteria for Inclusion and 
Exclusion:  Inclusion Criteria:  
1. Patients with the ability to understand the requirements of 
the trial, provide written informed consent, and can comply 
with the trial protocol procedures. 
2. Patients who participated in trial ARGX-113- 1704 and are 
eligible for roll over, ie: 
x Patients who reached EoS at day 182 in trial ARGX -
113-1704. 
x Patients who need (re-)treatment in trial ARGX-113 -
1704 but cannot complete a Treatment Cycle within the 
time frame of that trial may immediately roll over into 
this trial to receive treatment with efgartigimod. 
x Patients who discontinued early from randomized 
treatment for other reasons than pregnancy, rescue 
therapy or an (S)AE in trial ARGX-113- 1704 may be 
offered the option to roll over into this trial. 
x Patients who had a temporary interruption from 
randomized treatment in trial ARGX-113- 1704 may be 
offered the option to roll over into this trial. 
3. Patients are required to be on a stable dose of their MG 
treatment (SoC) prior to SEB. The SoC is limited to 
acetylcholinesterase (AChE) inhibitors, steroids and non -
steroidal immunosuppressive drugs (NSIDs) 
(eg, azathiopri ne, methotrexate, cyclosporine, tacrolimus, 
mycophenolate mofetil, and cyclophosphamide). 
Note: AChE inhibitors must be withheld for at least 
[ADDRESS_241004] as recommended by [CONTACT_202019] (MGFA), before the QMG assessment. 
 Exclusion Criteria : 
1. Patients who discontinued early from trial ARGX-113- [ADDRESS_241005] dosing. Women of childbearing potential 
(DEFINITION OF TERMS ) should have a negative urine 
pregnancy test at SEB. The contraceptive requirements for 
women of childbearing potential are described in Error! 
Not a valid result for table. . 
3. Male patients who are sexually active and do not intend to 
use effective methods of contraception (as mentioned 
above) during the trial or within [ADDRESS_241006] 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241007] dosing. The 
contraceptive requirements for male patients are described 
in Error! Not a valid result for table. . 
4. Patients with known hepatitis B virus (HBV), hepatitis C 
virus (HCV) or human immunodeficiency virus (HIV) 
seropositivity. 
5. Patients with known autoimmune disease other than MG 
(for example autoimmune thyroiditis, rheumatoid arthritis, 
‚Ä¶) that would interfere with an accurate assessment of 
clinical symptoms. 
6. Patients with clinical evidence of other significant disease 
or patients who underwent a recent major surgery, which 
could confound the results of the trial or put the patient at 
undue risk. Patients with renal/hepatic function impairment 
can be included. 
7. Patients with known medical history of hypersensitivity to 
any of the ingredients of efgartigimod.  
Test Product, Dose, and Mode 
of Administration:  In this trial, the test product is efgartigimod (ARGX-113), which is 
a human anti -FcRn IgG1 Fc fragment. In patients who need (re) -
treatment, a dose of 10  mg/kg of body weight of efgartigimod will 
be administered at visits 1, 2, 3 , and 4 of each treatment period as an 
intravenous (IV) infusion over a period of 1  hour. The total dose per 
efgartigimod infusion is capped at 1200 mg for patients with body 
weight ‚â•120 kg.  
Criteria for Evaluation:  
Primary Endpoint : 
x Incidence and severity of AEs, SAEs, vital sig ns, electrocardiogram (ECG) and laboratory 
assessments over the duration of the trial in AChR-Ab seropositive patients. 
Secondary Endpoint: 
x Incidence and severity of AEs, SAEs, vital si gns, ECG and laboratory assessments over the 
duration of the trial in the overall population (AChR- Ab seropositive patients and AChR-
Ab seronegative patients). 
Tertiary Endpoints : 
Part A only: 
x Total MG- ADL score changes compared to the treatment period baseline of the first cycle 
(TP 1B) and the corresponding TP nB in AChR-Ab seropositive patients. 
x Total MG-ADL score changes compared to TP 1B and the corresponding TP nB in the 
overall population (AChR-Ab seropositive and AChR-Ab seronegative patients). 
x Total QMG score changes compared to TP 1B and the corresponding TP nB in AChR- Ab 
seropositive patients. 
x Total QMG score changes compared to TP 1B and the corresponding TP nB in the overall 
population (AChR-Ab seropositive and AChR-Ab seronegative patients). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 18 x Percentage decrease (compared to TP 1B and the corresponding TP nB) of total IgG level 
and IgG subtypes in efgartigimod (re-)treated patients. 
x Percentage decrease (compared to TP 1B and the corresponding TP nB) of autoantibodies 
(anti-AChR antibodies and anti-MuSK antibodies) in efgartigimod (re- )treated patients. 
Part A and B: 
x Incidence and prevalence of anti-drug antibodies (ADA) to efgartigimod.  
Statistical Methods and Plan:   
A Statistical Analysis Plan detailing all statistica l methods and analyses will be issued before any 
database lock. A summary of the plan is described b elow. 
All endpoints will be summarized in all enrolled patients by [CONTACT_64161].  
Summary statistics will be provided for the continuous endpoints (eg, total MG -ADL score, total QMG 
score, levels of total IgG and subtypes, anti -AChR/anti-MuSK antibodies, laboratory values, vital 
signs, ECG) in terms of absolute values, changes from TP 1B or changes from TP nB, by [CONTACT_202020].  
Frequency tables will be made for all binary variables, ie, AEs and ADA by [CONTACT_89835].  
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241008] visit of a treatment period (TPnV4) and the next  intertreatment period visit (ITPnVn) should perform the ED as sessments 1 month (30 ¬± 2 
days) after the last dose administration. Patients who discontinue early from the trial at the ITP visit should perform the ED assessments instead of the ITPnVn 
assessments. Patients who discontinue from the trial after  the ITP visit should perform the ED assessments. 
e An unscheduled (UNS) visit can occur at the request of the patien t or the investigator. During the UNS visit, additional asses sments as indicated in the SoA can 
be performed at the discretion of the investigator, depending on the reason for the UNS visit. 
f No trial-related assessment is to be carried out before  the patient has signed the informed consent form (ICF). 
g Assessments of disease severity should be completed predose on  dosing days and before any othe r trial-specific assessment, exc ept for obtaining informed 
consent at SEB and the weight assessment, if applicable. The MG-ADL  scale should be administered before the QMG scale. Acetylch olinesterase inhibitors 
must be halted for at least 12 hours before the QMG assessment (consistent with the revised manual for the QMG test as recommen ded by [CONTACT_202021] [MGFA]). 
h Suicidal ideation and behavior will be assessed predose on dosing days via a targeted question based on the Patient Health Que stionnaire item 9 (PHQ-9). 
i The physical examination will be perfor med predose on dosing days. See Section 7.2.3  for an overview of the different assessments. 
j Weight will be measured at SEB, at the EoA/ED visit, and when th ere is an obvious weight change compared to the last weight as sessment. Height will be 
measured at SEB. 
k Vital signs (supi[INVESTIGATOR_9204], heart rate, body temperature) will be performed predose on dosing days. It is recommended that the method used to measure 
body temperature at SEB is maintained throughout the trial for each patient. 
l ECG will be performed predose on dosing days. 
m Samples for clinical laboratory tests (hematology, clinical ch emistry) will be collected pre dose on dosing days (see Appendix 3 ). Patients need to have fasted at 
least 8 hours prior to each sampling. 
n Urine samples will be collected predose on dosin g days (see Appendix 3 ). 
o A urine pregnancy test will be performed pr edose on dosing days on the urine samples taken for urinalysis (only for women of childbearing potential, see 
DEFINITION OF TERMS ). 
p Samples for pharmacodynamic (PD) biomarkers will be collected predose on dosing days (see Appendix 3 ). Anti-AChR antibodies will be measured in AChR-
Ab seropositive patients only. Anti-MuSK antibodies will be measured in MuSK-Ab seropositive patients only. Information on the AChR/MuSK-Ab serotype 
(seronegative or seropositive) is available from trial ARGX-113-1704. 
q Samples for anti-drug antibodies (ADAs)  will be collected predose on dosing days. 
r Efgartigimod will be administered as an intr avenous (IV) infusion over a pe riod of [ADDRESS_241009] 1 hour following the end of the infusion for safety monitoring based on the patient‚Äôs clinical status. At TPnV1, the conditions for (re -) 
treatment will be checked before administration of efgartigimod. 
s Clinically relevant prior treatment will only be recorded at SEB. All available vaccination history will be recorded as part of the participant‚Äôs prior medication 
for vaccinations received in the past or concomitant medication for vaccinations received during the trial. For vaccines where multiple doses or boosters are 
received, only the most recent one must be recorded. 
*Assessments highlighted by [CONTACT_202022] a telephone assessment visit un der the conditions outlined in 
Appendix 8 . 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 24 d For patients who discontinue early from the trial, the assessme nts will depend on the visit at which it was decided that the p atient had to discontinue (see 
Section 5.4). Patients who discontinue early from the trial within a treatmen t period should perform the planned assessments of the corres ponding treatment 
period visit. These patients wi ll not receive any further administration of efgartigimod during the trial and return for the ED  visit 1 month (30 ¬±2 days) after the 
last dose administration. An unscheduled visit can be organized if deemed necessary by [CONTACT_093]. Patients who discontin ue early from the trial between 
the last visit of a treatment period (TPE nV4) and the next intertreatment period visit (ITPE nVn) should perform the ED assessments 1 month (30 ¬±2 days) after 
the last dose administration. Patients who discontinue early from the trial at the ITPE visit should perform the ED assessments  instead of the ITPE nVn 
assessments. Patients who discontinue prematurely from the tr ial after the ITPE visit should perform the ED assessments. 
e Before enrolling in ARGX-113-[ADDRESS_241010] complete the early discontinuation (ED) visit assessments. T he previous efgartigimod IV 
dose must have been received at least 30 days before entry into ARGX-113-2002.  
f An unscheduled (UNS) visit can occur at the request of the p atient or the investigator. During the UNS visit, additional asses sments as indicated in the SoA can 
be performed at the investigator's discretion, depending on the reason for the UNS visit. 
g The transition to Part B can be either ITPE0Vn or TPE1V1, depe nding on the patient status regarding the need for (re-)treatmen t upon transition from Part A. 
The first visit in Part B will always coincide with the EoA vis it in Part A. The assessments done for the last visit in Part A should not be repeated in Part B. 
h Assessments of disease severity should be completed predose on  dosing days and before any othe r trial-specific assessment, exc ept weight, if applicable. 
i Weight will be measured at visit 1, the Eo S/ED visit, and any visit when  a weight change is obvious compared to the last weigh t measurement. 
j Vital signs (supi[INVESTIGATOR_9204], heart rate, body temperature) will be performed predose on dosing days. It is recommended that the method used to measure 
body temperature is maintained throughout the trial for each patient. 
k A 12-lead ECG will be recorded locally. The assessments on he art rate, PR, QT, and QRS intervals will be read centrally. 
l Samples for clinical laboratory tests (hematology, clinical chemis try) will be collected predose on dosing days, if applicable  (see Appendix 3 ). 
m Urine samples will be collected predose on dosin g days (see Appendix 3 ). 
n If a urine pregnancy test is carried out on a dosing day, then  it should be performed predose (only for women of childbearing potential, see DEFINITION OF 
TERMS ). 
o Samples for anti-drug antibodies (ADAs) will be collected predos e on dosing days (if applicable) and collected only in the cas e of early discontinuation and not 
at the EoS visit.  
p Efgartigimod will be administered as an intravenous (IV) infusion over a pe riod of [ADDRESS_241011] 1 hour following the end of the infusion  for safety monitoring based on the patient‚Äôs clinical statu s. At TPE nV1, the conditions for (re-) 
treatment will be checked before administration of efgartigimod. 
q All available vaccination history will be recorded as part of the participant‚Äôs prior medication for vaccinations received in the past or concomita nt medication 
for vaccinations received during the trial. For vaccines where mu ltiple doses or boosters are received, only the most recent on e must be recorded. 
*Assessments highlighted by [CONTACT_202022] a telephone assessment visit un der the conditions outlined in 
Appendix 8 . 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241012] of Care and Rationale for the Use of Efgartigimod .....................................39  
1.4. Benefit-Risk Assessment ............................................................................................40  
2. TRIAL OBJECTIVES ................................................................................................43  
2.1. Primary Objective .......................................................................................................43  
2.2. Secondary Objective ...................................................................................................43  
2.3. Tertiary Objectives .....................................................................................................43  
3. TRIAL ENDPOINTS .................................................................................................44  
3.1. Primary Endpoint ........................................................................................................44  
3.2. Secondary Endpoint ....................................................................................................44  
3.3. Tertiary Endpoints ......................................................................................................44  
4. INVESTIGATIONAL PLAN .....................................................................................45  
4.1. Summary of Trial Design ...........................................................................................45  
4.2. Discussion of Trial Design .........................................................................................49  
4.3. Selection of Trial Population ......................................................................................51  
4.3.1.  Inclusion Criteria ........................................................................................................51  
4.3.2.  Exclusion Criteria .......................................................................................................51  
4.4. Early Discontinuation .................................................................................................52  
4.4.1.  Temporary Interruption From Trial Treatment ...........................................................54  
4.4.2.  Missed Doses ..............................................................................................................54  
4.5. Protocol Deviations ....................................................................................................54  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241013] ............................................................62  
6.5. Method of Assigning Patients to Treatment Group ....................................................63  
6.6. Timing of Dose for Each Patient ................................................................................63  
6.7. Blinding ......................................................................................................................63  
6.8. Prior Treatments and Concomitant Medications ........................................................63  
6.8.1.  Prohibited Medications During the Trial ....................................................................63  
6.8.2.  Rescue Therapy (Part A only) ....................................................................................[ADDRESS_241014] .................................................65  
6.13.  Storage of Blood Samples in the Trial ........................................................................65  
7. TRIAL ASSESSMENTS ............................................................................................66  
7.1. Monitoring of Disease Severity ..................................................................................66  
7.1.1.  Myasthenia Gravis Activities of Daily Living ............................................................66  
7.1.2.  Quantitative Myasthenia Gravis .................................................................................66  
7.2. Safety ........................................................................................................................ ..66 
7.2.1.  Adverse Events ...........................................................................................................67  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 28 [IP_ADDRESS].  Adverse Events of Special Interest .............................................................................69  
[IP_ADDRESS].  Reporting of Adverse Events and Serious Adverse Events ........................................69  
[IP_ADDRESS].  Reporting of Serious Adverse Events to Regulatory Authorities and 
Investigators ................................................................................................................7 0 
[IP_ADDRESS].  Follow-up of Adverse Events and Serious Adverse Events .......................................71  
[IP_ADDRESS].  Reporting and Follow-up Require ments for Pregnancies ...........................................[ADDRESS_241015] (DSMB) .....................................................................74  
7.2.7.  Visit Reminder/Subject ID Card .................................................................................74  
7.3. Pharmacodynamics .....................................................................................................74  
7.4. Anti-Drug Antibodies .................................................................................................75  
8. STATISTICS ..............................................................................................................76  
8.1. Determination of Sample Size ....................................................................................76  
8.2. Analysis Populations ..................................................................................................76  
8.3. Patient Disposition, Characteristics and Concomitant Medication ............................76  
8.4. Statistical Methods ......................................................................................................76  
8.4.1.  Primary and Secondary Endpoint Analyses ...............................................................76  
8.4.2.  Tertiary Endpoint Analyses ........................................................................................77  
8.5. Interim Analyses .........................................................................................................77  
9. QUALITY CONTROL AND QUALITY ASSURANCE .........................................78  
9.1. Investigator‚Äôs Responsibility  ......................................................................................[ADDRESS_241016] of the Trial .......................................................................................81  
10.3.  Patient Information and Informed Consent ................................................................81  
10.4.  Patient Data Protection ...............................................................................................82  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241017] Access to Source Data/Documents ..................................................................83  
11.3.  Investigator Information .............................................................................................84  
11.3.1.  Investigator Obligations ..............................................................................................84  
11.3.2.  Protocol Signatures .....................................................................................................84  
11.3.3.  Publication Policy .......................................................................................................84  
11.3.4.  Financing and Insurance .............................................................................................84  
12. REFERENCES ...........................................................................................................85  
13. APPENDICES ............................................................................................................87  
APPENDIX 1: Myasthenia Gravis Activities of Daily Living ......................................................87  
APPENDIX 2:  Quantitative Myasthenia Gravis Score ...............................................................88  
APPENDIX 3:  Laboratory Evaluations ......................................................................................89  
APPENDIX 4:  Administrative Structure ....................................................................................90  
APPENDIX 5:  Decision Tree for Re-Treatment in Part A (Part 1) ............................................92  
APPENDIX 6:  Decision Tree for Re-Treatment in Part A and Part B (Part 2) ..........................93  
APPENDIX 7:  Summary of Changes From Prior Amendments ................................................94  
Protocol Version 3.1 compared to Protocol Version 3.2 ...............................................................94  
Protocol Version 3.0 compared to Protocol Version 3.1 ...............................................................95  
Protocol Version 2.0 compared to Protocol Version 3.0 ...............................................................96  
Protocol Version 1.0 compared to Protocol Version 2.0 .............................................................127  
APPENDIX 8:  Temporary Changes to Study P rocedures in ARGX-113-1705 Related 
to the COVID-19 Pandemic ......................................................................................135  
APPENDIX 9:  Contraceptive and Barrier Guidance ................................................................135  
 
 
 
  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241018] OF FIGURES 
Figure 1:  ARGX-113-1705 Trial Design for Part A ..................................................................22  
Figure 2:  ARGX-113-[ADDRESS_241019] OF ABBREVIATIONS 
ABDEG‚Ñ¢  antibody that enhances IgG degradation  
AChE  acetylcholinesterase  
AChR  acetylcholine receptor  
ADA  anti-drug antibodies 
ADL  activities of daily living  
ADR  adverse drug reaction  
AE adverse event  
CIOMS  Council for International Organizations of Medical Sciences  
CRO  contract research organization  
CTCAE  Common Terminology Criteria for Adverse Events  
CTR  clinical trial report  
DSMB  Data Safety Monitoring Board  
ECG  electrocardiogram  
eCRF  electronic case report form  
ED early discontinuation 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241020] allizable fragment 
FcRn  neonatal Fc receptor  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone 
GCP  good clinical practice  
gMG  generalized myasthenia gravis  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HEL -ABDEG‚Ñ¢ full-length monoclonal antibody analog of ABDEG‚Ñ¢  
HIV human immunodeficiency virus  
IB investigator‚Äôs Brochure  
ICF informed consent form  
ICH International Council for  Harmonisation 
IEC Independent Ethics Committee  
IgG immunoglobulin gamma  
IMP investigational medicinal product  
IND investigational new drug  
IRB Institutional Review Board  
ITPV  intertreatment  period visit in Part A 
ITPEV  intertreatment  period visit in Part B 
IV intravenous  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 32 IVIg  intravenous immunoglobulin  
LRP4  lipoprotein receptor -related protein 4 
MG myasthenia gravis  
MG-ADL Myasthenia Gravis Activities of Daily Living  
MGFA  Myasthenia Gravis Foundation of America  
MuSK  muscle -specific kinase 
NCI National Cancer Institute  
NSID  non-steroidal immunosuppressive drug 
PD pharmacodynamic(s)  
PHQ -9 Patient Health Questionnaire item 9  
PLEX  plasma exchange  
PK pharmacokinetic(s)  
QMG  Quantitative Myasthenia Gravis  
SAE  serious  adverse event 
SEB study entry baseline  
SoC standard of care  
SOP standard operating procedures  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TCB  treatment cycle baseline  
TEAE  treatment -emergent adverse event 
TPB treatment period baseline  
TPE treatment period in Part B  
TPnB subsequent treatment period baseline in Part A  
TPE nB subsequent treatment period baseline in Part B  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 33 UNS  unscheduled visit  
US [LOCATION_002]  
WBC  white blood count  
WHO( -DD) World Health Organization (Drug Dictionary)  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 34 DEFINITION OF TERMS 
Childbearing potential:  Women of childbearing potential are defined as all female 
participants unless they are postmenopausal (defined by [CONTACT_202023]) for at least 2
 years with a follicle-
stimulating hormone (FSH) >40  IU/L or are surgically sterile 
(ie, who had a hysterectomy, bilateral oophorectomy, or have 
current documented tubal ligation or any other permanent female sterilization procedure). 
 
Council for International 
Organizations of Medical 
Sciences (CIOMS):  The Council  for International Organizations of Medical 
Sciences (CIOMS) is an international, non -governmental, non-
profit organization established jointly by [CONTACT_202024] (WHO) and UNESCO in 1949. They provide a set of ethical principles regarding human experimentations, 
including International Reporting of Adverse Drug Reactions 
and International Reporting of Periodic Drug
-Safety Update 
Summaries.  
The CIOMS form provides a standardized format for the 
reporting of suspected adverse reactions to any partic ular 
medical product and is the acceptable and widely used format 
for reporting suspect adverse drug reaction (ADR)/suspected 
unexpected serious adverse reaction  (S[LOCATION_003]R) in clinical trials. 
Contract Research 
Organization (CRO):  A person, or a group of persons (commercial, academic, or 
other), who as an independent contractor with argenx BVBA, 
assume(s) 1 or more obligations of argenx BVBA, eg,
 development of a protocol, selection and/or monitoring of 
investigators, evaluation of reports, preparation of materials to 
be submitted to Health Authorities.  
Cycle  A cycle is a treatment period plus the intertreatment period. 
Database Lock:  An action taken to prevent further changes to a trial database. 
A database is locked after review, query resolution, data cleaning and determination that it is ready for analysis.
 
Data Safety Monitoring 
Board (DSMB):  Independent group of experts that advises and whose 
responsibilities are to periodically review and evaluate the accumulated trial data for partic ipant safety, trial conduct and 
progress and, when appropriate, efficacy and to make recommendation to the sponsor concerning the continuation, modification or termination of the trial.
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 35 Eligible:  Qualified for roll -over into the trial based upon strict adherence 
to inc lusion/exclusion criteria. 
Good Clinical Practice 
(GCP):  A standard for the design, conduct, performance, monitoring, 
auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are 
credible a
nd accurate, and that the rights, integrity, and 
confidentiality of trial subjects are protected (ICH E6).  
Institutional Review Board 
(IRB)/Independent Ethics 
Committee (IEC):  An independent body (a review board or a committee, 
institutional, regional, national,  or supranational), constituted 
of medical professionals and non -medical members, whose 
responsibility it is to ensure the protection of the rights, safety 
and well -being of human subjects involved in a trial and to 
provide public assurance of that protection, by, among other 
things, reviewing and approving / providing favorable opi[INVESTIGATOR_201985], the trial protocol, the suitability of the investigator(s), 
facilities, and the methods and material to be used in obtaining and documenting informed consent of t
he trial subjects. 
Informed Consent/ 
Informed Consent Form (ICF):
 A process by [CONTACT_9444] a clinical investigation participant 
voluntarily confirms his or her willingness to participate in a particular clinical trial, after having been informed of all 
aspects of the trial that are relevant to the participant‚Äôs decision 
to participate. Informed consent is documented by [CONTACT_3553] a 
dated and signed informed consent form (ICF).
 
International Conference 
on Harmoni sation (ICH):  The International Conference on Harmon isation of Technical 
Requirements for Registration of  Pharmaceuticals for Human 
Use (ICH) is a project that brings together the regulatory 
authorities of Europe, Japan and the [LOCATION_002] and experts 
from the pharmaceutical industry in the [ADDRESS_241021]:  A pharmaceutical form of an active ingredient being tested or 
used as a reference in a clinical trial, including a product with a 
marketing authorization when used in a way different from the 
approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.   
Protocol amendment:  A written description of a change(s) to or formal clarification 
of a protocol.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 36 Treatment:  Term used throughout the clinical trial to denote a set of 
investigational product(s) or mar keted product(s) intended to 
be administered to a subject.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 37 1. INTRODUCTION 
1.1. Background Information 
Myasthenia gravis (MG) is an autoimmune dis order characterized in mo st cases by T-cell and 
antibody responses to neuromuscular junction proteins such as skeletal muscle nicotinic 
acetylcholine receptor (AChR). Antibodies against epi[INVESTIGATOR_201986], resulting in the characteristic fatigue and 
weakness associated with this severe disorder. The muscle weakness fluctuates with activity, and periods of rest offer only a temporary reprieve.
[ADDRESS_241022]-synaptic AChRs. Anti-AChR antibodies are present in approximately 80% of all 
autoimmune MG patients. Less frequent autoantibodies found in autoimmune MG include the anti-muscle-specific kinase (MuSK) antibod y (4% of the cases), and the anti-lipoprotein 
receptor-related protein 4 (LRP4) antibody (2% of the cases) directed against LRP4. All these autoantibodies belong to the immunoglobulin gamma (IgG) class.
2,3  
In approximately 5% to 20% of the MG patients , no serum antibodies against neuromuscular 
junction proteins can be detected.4,5  Although in some seronegative MG patients the disease 
may not be mediated by [CONTACT_79425], in other cases the (apparent) absence of specific autoantibodies in patients may be due to insufficient sensitivity of the assay. Indeed, one-third of 
MG patients, who are seronegative on standard te sting, are seropositive on cell-based testing. 
The seronegative group probably includes some pa tients with anti-AChR, -MuSK or -LRP4 
antibodies that are not detected because of insufficient test sensitivity.
3  
The treatment of MG is based on a variety of me dications and medical procedures used either 
alone or in combination (see Section  1.3). 
Given the pathogenic role of autoantibodies in MG, a possible novel therapeutic approach to this disease may include the use of drugs that lower the level of pathogenic autoantibodies rapi[INVESTIGATOR_201987]. Since all the specific autoantibodies found in MG belong to the IgG isotype, 
agents that specifically lower the level of these antibodies without affecting the level of other isotypes such as IgA, IgE and IgM may be of special interest. 
One such strategy involves inhibition of the neonatal crystallizable fragment (Fc) receptor 
(FcRn). FcRn was shown to play a central role in trafficking IgGs and albumin into recycling 
pathways rescuing them from lysosomal degrada tion. Molecules that block the interaction of 
FcRn with IgGs are expected to induce degradation and fast clearance of pathogenic IgGs 
leading to a lowering of their serum level.
6,7 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241023] 
Efgartigimod (ARGX-113) is a human IgG1-derived Fc fragment of the za allotype that binds 
with nanomolar affinity to human FcRn. Efgartigimod encompasses IgG1 residues D220-K447 
(EU numbering scheme) and has been modified with the so- called ABDEG‚Ñ¢ technology 
(ABDEG‚Ñ¢ = antibody that enhances IgG degradation)8 to increase its affinity for FcRn at both 
physiological and acidic pH. The increased affini ty for FcRn of efgartigimod at both acidic and 
physiological pH results in a constitutively blockage of FcRn-mediated recycling of IgGs. 
Given the essential role of the FcRn receptor in IgG homeostasis, inhibiting this FcRn function, 
as achieved by [CONTACT_202025], leads to rapid degradation of IgGs, which is expected to include autoantibodies in IgG-driven autoimmune diseases. 
This concept has been validated in various  murine disease models together with 
pharmacokinetic/pharmacodynamic (PK/PD) studies in cynomolgus monkeys, either by [CONTACT_202026] a full-lengthmonoclonal antibody analog (HEL- ABDEG‚Ñ¢).
9,10 
The antibody clearing properties of efgartigimod were confirmed in PK/PD studies in cynomolgus monkeys. A single infusion of efgartigimod resulted in a decrease of IgG up to 55% 
without altering serum albumin concentrations nor IgM or IgA levels. This PD effect as 
measured with a tracer IgG molecule was proven to be more potent than intravenous immunoglobulin (IVIg), both in rapi[INVESTIGATOR_201988]. Repeated dosing could 
improve the PD effect up to a maximum IgG reduction of 75%. 
These nonclinical data validated the further development of efgartigimod for assessing its 
therapeutic potential in IgG-driven autoimmune indications. 
To date, a phase 1 (ARGX-113-1501) and a pha se 2 (ARGX-113-1602) trial are completed as 
part of the clinical development of efgartigimod for the treatment of generalized myasthenia 
gravis
 (gMG).  
ARGX-113-[ADDRESS_241024]-in-Human (FIH) 
phase 1 trial conducted in 62 healthy volunteers to assess the safety and tolerability and to 
evaluate the PK and PD characteristics of single and multiple ascending intravenous (IV) doses 
of efgartigimod. The trial showed that a single ad ministration of efgartigimod reduced IgG levels 
up to 50%, while multiple dosing further lowe red IgGs up to approximately 70%. IgG levels 
returned to baseline approximately [ADDRESS_241025] administration of efgartigimod. IV 
administration of efgartigimod at single doses up to 25 mg/kg and multiple doses of 10 mg/kg and 25 mg/kg were safe and well tolerated.  
Based on an optimal PD effect combined with minimal number of observed adverse events 
(AEs) (compared to the 25 mg/kg dose level), the dose of 10 mg/kg once weekly for [ADDRESS_241026] favorable risk-benefit profile and was therefore selected for further testing in the phase 2 trial. The outcome of the phase 2 trial indicated the efficacy and safety of 10 mg/kg in 4 weekly infusions in gMG patients 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 39 ARGX-113-1602 was a randomized, double-blind, plac ebo-controlled, multicenter phase 2 trial 
to evaluate the safety, efficacy, and PK of ef gartigimod for the treatment of autoimmune MG 
patients with generalized muscle weakness. Eligible patients (24 in total) were randomized at a 
1:1 ratio to receive efgartigimod (10 mg/kg) or pl acebo in [ADDRESS_241027] of care (SoC). The clinical effect of efgartigimod was explored in this trial using validated efficacy scales commonly used in MG clinical research and practice: Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis 
(QMG), MGC, and MGQoL15r. The efficacy data of the 4 scales consistently point in the same 
direction and show a rapid onset of action, a nd a relevant and long-lasting clinical improvement 
over placebo. More specifically, on the MG-ADL  scale, 75% of the patients treated with 
efgartigimod had a sustained clinically relevant reduction in total MG-ADL scores (defined as a 
reduction of at least 2 points from baseline) for a period of at least 6 consecutive weeks (starting 
at the latest [ADDRESS_241028] [IMP]) versus 25% of 
patients on placebo (difference was found to be statistically significant). Furthermore, this 
clinical improvement observed in all scales was consistent with the observed PD data, namely a reduction of total IgG and subtypes and a decreased level of AChR autoantibodies. 
The proposed phase 3 trial aims to establish the safety and tolerability of efgartigimod in 
class II-IVb gMG patients, and thereby [CONTACT_202027] a 
therapeutic treatment modality in this indication. 
This trial will be performed in complian ce with the protocol, International Council for 
Harmonisation Good Clinical Practice (ICH GCP), Declaration of Helsinki, and other applicable 
regulatory requirements. 
1.3. Standard of Care and Rationale for the Use of Efgartigimod 
Several drugs and medical procedures are routinely used in the management of gMG. 
Acetylcholinesterase (AChE) inhibitors are freque ntly used in treating MG, particularly in the 
mild forms of the disease. These agents include drugs such as pyridostigmine, neostigmine, and 
edrophonium, and their effectivene ss varies widely. These drugs act by [CONTACT_202028], which is responsible for the degradation of acetylcholine. This prolongs acetylcholine 
exposure, which leads to an amelioration of the signs/symptoms of MG. AChE inhibitors provide 
a symptomatic treatment of MG and do not act on the disease's underlying pathogenic 
mechanism. AChE inhibitors are not efficacious  in all patients with MG and can have a short 
duration of action, necessitating dosing several times daily. 
Corticosteroids and non-steroidal immunosuppressive drugs (NSIDs) are also used in the 
treatment of MG. These drugs are frequently used in the more advanced stage of the disease. 
Corticosteroids and NSIDs are typi[INVESTIGATOR_201989]. Because of 
their multiple side effects, the lowest effective dose of corticosteroids is recommended for long-term treatment that is often indicated for chronic conditions such as MG. NSIDs are commonly used and include azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. 
The use of corticosteroids and NSIDs however is  associated with dose-dependent, frequent and 
often serious side effects whose management requires to lower the dose and to use these drugs in various combinations to find the right balance between efficacy and side effects.
2,3  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 40 Apart from the SoC described a bove, new biologic agents such as rituximab and eculizumab are 
also used to treat specific cases of MG, such as resistant and refractory forms. However, the use 
of these drugs is also associated with serious  and sometimes life-threatening side effects.11,12  
Exacerbations of MG are treated using either therapeutic plasma exchange (PLEX), 
immunoadsorption or IVIg. In the case of PLEX, typi[INVESTIGATOR_897] 1 exchange, removing 1 to 2 plasma 
volumes, is done every other day up to a total of 4 to 6 times, to improve muscle strength or 
ameliorate a myasthenic crisis. Unfortunately, this treatment is invasive and has frequent side 
effects such as hypotension, paresthesia, infections, and thrombotic complications. IVIg is widely used for patients with exacerbating MG . The mechanism of action of IVIg in MG is still 
unclear and may include interference with autoantibodies, B-cell modulation, saturation of FcRn 
and complement.
13,14 In addition, the use of IVIg is burdensome for the patient. 
These approaches however are not always availabl e in all clinical centers since they require 
specific facilities and instrumentation.2,3 
Finally, in selected cases, surgical removal of the thymus gland is also used to ameliorate the 
clinical manifestations of MG. However, thymectomy is not always effective in all patients and is associated with surgery-specific risks.
2,3,15,16 
Following administration of efgartigimod (10 mg/kg)  in 4 infusions administered 1 week apart in 
addition to SoC in patients with autoimmune MG  with generalized muscle weakness in the phase 
2 trial (ARGX-113-1602, also see Section 1.2), overall efgartigimod was well tolerated and 
demonstrated a good safety profile consistent with  phase 1 data. No serious or severe AEs were 
reported. The following events were reported as related to efgartigimod administration: 
rhinorrhea, gingivitis, headache, nausea, pruritus, paresthesia, myalgia, lymphocyte count 
decreased, monocyte count decreased, neutrophi l count decreased, contusion, feeling hot, 
infusion site pain and pruritus, and herpes zoster. All these events were reported as mild, except 
the herpes zoster, which was considered as moderate and occurred in a patient concomitantly 
treated with a systemic corticosteroid and NSID. Ef gartigimod demonstrated a relevant and long-
lasting improvement over placebo of the clinical manifestations of MG as measured by [CONTACT_21129] 4 
clinical efficacy MG scales, which reached statistical significance at specific timepoints on the 
MG-ADL, QMG, and MGQoL15r scales. Pharmac okinetic, PD, and immunogenicity profiles 
were consistent with phase 1 data. In addition, a potent and long-lasting reduction of AChR 
autoantibodies was observed. 
Myasthenia gravis is considered a highly autoantibody driven disease. Efgartigimod is a highly 
targeted therapy postulated to result in reduced  autoantibody levels. Results from the phase 2 
trial indicate that it induces a strong and long-lasting improvement of the disease as measured by 
[CONTACT_202029] a favorable safety profile. Furthermore, this clinical 
improvement was consistent with the observed PD data, namely a reduction of total IgG and subtypes and a decreased level of AChR autoanti bodies. Therefore, efgartigimod is believed to 
be a promising treatment to reduce autoantibodies in gMG patients. 
1.4. Benefit-Risk Assessment 
Benefits 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241029] of efgartigimod was explored us ing clinical activity tools commonly used in 
MG clinical research and practice: total MG-ADL, QMG, MGC, and MG-QoL15r scores. A 
mean total score change from baseline in  total MG-ADL, QMG, MGC, and MG-QoL15r scores 
was observed as early as day 8 in patients treated with efgartigimod. A long-lasting reduction in 
total MG-ADL and MGC scores was observed, with  the reduction in total scores still seen at 
day 78 (end of study [EoS]). Efgartigimod showed  a statistically significant reduction in total 
MG-ADL, QMG, and MG-QoL15r scores compared with placebo at specific time points, 
indicating a clinical improvement in efgartigimod treatment over placebo. For all MG scales, a 
greater maximum mean change from baseline  (reduction) was observed in the efgartigimod 
treatment group compared with placebo. 
Eligible participants of trial ARGX-113-1704 will be  offered the option to roll over to this 
follow-on trial where (re- )treatment of efgartigimod can be done on an ‚Äúas needed basis ,‚Äù which 
is a substantial benefit for the patient. 
Patients who have completed at least [ADDRESS_241030] arisen in the on going and completed trials, nor any pattern of AEs 
which would raise concerns or alter the poten tial benefit-risk profile of efgartigimod.  
In the phase 3 trials in patients with gMG, the majority of TEAEs were reported as mild (grade 
1) or moderate (grade 2) in severity. The most frequently ( ‚â•5%) reported TEAE s during all 
cycles of efgartigimod 10 mg/kg treatment in the overall population who received at least [ADDRESS_241031] infection, nausea, myalgia, and orophar yngeal pain. TEAEs of severity of grade ‚â•3 
that occurred in >2 patients who received efgartigimod were headache and myasthenia gravis. 
The only TEAE that led to efgartigimod discontinuation reported in >[ADDRESS_241032] frequently report ed treatment-emergent AESIs by [CONTACT_11702] 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 42 (PT) were nasopharyngitis, upper respi[INVESTIGATOR_1092], urinary tract infection, and 
bronchitis. Most AESIs were mild or moderate in severity. Few patients had severe or serious 
AESIs reported, and no SAEs of AESIs were assessed by [CONTACT_202030]. 
All therapeutic proteins have the potential to el icit immune responses, potentially resulting in 
hypersensitivity or allergic reactions. As with any IV injection, the potential exists for infusion-
related reactions (IRRs) to occur during or within [ADDRESS_241033] frequently reported grade ‚â•3 abnormalities were lymphocyte count decreased.  
No clinically significant changes in vital signs and/or electrocardiogram (ECG) findings have been observed in clinical trials to date.  
Safety for use during pregnancy has not been established. Therefore, efgartigimod should not be 
administered to pregnant or lactating women. 
In summary, efgartigimod has been well to lerated in clinical trials conducted to date. 
Please refer to the current investigator‚Äôs brochur e (IB) for a full safety and efficacy summary.  
An independent Data Safety Monitoring Boa rd (DSMB) is responsible for ongoing safety 
monitoring during the trial and will meet on a regular basis (see Section  7.2.6). 
Considering the efficacy and safety data collected up to date and the design of the trial that has 
appropriate measures to ensure safe trial partic ipation, which minimizes the risk to patients 
participating in this trial, the potential risks identified in association with efgartigimod are justified by [CONTACT_202031]. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 43 2. TRIAL OBJECTIVES 
2.1. Primary Objective 
To evaluate the long-term safety and tolerabi lity of efgartigimod in acetylcholine receptor 
antibody (AChR-Ab) seropositive patients.  
2.2. Secondary Objective 
To evaluate the long-term safety and tolerability of efgartigimod in the overall population 
(AChR-Ab seropositive and AChR -Ab seronegative patients). 
2.3. Tertiary Objectives 
Part A only: 
x To evaluate the disease severity as assessed by [CONTACT_202014]-ADL score changes in AChR-Ab seropositive patients. 
x To evaluate the disease severity as assessed by [CONTACT_202014]-ADL score changes in the overall population (AChR-Ab seropositive patients and AChR-Ab seronegative 
patients). 
x To evaluate disease severity as assessed by [CONTACT_202032]-Ab seropositive patients. 
x To evaluate disease severity as assessed by [CONTACT_202033] (AChR-Ab seropositive patients and AChR-Ab seronegative patients). 
x To evaluate the effect of efgartigimod on PD (total IgG, IgG subtypes, autoantibodies [anti-AChR antibodies and anti-MuSK antibodies]). 
Part A and B: 
x To evaluate the immunogenicity of efgartigimod. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 44 3. TRIAL ENDPOINTS 
3.1. Primary Endpoint 
Incidence and severity of AEs, serious adverse events (SAEs), vital signs, ECG and laboratory 
assessments over the duration of the trial in AChR-Ab seropositive patients. 
3.2. Secondary Endpoint 
Incidence and severity of AEs, SAEs, vital si gns, ECG and laboratory assessments over the 
duration of the trial in the overall population (AChR-Ab seropositive patients and AChR-Ab seronegative patients). 
3.3. Tertiary Endpoints 
Part A only: 
x Total MG-ADL score changes compared to the treatment period baseline of the first cycle (TP
1B) and the corresponding TP nB in AChR-Ab seropositive patients. 
x Total MG-ADL score changes compared to TP 1B and the corresponding TP nB in the 
overall population (AChR-Ab seropositive and AChR-Ab seronegative patients). 
x Total QMG score changes compared to TP 1B and the corresponding TP nB in AChR-
Ab seropositive patients. 
x Total QMG score changes compared to TP 1B and the corresponding TP nB in the 
overall population (AChR-Ab seropositive and AChR-Ab seronegative patients). 
x Percentage decrease (compared to TP 1B and the corresponding TP nB) of total IgG 
level and IgG subtypes in efgartigimod (re-)treated patients. 
x Percentage decrease (compared to TP 1B and the corresponding TP nB) of 
autoantibodies (anti-AChR antibodies a nd anti-MuSK antibodies) in efgartigimod 
(re-)treated patients. 
Part A and B: 
x Incidence and prevalence of anti-dru g antibodies (ADA) to efgartigimod. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 45 4. INVESTIGATIONAL PLAN 
4.1. Summary of Trial Design 
Methodology 
DESCRIPTION 
This is a 3-year (maximum), single-arm, open-label, multicenter, phase 3 follow-on trial of 
ARGX-113-1704 to evaluate the long-term safety and tolerability of efgartigimod in patients 
with gMG. The trial consists of 2 parts: Part A (1 year) and Part B (up to maximum [ADDRESS_241034]. The a dditional part (Part B) was added to ARGX-113-
[ADDRESS_241035] access to efgartigimod while it is not yet commercially available or available through another patient program. This extension will 
also enable additional long-term safety and tolerability data to be collected. 
A variable number of treatment periods consisting of 4 weekly infusions of efgartigimod 
(10 mg/kg of body weight) infused over a period of 3 weeks will be administered to eligible 
patients on an ‚Äúas needed basis‚Äù on t op of their SoC. The time between treatment periods is 
based on the duration of the treatment effect and may vary from patient to patient and within 
each patient from period to period (patient-tailored approach). 
The first visit of trial ARGX-113-[ADDRESS_241036] trial visit, while the baseline of each subsequent treatment period 
(TP
nB for Part A or TPE nB for Part B) will be set at visit 1 of each corresponding treatment 
period. 
ROLL-OVER 
At the EoS visit of trial ARGX-113-1704, eligible patients will be offered the option to roll over 
into this trial. Patients in need of (re-)treatment in trial ARGX-113-[ADDRESS_241037] started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to 
receive efgartigimod by [CONTACT_202012]. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241038] complete the early 
discontinuation (ED) visit assessments specified in Table 2. The previous efgartigimod IV dose 
must have been received at least 30 days before entry into ARGX-113-2002. 
Patients can enroll in ARGX-113- 2002 until recruitment for this study is closed. Patients who 
enroll in ARGX-113-2002 will not return to ARGX-113-1705. 
(RE-)TREATMENT (Part A) 
Each patient will start a (new) treatment peri od with efgartigimod when all of the following 
criteria are met:  
x The patient has completed the previous treatment period (ie, after visit 4) 
x The patient has a total MG- ADL score of ‚â•5 points with more than 50% of the total 
score due to non-ocular symptoms 
x The patient has a reduction in the total MG-ADL score of <2 points compared to the 
score at: 
1. The last treatment cycle baseline (TCB)  in trial ARGX-113-[ADDRESS_241039] 
treatment period (TP 1) in trial ARGX-113-[ADDRESS_241040] treatment period Baseline (TP nB) for all subsequent treatment periods 
(TP n+1) in trial ARGX-113-1705 
However, patients may not receive (re-)treatment with efgartigimod if, at the time of (re-)treatment, they have clinical evidence of bacterial, viral or fungal disease, or any other 
significant disease which could confound the resu lts of the trial or put patients at undue risk. 
Patients who require an additional treatment but w ho are not eligible to receive (re-)treatment for 
the reasons listed here will remain in the tria l to receive appropriate alternative MG treatment 
(see Appendix 5 and Appendix 6).  
Patients who have a treatment failure to efgartig imod for [ADDRESS_241041] 50% of the assessments 
(ie, TP nV2, TP nV3, TP nV4, and the first posttreatment period visit).  
If a patient becomes eligible for (re-)treatment with efgartigimod by [CONTACT_202034]-ADL score as stated in Section 4.1, but cannot complete the entire treatment period 
during Part A (ie, after day 336) then the patient can be transitioned to Part B after completing 
the end of Part A (EoA) visit assessments ( Table 1 ). These assessments should be completed 
even if the patient is unwilling or unable to continue to Part B. 
The transition to Part B can be either at ITPE 0Vn or TPE 1V1, depending on the patient status 
regarding the need for (re-)treatment upon transition from Part A. The first visit in Part B will 
always coincide with the EoA visit in Part A. The assessments done for the last visit in Part A should not be repeated in Part B. 
(RE-)TREATMENT (Part B) 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 47 If the patient feels that his/her condition has deteriorated, then the investigator may start a new 
treatment period at an intertreatment period (ITPE) visit or the patient may contact [CONTACT_202035]. 
A patient can start the next treatment period a nd receive efgartigimod if all of the following 
criteria are met:  
x The patient has completed the previous treatment period (ie, after visit 4)* 
x The investigator determines that the patient will benefit from re-treatment 
x There is at least 1 calendar month (minimum 4 weeks) between treatment periods (ie, 
between TPE nV4 and TPE n+1V1) 
*A patient who has had a temporary interruption of trial treatment in Part A may also continue 
into Part B of the trial and receive (re- )treatment if the conditions in Section 4.4.1  are met. 
However, patients may not receive (re-)treat ment with efgartigimod if, at the time of 
(re-)treatment, they have clinical evidence of bacterial, viral or fungal disease, or any other significant disease which could confound the resu lts of the trial or put patients at undue risk. 
If a patient becomes eligible for (re-)treatment with efgartigimod but cannot complete the entire 
treatment period within the duration of the trial, the patient should continue to the EoS visit. 
If the investigator considers that the patient will  not have a clinical benefit from (re-)treatment 
then the patient cannot start a new treatment perio d. The patient should then continue to the EoS 
visit. 
STANDARD OF CARE (SoC) 
In Part A: 
Permitted SoC for MG treatment under this protocol include NSIDs (eg, azathioprine, 
methotrexate, cyclosporine, tacrolimus, myc ophenolate mofetil, and cyclophosphamide), 
steroids, as well as acetylcholinesterase (AChE) inhibitors.  
A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment 
of the SoC dose and/or frequency) is not allowed: 
x From trial entry until [ADDRESS_241042] 12 hours prior to performing the 
QMG assessment. Following this requirement, this possible temporary change in dosing regimen 
of AChE inhibitors will not be considered as a change in SoC. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 48 In Part B: 
A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment 
of the SoC dose and/or frequency) is allowed, without restrictions, following current medical practice. 
PLEX, intravenous immunoglobulin (IVIg), immunoadsorption or use of a new type of 
corticosteroid or an increased dose of the current corticosteroids used as stand-alone therapy or in combination is also allowed in Part B. 
TIME BETWEEN TREATMENT PERIODS 
At the end of each treatment period, patients will enter a variable intertreatment period during 
which they will be treated with their SoC only.  The length of the intertreatment period may vary 
from patient to patient and for each patient from period to period (patient-tailored approach). For 
Part A, the visit frequency in the Intertreatment period is every 30 days (¬± 2 days) after the previous visit. For Part B, the visit frequency in  the intertreatment period is every 90 days (¬± 7 
days) after the previous visit. If an ITP visit for  Part A is scheduled within 14 days of the EoA 
visit, then the EoA visit should be performed instead. 
RESCUE THERAPY (Part A only) 
Rescue therapy will be limited to PLEX, IVI g, immunoadsorption or use of a new type of 
corticosteroid or an increased dose of the current corticosteroids used as stand-alone therapy or 
in combination. Rescue therapy is permitted fo r patients experiencing protocol-defined MG 
clinical deterioration AND if in addition the treati ng physician believes that the patient‚Äôs health 
is in jeopardy if rescue therapy is not given. An MG clinical deterioration permitting rescue therapy to be given is defined as a patient expe riencing at least 1 of the following: (1) new or 
worsening of respi[INVESTIGATOR_696] / bulbar symptoms or (2) at least 2-point increase of individual non-ocular MG-ADL items. Whenever possible, prior to giving rescue therapy to a patient, the Medical Director at the sponsor and the Medical Monitor at the sponsor‚Äôs designated contract 
research organization (CRO) should be informed. 
In situations where the treatments as listed above are given under the protocol-defined
 rescue 
criteria, patients will be discontinued early from the trial. 
EARLY DISCONTINUATION  
For patients who discontinue early from trial, the assessments will depend on the visit at which it 
was decided that the patient had to discontinue (see Section 5.4, Figure 1,  and Figure 2 ). 
Patients who discontinue early from the tria l within a treatment period should perform the 
planned assessments of the corresponding treatment period visit. These patients will not receive any further administration of efgartigimod durin g the trial and will return for the ED visit 1 
month (30 ¬± 2 days) after the last dose administra tion. An unscheduled visit can be organized if 
deemed necessary by [CONTACT_093]. 
Patients who discontinue early from the trial between the last visit of a treatment period (TP
nV4 
or TPE nV4) and the next intertreatment period visit (ITP nVn or ITPE nVn) should perform the ED 
assessments 1 month (30 ¬± 2 days) after the last dose administration. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 49 Patients who discontinue early from the trial at the ITP (Part A) or ITPE (Part B) visit should 
perform the ED assessments  instead of the ITP nVn (Part A) or ITPE nVn (Part B) assessments. 
Patients who discontinue early from the trial afte r the ITP (Part A) or ITPE (Part B) visit should 
perform the ED assessments. 
Any patient prematurely discontinuing the trial during Part A should perform the EoA/ED 
assessments according to the General Schedule of Assessments for Part A ( Table 1 ). Any patient 
prematurely discontinuing the trial during Part B should perform the EoS/ED assessments for Part B ( Table 2). 
Before enrolling in ARGX-113-[ADDRESS_241043] complete the early 
discontinuation (ED) visit assessments specified in Table 2. The previous efgartigimod IV dose 
must have been received at least [ADDRESS_241044] to complete the current treatment period and 
will continue the trial as per the Gene ral Schedule of Assessments for Part A ( Table 1 ) or for 
Part B ( Table 2) but without drug administration. A patient who has had a temporary interruption 
of trial treatment in Part A may also continue into Part B of the trial and receive (re-)treatment if 
the conditions mentioned above are met. 
A schematic of the trial design is presented in Figure 1  for Part A and in Figure 2  for Part B. 
4.2. Discussion of Trial Design 
In the current trial, efgartigimod will be admi nistered in patients with gMG, with the aim to 
evaluate the long-term safety and tolerability of efgartigimod.  This trial is designed as a 3-year (maximum), single-arm, open-label, follow-on trial of 
ARGX-113-1704. The trial consists of 2 parts: Part A (1 year) and Part B (up to maximum 
[ADDRESS_241045]. The additional part (Part B) was added 
to ARGX-113-[ADDRESS_241046] started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to 
receive efgartigimod by [CONTACT_202012]. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241047] visit of Part A for each patient. 
Efgartigimod will be administered to eligible patients on an ‚Äúas needed basis‚Äù on top of their 
SoC in treatment periods. This SoC serves as a rational therapeutic approach for IgG-mediated 
immune diseases such as MG by [CONTACT_202036]-IgG interaction and alleviating autoimmune disease symptoms by [CONTACT_28423][INVESTIGATOR_201990]. The time between treatment 
periods is based on the duration of the treatment ef fect and may vary from patient to patient and 
within each patient from period to  period (patient-tailored approach). 
In Part A, a change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment of the SoC dose and/or frequency) is not allowed from trial entry until [ADDRESS_241048] infusion of the next treatment 
period, a dose reduction in SoC consistent with  current medical practice is allowed. 
In Part B, a change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or 
adjustment of the SoC dose and/or frequency) is allowed without restrictions, following current 
medical practice. 
PLEX, IVIg, immunoadsorption or use of a new type of corticosteroid or an increased dose of 
the current corticosteroids used as stand-alone ther apy or in combination is also allowed in Part 
B. 
The chosen primary and secondary endpoints in this  trial are to evaluate the long-term safety and 
tolerability of efgartigimod over the duration of the trial, as well as by [CONTACT_5265], in AChR-Ab 
seropositive patients and in the overall population (AChR-Ab seropositive and seronegative patients). 
Both MG AChR-Ab seropositive as well as MG AC hR-Ab seronegative patients will be included 
in the trial. AChR-Ab seronegati ve patients are patients in which AChR-Ab cannot be detected 
in serum using routine laboratory methods. However, there is evidence that in these seronegative 
patients, MG is also driven by [CONTACT_202037], such as MuSK, LRP4 or by 
[CONTACT_202038]. In addition, in other cases, the absence of AChR-Ab may be due to the insufficient sensitivity of the 
routine assays which are unable to detect low affinity autoantibodies. Therefore, given the 
mechanism of action of efgartigimod and the Ig G pathogenesis of MG in most of the so-called 
seronegative patients, there is reason to believe that, similarly to the AChR-Ab seropositive 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 51 patients, AChR-Ab seronegative pati ents will also benefit from tr eatment with efgartigimod. The 
dose regimen selected for this trial is the same as in trial ARGX-113-1704.  
The choice of the dose/regimen of efgartigimod (4 weekly infusions of 10 mg/kg) was made 
because, as observed in a phase 1 trial in human volunteers, it causes a marked and long-lasting 
decrease of IgG level believed to be related to efficacy with only few mild AEs. In the same trial, 
higher doses did not result in significant further reductions of IgG while, at the same time, the number of subjects experiencing efgartigimod-rel ated AEs increased. On the other hand, a lower 
dose of 2 mg/kg resulted in substantially less reduction of IgG concentrations (2.3-fold difference in maximum IgG decrease). As suggested by [CONTACT_36532]/PD modeling, lower doses (eg, 5 mg/kg) will result in a less marked decrease of the IgG level and therefore may result in a 
less pronounced therapeutic effect. In addition, in a phase 2 trial (ARGX-113-1602) in patients 
with gMG, the dose/regimen chosen for the current trial induced a clinically meaningful improvement on the MG-ADL and QMG scales and, at  the same time, confirming the acceptable 
safety profile of the drug. Therefore, the dose of 10 mg/kg of efgartigimod administered weekly for [ADDRESS_241049] benefit/risk ratio and was selected for future trials.  
All safety and disease severity assessments used  in this trial are standard, ie, widely used and 
generally recognized as reliable, accurate, and relevant. 
4.3. Selection of Trial Population 
4.3.1. Inclusion Criteria 
Patients will roll over in this trial only if they meet all of the following criteria: 
1. Patients with the ability to understand the requirements of the trial, provide 
written informed consent, and can comply with the trial protocol procedures. 
2. Patients who participated in trial ARGX-113-1704 and are eligible for roll over, ie: 
 Patients who reached EoS at day 182 in trial ARGX-113-1704. 
 Patients who need (re-)treatment in trial ARGX-113-1704 but cannot complete a 
Treatment Cycle within the time frame of that trial may immediately roll over into this trial to receive treatment with efgartigimod. 
 Patients who discontinued early from randomized treatment for other reasons than 
pregnancy, rescue therapy or an (S)AE in trial ARGX-113-1704 may be offered 
the option to roll over into this trial. 
 Patients who had a temporary interruption from randomized treatment in trial ARGX-113-1704 may be offered the option to roll over into this trial. 
3. Patients are required to be on a stable dose of their MG treatment (SoC) prior to SEB. The SoC is limited to AChE inhibitors, steroids and NSIDs (eg, azathioprine, methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil, and cyclophosphamide). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 52 Note: AChE inhibitors must be withheld for at least [ADDRESS_241050] as recommended by [CONTACT_202039] (MGFA), 
before the QMG assessment. 
4.3.2. Exclusion Criteria 
Patients will not roll over in this trial if they meet any of the following criteria: 
1. Patients who discontinued early from trial ARGX-113-[ADDRESS_241051] dosing. Women of childbearing potential 
(DEFINITION OF TERMS ) should have a negative urine  pregnancy test at SEB. 
The contraceptive requirements for women of childbearing potential are described 
in Appendix 8:Temporary Changes to Study Procedures in ARGX-113-[ADDRESS_241052] patient safety, while still being able to gather additional data.  
The risk/benefit, safety profile, guidance for site conduct in terms of visits and assessments, as 
well as data entry, and potential changes in th e Schedule of Assessments are included below. 
Safety of Efgartigimod: Mechanism of Action , Pharmacodynamics and Risk/Benefit in  
Patient Safety 
Efgartigimod administration results in a targe ted reduction in levels of all IgG subtypes. 
However, and more importantly, it does not impact levels of other immunoglobulin isotypes, 
such as IgA and IgM. Other elements of the immune system are not impacted by [CONTACT_202040]. 
Efgartigimod induces a targeted reduction of Ig G levels, without impacting IgG production. The 
maximum mean reduction in total IgG is approximately 70%; therefore, residual IgG and other 
immunoglobulin levels remain consta nt during treatment. It is therefore anticipated that patients 
can mount an immune response. In support of this, experiments in FcRn knockout animals and in 
animals treated with FcRn antagonist demonstrated that a specific immune response was 
obtained following an antigen trigger, albeit with reduced (antigen-specific) IgG titers. Additionally, after ceasing efga rtigimod treatment, IgG recycling returns and total IgG levels 
increase and return to baseline levels within a few weeks. 
Looking at administration in humans, efgartigimod treatment at doses ‚â•10 mg/kg have been 
administered to more than 120 healthy volunteers  and patients with generalized myasthenia 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 53 gravis (gMG), immune thrombocytopenia, and pemphigus in studies carried out prior to phase [ADDRESS_241053] not identified any increased risk of 
infection. 
 
ADAPT/ADAPT+: Pre-existing Safety Measures  and Changes to Be Implemented in the 
Current Situation 
The phase [ADDRESS_241054] (AESI) and 
is subject to structured safety reporting with standardized questions in the eCRF. 
The current COVID-19 situation warrants new measures to be introduced for patient safety. 
These measures will allow patients to be evaluated remotely if/when quarantine is imposed. For 
example, any remaining visits in an interrupted Treatment Period, may be performed remotely, in 
cases where the patient is not allowed or cannot physically visit the site. These measures respect both patient safety and local guidance, as well as  allowing basic safety data to be collected. 
The assessments identified for telephone assessment visits are highlighted with the use of bold italics in the existing Schedu le of Assessments for Part A in Table 1  and for Part B in Table 2. 
Guidance on the execution of these visits and assessments is given below. 
By [CONTACT_1541] a structured back-up plan, we aim to mitigate the risks of the COVID-19 pandemic, 
while still respecting both patient safety and co llection of safety data and remaining compliant 
with GCP. 
 
Visits with the possibility of remote assessment by [CONTACT_756]: 
TPxV2, TPE xV2, TP xV3, TPE xV3, TP xV4, TPE xV4, ITP xVx, ITPE xVx, EoA, EoS, ED, and 
UNS. See the Schedule of Assessments for Part A (Table 1) and for Part B ( Table 2 ). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 54 Treatment Period visits will be replaced by  [CONTACT_202041]-19 situation when the Treatment Period is considered interrupted.  
 
Mandatory physical visits: 
Initiating a new Treatment Period can only be done when the patient is physically on site. 
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241055] the following COVID-19 
assessments:  
1. Does the patient have symptoms, such as cough, fever, muscle pain, shortness of breath *? 
- If NO: Go to Questions 2 and 3. 
- If YES: 
‚Ä¢ The patient should b e tested for COVID-19:  
The investigator needs to document a positive COVID-[ADDRESS_241056] as an AESI. The anonymized 
result needs to be sent to the sponsor for filing. If COVID-19 safety measures are stopped 
according to local regulations, COVID-19 tests should continue to be performed and the 
results sent to the sponsor. 
*Shortness of breath includes an otherwise une xplained deterioration in the patient‚Äôs MG -
ADL score for breathing. In cases where the MG-ADL score for breathing is [ADDRESS_241057] to be interrupted. A new treatment 
cycle may be initiated later. Remaining visits in the Treatm ent Period can be performed 
as telephone assessment visits.  
‚Ä¢ If the patient is tested and found to be COVID -19 negative:  
The patient can come to the next visit as sche duled. Follow-up of the patient should be done 
according to the protocol (decision to be take n if treatment can be given or is to be 
postponed). 
‚Ä¢ If the patient is tested and found to be COVID -19 positive:  
The patient can only come to the site once he/she has a negative test for COVID-19, and so the planned visit may need to be rescheduled or replaced by a telephone assessment visit. If 
the patient was in a treatment cycle, the treatment will have to be interrupted. A new 
treatment cycle may be initiated later. The remaining visits in the Treatment Period can 
be replaced by [CONTACT_202042].  
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241058] he/she may have 
had with someone who tested positive for COVID-19:  
‚Ä¢ The visit can proceed as planned. If the patient cannot physically come to the clinic due to the 
local COVID-[ADDRESS_241059] with someone who tested 
positive for Corona virus: 
‚Ä¢ If the contact [INVESTIGATOR_30647] 14 days or longer before the study visit => the visit can go ahead as planned. 
If the patient cannot physically come to the clinic due to the local COVID-19 situation, the visit can be replaced by a telephone assessment visit. 
‚Ä¢ If the contact [CONTACT_202043] 14 days before the study visit => the visit needs to be rescheduled at 
least [ADDRESS_241060] occurred or be replaced by a telephone assessment visit. 
 
How to: Information related to study procedures and data collection 
The assessments deemed suitable for telephone consultation are: 
x Re-consenting where warranted, MG-ADL, Adverse Event and Concomitant 
Medication questioning.  
Since QMG needs quantification by [CONTACT_202044] n, using specific equipment, such as a 
dynamometer and spi[INVESTIGATOR_14007], this assessment is not deemed suitable for telephone assessment.  
Telephone consultation will allow safety data to be  collected and to check on the patient‚Äôs well -
being, while the derived MG-ADL score may give an indication of the need for another 
treatment with efgartigimod. 
Re-consenting with the updated ICF, or cons ent to Part B of the ADAPT+ study can be done 
remotely in view of the COVID-19 situation.  
Options for consent might entail: 
x physical signature [CONTACT_3265] [CONTACT_202045] a phone 
call with the patient, then having the signed document sent back to the site. 
x phone call with the patient, asking for email confirmation to corroborate verbal consent. 
x organize a conference call or video call tog ether with the patient and impartial 
witness, where needed. 
x if no phone call or video call is possible, email documented consent. 
Depending on regional requirements the options can be limited, after consultation with the relevant IRB/IEC and/or regulatory authority. 
Data collected during a telephone assessment visit can be entered into the e-CRF pages of the 
corresponding ‚Äúmissed‚Äù visit. Enter the date of th e phone call as the ‚Äúdate of visit‚Äù and enter the 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 57 data obtained in the applicable CRF pages. For the assessments that are not performed, answer 
‚Äúno‚Äù to the question if the assessment was made in the respective forms. Add ‚ÄúCOVID -19 
telephone‚Äù in the comment section of the CRF.  
If you are not able to contact [CONTACT_102], inacti vate the full study visit in the CRF and confirm 
the missing visit in the comments section as ‚ÄúCOVID -19.‚Äù 
Other than conducting telephone assessments, there may be other changes in the current practice 
on site. Halting spi[INVESTIGATOR_201991]-19 patients may be required, or only allowing use of a 
dedicated spi[INVESTIGATOR_201992] (for contamination reasons).  There can be a temporary halt in 
performing this assessment, or conducting a partial assessment is also permitted. 
In order to give a clear overview of protocol deviations related to the specific COVID-[ADDRESS_241061] been created to which any 
missed visit or assessment can be attributed.  
 
3. APPENDIX 9. 
4. Male patients who are sexually active a nd do not intend to use effective methods 
of contraception (as mentioned above) during the trial or within [ADDRESS_241062] dosing. The contraceptive requirements for male patients are described in Appendix 8: Temporary Changes to Study Procedures in ARGX-
113-[ADDRESS_241063] patient safety, while still being able to gather additional data.  
The risk/benefit, safety profile, guidance for site conduct in terms of visits and assessments, as 
well as data entry, and potential changes in th e Schedule of Assessments are included below. 
Safety of Efgartigimod: Mechanism of Action , Pharmacodynamics and Risk/Benefit in  
Patient Safety 
Efgartigimod administration results in a targe ted reduction in levels of all IgG subtypes. 
However, and more importantly, it does not impact levels of other immunoglobulin isotypes, 
such as IgA and IgM. Other elements of the immune system are not impacted by [CONTACT_202040]. 
Efgartigimod induces a targeted reduction of Ig G levels, without impacting IgG production. The 
maximum mean reduction in total IgG is approximately 70%; therefore, residual IgG and other 
immunoglobulin levels remain consta nt during treatment. It is therefore anticipated that patients 
can mount an immune response. In support of this, experiments in FcRn knockout animals and in 
animals treated with FcRn antagonist demonstrated that a specific immune response was 
obtained following an antigen trigger, albeit with reduced (antigen-specific) IgG titers. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 58 Additionally, after ceasing efga rtigimod treatment, IgG recycling returns and total IgG levels 
increase and return to baseline levels within a few weeks. 
Looking at administration in humans, efgartigimod treatment at doses ‚â•10 mg/kg have been 
administered to more than 120 healthy volunteers  and patients with generalized myasthenia 
gravis (gMG), immune thrombocytopenia, and pemphigus in studies carried out prior to phase [ADDRESS_241064] not identified any increased risk of 
infection. 
 
ADAPT/ADAPT+: Pre-existing Safety Measures  and Changes to Be Implemented in the 
Current Situation 
The phase [ADDRESS_241065] (AESI) and is subject to structured safety reporting with standardized questions in the eCRF. 
The current COVID-19 situation warrants new measures to be introduced for patient safety. 
These measures will allow patients to be evaluated remotely if/when quarantine is imposed. For 
example, any remaining visits in an interrupted Treatment Period, may be performed remotely, in cases where the patient is not allowed or cannot physically visit the site. These measures respect 
both patient safety and local guidance, as well as  allowing basic safety data to be collected. 
The assessments identified for telephone assessment visits are highlighted with the use of bold 
italics in the existing Schedu le of Assessments for Part A in Table 1  and for Part B in Table 2. 
Guidance on the execution of these visits and assessments is given below. 
By [CONTACT_1541] a structured back-up plan, we aim to mitigate the risks of the COVID-19 pandemic, 
while still respecting both patient safety and co llection of safety data and remaining compliant 
with GCP. 
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 59 Visits with the possibility of remote assessment by [CONTACT_756]: 
TPxV2, TPE xV2, TP xV3, TPE xV3, TP xV4, TPE xV4, ITP xVx, ITPE xVx, EoA, EoS, ED, and 
UNS. See the Schedule of Assessments for Part A (Table 1) and for Part B ( Table 2 ). 
Treatment Period visits will be replaced by  [CONTACT_202041]-19 situation when the Treatment Period is considered interrupted.  
 
Mandatory physical visits: 
Initiating a new Treatment Period can only be done when the patient is physically on site. 
 
Guidance to Sites in Case of Su spected COVID-[ADDRESS_241066] the following COVID-19 
assessments:  
1. Does the patient have symptoms, such as cough, fever, muscle pain, shortness of breath *? 
- If NO: Go to Questions 2 and 3. 
- If YES: 
‚Ä¢ The patient should b e tested for COVID-19:  
The investigator needs to document a positive COVID-[ADDRESS_241067] as an AESI. The anonymized 
result needs to be sent to the sponsor for filing. If COVID-19 safety measures are stopped 
according to local regulations, COVID-19 tests should continue to be performed and the 
results sent to the sponsor. 
*Shortness of breath includes an otherwise une xplained deterioration in the patient‚Äôs MG -
ADL score for breathing. In cases where the MG-ADL score for breathing is [ADDRESS_241068] to be interrupted. A new treatment 
cycle may be initiated later. Remaining visits in the Treatm ent Period can be performed 
as telephone assessment visits.  
‚Ä¢ If the patient is tested and found to be COVID -19 negative:  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 60 The patient can come to the next visit as sche duled. Follow-up of the patient should be done 
according to the protocol (decision to be take n if treatment can be given or is to be 
postponed). 
‚Ä¢ If the patient is tested and found to be COVID -19 positive:  
The patient can only come to the site once he/she has a negative test for COVID-19, and so 
the planned visit may need to be rescheduled or replaced by a telephone assessment visit. If 
the patient was in a treatment cycle, the treatment will have to be interrupted. A new treatment cycle may be initiated later. The remaining visits in the Treatment Period can 
be replaced by [CONTACT_202042].  
 
2. The patient has no Corona-like symptoms and is not aware of any contact [CONTACT_202046]/she may have 
had with someone who tested positive for COVID-19:  
‚Ä¢ The visit can proceed as planned. If the patient cannot physically come to the clinic due to the local COVID-[ADDRESS_241069] with someone who tested 
positive for Corona virus: 
‚Ä¢ If the contact [INVESTIGATOR_30647] 14 days or longer before the study visit => the visit can go ahead as planned. 
If the patient cannot physically come to the clinic due to the local COVID-19 situation, the visit can be replaced by a telephone assessment visit. 
‚Ä¢ If the contact [CONTACT_202043] 14 days before the study visit => the visit needs to be rescheduled at 
least [ADDRESS_241070] occurred or be replaced by a telephone assessment visit. 
 
How to: Information related to study procedures and data collection 
The assessments deemed suitable for telephone consultation are: 
x Re-consenting where warranted, MG-ADL, Adverse Event and Concomitant 
Medication questioning.  
Since QMG needs quantification by [CONTACT_202044] n, using specific equipment, such as a 
dynamometer and spi[INVESTIGATOR_14007], this assessment is not deemed suitable for telephone assessment.  
Telephone consultation will allow safety data to be  collected and to check on the patient‚Äôs well -
being, while the derived MG-ADL score may give an indication of the need for another 
treatment with efgartigimod. 
Re-consenting with the updated ICF, or cons ent to Part B of the ADAPT+ study can be done 
remotely in view of the COVID-19 situation.  
Options for consent might entail: 
x physical signature [CONTACT_3265] [CONTACT_202045] a phone 
call with the patient, then having the signed document sent back to the site. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 61 x phone call with the patient, asking for email confirmation to corroborate verbal 
consent. 
x organize a conference call or video call tog ether with the patient and impartial 
witness, where needed. 
x if no phone call or video call is possible, email documented consent. 
Depending on regional requirements the options can be limited, after consultation with the 
relevant IRB/IEC and/or regulatory authority. 
Data collected during a telephone assessment visit can be entered into the e-CRF pages of the 
corresponding ‚Äúmissed‚Äù visit. Enter the date of th e phone call as the ‚Äúdate of visit‚Äù and enter the 
data obtained in the applicable CRF pages. For the assessments that are not performed, answer 
‚Äúno‚Äù to the question if the assessment was made in the respective forms. Add ‚ÄúCOVID -19 
telephone‚Äù in the comment section of the CRF.  
If you are not able to contact [CONTACT_102], inacti vate the full study visit in the CRF and confirm 
the missing visit in the comments section as ‚ÄúCOVID -19.‚Äù 
Other than conducting telephone assessments, there may be other changes in the current practice 
on site. Halting spi[INVESTIGATOR_201991]-19 patients may be required, or only allowing use of a 
dedicated spi[INVESTIGATOR_201992] (for contamination reasons).  There can be a temporary halt in 
performing this assessment, or conducting a partial assessment is also permitted. 
In order to give a clear overview of protocol deviations related to the specific COVID-[ADDRESS_241071] been created to which any 
missed visit or assessment can be attributed.  
 
5. APPENDIX 9. 
6. Patients with known hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) seropositivity. 
7. Patients with known autoimmune dise ase other than MG (for example 
autoimmune thyroiditis, rheumatoid arthritis‚Ä¶) that would interfere with an accurate assessment of clinical symptoms. 
8. Patients with clinical evidence of other significant disease or patients who underwent a recent major surgery, which c ould confound the results of the trial or 
put the patient at undue risk. Patients with renal/hepatic function impairment can 
be included. 
9. Patients with known medical history of hypersensitivity to any of the ingredients 
of efgartigimod or placebo. 
4.4. Early Discontinuation 
The criteria for roll-over into this trial (see Section 4.3) are to be followed explicitly. If it is noted 
that a patient who does not meet 1 or more of the inclusion and/or meets 1 or more of the 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 62 exclusion criteria is inadvertently rolled over, the Medical Monitor at sponsor‚Äôs designated CRO 
and the sponsor‚Äôs Medical Direct or must be contact[CONTACT_15608].  
Early discontinuation from the trial is defined as  the permanent cessation of further participation 
in the trial prior to its planned completion.  
Patients must  be discontinued early from the trial if: 
x They withdraw their consent. 
x The investigator, after discussion with the sponsor‚Äôs Medical Director, deems it is in 
the patient‚Äôs best interest.  
x Patient is pregnant. 
x Patient receives rescue therapy (Part A only). 
x Patient develops an SAE that is likely to re sult in a life-threatening situation or pose a 
serious safety risk to the patient. 
x Prohibited medication is taken (Part A only) (see Section 6.8.1). 
Patients might discontinue early from the trial if: 
x Patient has clinical evidence of bacterial,  viral or fungal disease or any other 
significant disease which could confound the results of the trial or put the patient at 
undue risk. In this situation, decision on whether or not to discontinue patients early from trial will depend on the evaluation on a case-by-case basis. Patients who, after evaluation of the above situations are not discontinued from the trial, may have a 
temporary interruption from trial treatment (see Section 4.4.1). 
For patients who discontinue early from trial, th e assessments will depend on the visit at which it 
was decided that the patient had to discontinue (see Section 5.4, Figure 1,  and Figure 2).   
Patients who discontinue early from the tria l within a treatment period should perform the 
planned assessments of the corresponding treatment period visit. These patients will not receive 
any further administration of efgartigimod during  the trial and will return for the ED visit 1 
month (30 ¬± 2 days) after the last dose administra tion. An unscheduled visit can be organized if 
deemed necessary by [CONTACT_093]. 
Patients who discontinue early from the trial between the last visit of a treatment period (TP
nV4 
or TPE nV4) and the next intertreatment period visit (ITP nVn or ITPE nVn) should perform the ED 
assessments 1 month (30 ¬± 2 days) after the last dose administration. 
Patients who discontinue early from the trial at the ITP (Part A) or ITPE (Part B) visit should 
perform the ED assessments, instead of the ITP nVn (Part A) or ITPE nVn (Part B) assessments. 
Patients who discontinue early from the trial after the ITP (Part A) or ITPE (Part B) visit should perform the ED assessments. 
Any patient prematurely discontinuing the trial during Part A should perform the EoA/ED 
assessments according to the General Schedule of Assessments for Part A ( Table 1 ). Any patient 
prematurely discontinuing the trial during Part B should perform the EoS/ED assessments according to the General Schedu le of Assessments for Part B ( Table 2 ). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 63 All patients are free to withdraw consent from participation in the trial at any time, for any 
reason, specified or unspecified, and without prejudice to further treatment. Prior to actual 
withdrawal of consent, an effort should be made to perform a final set of assessments as per the 
EoA/ED visit in the General Sche dule of Assessments for Part A ( Table 1) or the EoS/ED visit in 
the General Schedule of Assessments for Part B ( Table 2). Investigators will make and document 
all efforts made to contact [CONTACT_202006]. 
Before enrolling in ARGX-113-[ADDRESS_241072] complete the early 
discontinuation (ED) visit assessments specified in Table 2. The previous efgartigimod IV dose 
must have been received at least [ADDRESS_241073] to complete the current treatment period and 
will continue the trial as per the Gene ral Schedule of Assessments for Part A ( Table 1 ) or for 
Part B ( Table 2). A patient who has had a temporary interrupt ion of trial treatment in Part A may 
also continue into Part B of the trial and receive (re-)treatment if the conditions mentioned above 
are met. 
4.4.2. Missed Doses 
Patients who miss 1, 2, or 3 infusions per treatment period will stay in the trial and will follow 
the assessments as per the General Schedule of Assessments for Part A ( Table 1 ) or for Part B 
(Table 2 ). These patients may be eligible for furthe r treatment periods during the trial. A patient 
who has missed doses in Part A may also continue into Part B of the trial and receive (re-)treatment if the conditions in Section 4.4.[ADDRESS_241074]/Independent Ethics Committee (IRB/IEC) of an amendment from the IRB/IEC 
and Regulatory Authority as per local regulation, except where necessary to eliminate an 
immediate hazard to trial patients, or when the ch ange involves only logistical or administrative 
aspects of the trial (eg, change of telephone numbe rs, ‚Ä¶). The investigator (or delegate) should 
document and explain any deviation from the approved protocol. 
Planned protocol exemptions or waivers will not be approved by [CONTACT_456]. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 64 4.6. Early Termination of Trial or Site 
The trial may be terminated at any time by [CONTACT_202047], inability 
to achieve the recruitment target within reasonable time or if in the sponsor's judgment, there are 
no further benefits to be expected from the trial. In such a case, the sponsor or delegate will inform the trial investigators, institutions, and all regulatory authorities. 
The trial can also be terminated by [CONTACT_202048], or at a site level by [CONTACT_1201]/IEC. The sponsor may close individual trial sites 
prematurely for reasons such as poor protocol compliance or unsatisfactory recruitment of 
patients. 
4.7. End of Trial Definition 
The end of trial is defined as last patient last visit. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 65 5. TRIAL PROCEDURES 
Every effort should be made to ensure that th e protocol-required tests and procedures are 
completed as described. When a protocol-r equired procedure cannot be performed, the 
investigator will document the reason and any corrective and preventive actions that he/she has 
taken to ensure that the normal processes are adhered to in source documents. The trial team 
should be informed of these incidents in a timely manner. 
Patients should be seen for all visits on the de signated days or as closely as possible to the 
original planned visit schedule. There is a permissible window of ¬±1 day for treatment period 
visits (visit 1 to visit 4), of ¬±2 days for ITP nVn (Part A), and of ¬±7 days for the ITPE nVn 
(Part B), EoA visit (day 365) and the EoS visit (day [ADDRESS_241075]). Every effort should be made to schedule every visit on the exact day (which is 
relative to the baseline visit [SEB, TP nB or TPE nB]) within the window as described in the 
General Schedule of Assessments for Part A ( Table 1 ) and for Part B ( Table 2). 
Each treatment period consists of [ADDRESS_241076] trial visit, while the baseline of each subsequent treatment period 
(TP nB or TPE nB) will be set at visit [ADDRESS_241077], before any other trial-
specific assessments, with the only excepti on of obtaining informed consent at SEB and the 
weight assessment. The MG-ADL scale needs to be performed prior to the QMG scale (Part A) 
as per Table 1. Acetylcholinesterase inhibitors must be halted for at least 12 hours before the 
QMG assessment (Part A). 
As from signature [CONTACT_202096], all AEs that occur and all 
concomitant medications, whether allowed or not, that are taken during the trial are to be recorded on the appropriate pages in the electronic case report form (eCRF). 
5.1. Informed Consent and Roll-Over Visit 
The roll-over visit (SEB) can be either ITP 0V1 or TP 1V1, depending on the patient status 
regarding the need for (re-)treatment upon roll-over from trial ARGX-113-1704. The first visit in trial ARGX-113-[ADDRESS_241078] sign the informed consent form (ICF) prior to any trial-related assessment. The assessments done for the last visit in trial ARGX-113-1704 should not be repeated. 
Prior to signing the ICF, trial patients will be instructed not to participate in any other clinical 
trial that involves an intervention or collection of  data until the completion of the current trial. 
After informed consent has been obtained, partic ipants of trial ARGX-113-1704 will be screened 
at the site for eligibility to roll over to this trial based on the inclusion and exclusion criteria defined in Sections 4.3.1 and 4.3.2, respectively. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 66 In addition to obtaining written informed consent and the eligibility check, the following 
assessments will be performed at SEB: 
x Clinically relevant medical and surgical history, clinically relevant prior treatments and all concomitant medications (see Sections 6.8 and 7.2.5) 
x Demographic characteristics (date of birth, sex, race, and ethnicity, per national regulations) 
x Assessments of disease severity ‚Äì the MG-ADL scale should be administered before 
the QMG scale  
x Suicidal ideation and behavior will be assessed via a targeted question based on the Patient Health Questionnaire item 9 (PHQ-9)
17 
x Complete physical examination, including at a minimum: general appearance, skin, lymph nodes, musculoskeletal/extremities, abdomen, cardiovascular, respi[INVESTIGATOR_696], and neurological systems 
x Weight and height 
x Vital signs (supi[INVESTIGATOR_9204], heart ra te, body temperature). It is recommended 
that the method used to measure body temperature at SEB is maintained throughout the trial for each patient 
x ECG (heart rate, PR, QT, and QRS interval) 
x Clinical laboratory tests (see Appendix 3 for an overview of the clinical laboratory 
tests that will be assessed). Patients need to have fasted at least [ADDRESS_241079] (only for women of childbearing potential, see DEFINITION 
OF TERMS ) 
x Pharmacodynamic biomarkers (anti-AChR antibodies in AChR-Ab seropositive 
patients only, total IgG and subtypes [IgG1, IgG2, IgG3 and IgG4], and anti-MuSK 
antibodies in MuSK-Ab seropositive patients only). Information on the AChR/MuSK-
Ab serotype (seronegative or seropositive) is available from trial ARGX-113-1704 
x Anti-drug antibodies (ADA) 
x Assess AEs, if any 
5.2. Treatment Period 
5.2.1. Treatment Period Part A 
A treatment period will include assessments in 4 weekly visits including treatment with efgartigimod in eligible patients in need for (re-)treatment. A new treatment period can only be 
started if it can be completed within the 1-year duration of Part A of the trial (re-treatment in 
Part A can start at the latest on day 336). Otherwise, the patient can be transitioned to Part B 
after completing the EoA visit assessments ( Table 1 ). These assessments should be completed 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 67 even if the patient is unwilling or unable to continue  to Part B, then he/she should continue to the 
EoA visit.  
The following assessments will be performed from visit 1 to visit 4 of each treatment period: 
x Assessments of disease severity ‚Äì the MG-ADL scale should be administered before 
the QMG scale* 
x Suicidality assessment* 
x Physical examination* 
x Weight will only be measured in case there is an obvious weight change compared to 
the last weight assessment* 
x Vital signs* 
x ECG, only at visit 1 and visit 4 of each treatment period* 
x Clinical laboratory tests. Patients need to have fasted at least 8 hours prior to sampling* 
x Urinalysis* 
x Urine pregnancy test (only for women of childbearing potential, see DEFINITION 
OF TERMS )* 
x Pharmacodynamic biomarkers (anti-AChR antibodies in AChR-Ab seropositive 
patients only, total IgG and subtypes [IgG1, IgG2, IgG3 and IgG4], and anti-MuSK 
antibodies in MuSK-Ab seropositive patients only)* 
x ADA, only at visit 1 and visit 4 of each treatment period* 
x Administration of efgartigimod as an IV infusion over a period of [ADDRESS_241080] 1 hour following the end of the infusion for safety monitoring, based on the patient‚Äôs clinical status  
x Review of concomitant medication and rescue therapy 
x Assess AEs, if any 
*These assessments should be performed prior to administration of efgartigimod (predose). 
At visit 1 of each subsequent treatment period, th e conditions for (re-)treatment will be checked 
before administration of ef gartigimod (see Section 4.1). 
Patients may not receive (re-)treatment with efga rtigimod if, at the time of (re-)treatment, they 
have clinical evidence of bacterial, viral or fungal disease, or any other significant disease which could confound the results of the trial or put patients at undue risk. Patients who are in need of an additional treatment but who are not eligible to recei ve (re-)treatment for reasons listed here will 
remain in the trial to receive appropriate alternative MG treatment. 
Patients who fail to respond to efgartigimod  for [ADDRESS_241081] 50% of the assessments 
(ie, TP nV2, TP nV3, TP nV4 and the first posttreatment period visit).  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 68 If a patient becomes eligible for (re-)treatment wi th efgartigimod by [CONTACT_202034]-ADL score as stated in Section 4.1, but cannot complete the entire treatment period 
during Part A (ie, after day 336) then the patient can be transitioned to Part B after completing 
the EoA visit assessments in Table 1 . These assessments should be completed even if the patient 
is unwilling or unable to continue to Part B (see Section 5.1). 
The transition to Part B can be either ITPE 0Vn or TPE 1V1, depending on the patient status 
regarding the need for (re-)treatment upon transition from Part A. The first visit in Part B will always coincide with the EoA visit in Part A. The assessments done for the last visit in Part A should not be repeated in Part B. 
A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment 
of the SoC dose and/or frequency) is not allowed from trial entry until [ADDRESS_241082] infusion of the next Treatment Period, a dose reduction in SoC 
consistent with current medical practice is allowed. 
5.2.2. Treatment Period Part B 
A Treatment Period will include assessments in 4 weekly visits including treatment with 
efgartigimod in eligible patients in need for (re-)treatment. A new Treatment Period can only be 
started if it can be completed within the trial duration (up to maximum [ADDRESS_241083]). 
The following assessments will be performed from visit 1 to visit 4 of each Treatment Period: 
x Assessments of disease severity (MG-ADL scale)* 
x Weight will be measured at visit [ADDRESS_241084] weight assessment* 
x Vital signs* 
x ECG, only at visit 1 and visit 4 of each Treatment Period* 
x Clinical laboratory tests (local labs), only at visit 1 and visit 4 of each Treatment 
Period.* 
x Urinalysis, only at visit 1 and visit 4 of each Treatment Period* 
x Urine pregnancy test (only for women of childbearing potential, see DEFINITION 
OF TERMS ), only at visit 1 and visit 4 of each Treatment Period* 
x ADA, only at visit 1 of each Treatment Period* 
x Administration of efgartigimod as an IV infusion over a period of [ADDRESS_241085] 1 hour following the end of the infusion for safety monitoring, based on the patient‚Äôs clini cal status 
x Review of concomitant medication 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 69 x Assess AEs if any 
*These assessments should be performed prior to administration of efgartigimod (predose). 
At visit 1 of each Treatment Period, the conditions for (re-)treatment will be checked before 
administration of efgart igimod (see Section 4.1). 
Patients may not receive (re-)treatment with efga rtigimod if, at the time of (re-)treatment, they 
have clinical evidence of bacterial, viral or fungal  disease, or any other significant disease which 
could confound the results of the trial or put patients at undue risk. 
If a patient becomes eligible for (re-)treatment with efgartigimod but cannot complete the entire 
Treatment Period within duration of the trial, the patient should continue to the EoS visit. 
If the investigator considers that the patient will  not have a clinical benefit from re-treatment 
then the patient cannot start a new Treatment Peri od. The patient should then continue to the EoS 
visit. A change of the type or dose/regimen of SoC (replacing, adding or removing SoC, or adjustment 
of the SoC dose and/or frequency) is allowed, without restrictions, following current medical 
practice. 
5.3. Intertreatment Period 
Intertreatment period visits occur every 30 days after the previous visit in Part A and every 
90 days after the previous visit in Part B. 
At each ITP nVn (Part A) or ITPE nVn (Part B) an evaluation of the need for (re-)treatment should 
be done. In case the patient is not in ne ed of (re-)treatment, assessments for ITP nVn (Part A) or 
ITPE nVn (Part B) should be performed as listed below and per the General Schedule of 
Assessments for Part A ( Table 1 ) or for Part B ( Table 2 ). However, in case the evaluation shows 
that the patient is in need of (re-)treatment and is  also eligible for (re-)treatment, the assessments 
according to TP nV1 (Part A) or TPE nV1 (Part B) are to be performed instead (see Section 5.2). If 
an ITP visit for Part A is scheduled within 14 days of the EoA visit, then the EoA visit should be 
performed instead. 
The following assessments will be performed in Part A: 
x Assessments of disease severity ‚Äì the MG-ADL scale should be administered before 
the QMG scale 
x Suicidality assessment 
x Physical examination 
x Weight will only be measured in case there is an obvious weight change compared to 
the last weight assessment 
x Vital signs 
x ECG 
x Clinical laboratory tests. Patients need to be fasted at least 8 hours prior to sampling 
x Urinalysis 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241086] (only for women of childbearing potential, see DEFINITION 
OF TERMS ) 
x Pharmacodynamic biomarkers (anti-AChR antibodies in AChR-Ab seropositive 
patients only, total IgG and subtypes [IgG1, IgG2, IgG3 and IgG4], and anti-MuSK antibodies in MuSK-Ab seropositive patients only) 
x Review of concomitant medication and rescue therapy 
x Assess AEs, if any 
The following assessments will be performed in Part B: 
x Assessments of disease severity (MG-ADL scale) 
x Vital signs 
x ECG 
x Urine pregnancy test (only for women of childbearing potential, see DEFINITION 
OF TERMS ) 
x Review of concomitant medication 
x Assess AEs, if any 
5.4. End of Part A, End of Study, and Early Discontinuation Visit 
In case of early discontinuation, the same assessments as scheduled for EoA (day 365) or EoS (day [ADDRESS_241087]) must be performed as follows: 
For EoA/ED (Part A): 
x Assessments of disease severity ‚Äì the MG-ADL scale should be administered before 
the QMG scale and before any other assessments except for weight 
x Suicidality assessment 
x Physical examination 
x Weight 
x Vital signs 
x ECG 
x Clinical laboratory tests ‚Äì Patients should have fasted at  least [ADDRESS_241088] (only for women of childbearing potential, see DEFINITION 
OF TERMS ) 
x Pharmacodynamic biomarkers (anti-A ChR antibodies in AChR-Ab seropositive 
patients only, total IgG and subtypes [IgG1, IgG2, IgG3, and IgG4], and anti-MuSK antibodies in MuSK-Ab seropositive patients only) 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 71 x ADA 
x Review of concomitant medication and rescue therapy 
x Assess AEs if any 
For EoS/ED (Part B): 
x Before enrolling in ARGX-113-[ADDRESS_241089] complete the 
early discontinuation (ED) visit assessments specified in Table [ADDRESS_241090] 30 days before entry into 
ARGX-113-2002. Patients who enroll in ARGX-113-2002 will not return to ARGX-113-1705 
x Assessments of disease severity (MG-ADL sc ale) should be administered before any 
other assessments except weight 
x Physical examination 
x Weight 
x Vital signs 
x ECG 
x Clinical laboratory tests (local labs) 
x Urinalysis 
x Urine pregnancy test (only for women of childbearing potential, see DEFINITION 
OF TERMS ) 
x ADA (only in case of ED) 
x Review of concomitant medication 
x Assess AEs, if any 
5.5. Unscheduled Visit 
It is at the investigator‚Äôs discretion or at patient‚Äôs request to initi ate an unscheduled (UNS) visit, 
if deemed necessary for the patient‚Äôs safety and well -being. All such visits will be documented in 
the eCRF with any additional required documen tation based on the nature of UNS visit. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241091] be stored refrigerated (2-8 ¬∞C or 35-46¬∞F) in their secondary packaging, 
should not be exposed to freezing temperatures, should not be shaken and should be protected 
from direct sunlight during storage at the clinical site. 
Further requirements on temperature logging duri ng storage and information on how to handle 
temperature excursions can be found in the IMP management manual (pharmacy manual). 
6.5. Method of Assigning Patients to Treatment Group 
Not applicable. 
6.6. Timing of Dose for Each Patient 
Only to patients who need (re-)treatment, efgartig imod will be administered IV over a period of 
1 hour as 4 weekly infusions at visits 1, 2, 3, a nd 4 of each Treatment Period, provided they are 
eligible. Patients will be asked to remain at the site for a minimum of 1 hour after the end of 
infusion as part of routine safety monitoring at visits 1, 2, 3, and 4 of each Treatment Period. 
6.7. Blinding 
This is an open-label trial with a single treatment group; no blinding will be applied. 
6.8. Prior Treatments and Concomitant Medications 
Clinically relevant prior treatments received by [CONTACT_202049] (1) previous MG treatments 
(including SoC) with patient‚Äôs response and reason for changing treatment/dose in the last 
12 months and (2) non-MG treatment in the la st 6 months, prior to Screening in trial 
ARGX-113-1704. Information should include start and stop dates and tick box for those 
continuing as concomitant medication. 
Vaccines (except for live/live-attenuated vaccines) will be allowed during the trial when 
administered at least [ADDRESS_241092] be recorded in the eCRF. 
6.8.1. Prohibited Medications During the Trial 
The following medications or treatments will lead to discontinuation from treatment during 
Part A of the trial as from SEB onwards: 
x Any IgG therapy 
x A change in the type or an increase of the dose/frequency of SoC, even if used for indications other than MG 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 74 x Any monoclonal antibody for immunomodulation 
x Live/live-attenuated vaccines 
x Rescue therapy when used in patients who meet the criteria to be rescued 
x Use of PLEX or immunoadsorption more than once during study period 
In Part B of the trial, a change of the type or dose/regimen of SoC (replacing, adding or 
removing SoC, or adjustment of the SoC dose and/or frequency) is allowed without restrictions, 
following standard clinical practice. 
PLEX, IVIg, immunoadsorption or use of a new type of corticosteroid or an increased dose of 
the current corticosteroids used as stand-alone ther apy or in combination is also allowed in Part 
B. 
6.8.2. Rescue Therapy (Part A only) 
Rescue therapy is permitted for patients experi encing protocol-defined MG clinical deterioration 
AND if in addition the treating physician believes th at the patient‚Äôs health is in jeopardy if rescue 
therapy is not given. An MG clinical deterioration permitting rescue therapy to be given is 
defined as a patient experiencing at least 1 of th e following: (1) new or worsening of respi[INVESTIGATOR_696] / 
bulbar symptoms or (2) at least 2-point increase of individual non-ocular MG-ADL items. 
Rescue therapy will be limited to PLEX, IVI g, immunoadsorption or use of a new type of 
corticosteroid or an increased dose of the current corticosteroids used as stand-alone therapy or 
in combination. The type of rescue therapy used should be documented. 
In case a patient needs rescue therapy according to the treating investigator, the Medical Director 
at the sponsor should be informed in addition to the Medical Monitor at the sponsor‚Äôs designated 
CRO; whenever possible prior to actual implementation of the rescue therapy. 
In situations where the treatments as listed above are given under the protocol-defined  rescue 
criteria, patients will be discontinued early from the trial. 
6.9. Medical Care of Patients After End of Study 
After a patient has completed the trial, or has w ithdrawn/discontinued early, usual treatment will 
be administered, if required, in accordance with the trial site‚Äôs SoC and generally accepted 
medical practice depending on the patient‚Äôs indi vidual needs. The sponsor will not provide any 
additional care to these patients.  
6.10. Treatment Compliance 
The investigator should promote treatment compliance by [CONTACT_202050]‚Äôs safety and the validity of the trial. The prescribed dose, timing, and mode of administration may not be changed. All dates and start and end time of efgartigimod administration and any deviations from the intended regimen must be recorded. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241093] 
Patients in need for (re-)treatment will receive 4 weekly IV infusions of efgartigimod at a dose of 
10 mg/kg over a period of 1 hour during each Treatment Period, provided they are eligible. 
All efforts will be done to ensure that the patient receives the 4 administrations of efgartigimod 
within the allowed time windows. However, if a pa tient misses 1 or more doses in any Treatment 
Period, the patient will not be discontinued from th e trial or from further trial treatment and will 
complete all further visits and assessments acc ording to the General Schedule of Assessments for 
Part A ( Table 1 ) and for Part B ( Table 2). This patient may be eligible for further Treatment 
Periods during the trial. 
In case a dose needs to be delayed for more than [ADDRESS_241094] 
Detailed instructions on accountability of efgartigim od will be included in the IMP management 
manual (pharmacy manual). 
6.13. Storage of Blood Samples in the Trial 
Any remaining samples after the analysis per prot ocol has been completed may be stored for up 
to 15 years for future additional research to  address any scientific questions related to 
efgartigimod or MG, unless this would not be allowed according to local regulations or the patient would not agree. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 76 7. TRIAL ASSESSMENTS 
7.1. Monitoring of Disease Severity 
Monitoring of disease severity will be assessed using MG-ADL (Part A and B) and QMG 
(Part A only). The assessments, where applicable, have to be performed predose on all efgartigimod infusion days and prior to any ot her assessment at each visit, except for the 
assessment of weight (if applicable) and signing of the ICF at SEB. The MG-ADL scale needs to 
be performed prior to th e QMG scale in Part A ( Table 1 ). 
Monitoring of disease severity for a given patient is preferentially assessed, whenever possible, by 1 and the same trained evaluator throughout the course of the trial. 
7.1.1. Myasthenia Gravis Activities of Daily Living 
The MG-ADL is an 8-item patient-reported scale ( Appendix 1)  to assess MG symptoms and their 
effects on daily activities. It evaluates the capacity to perform different activities of daily living 
such as talking, chewing, swallowing, breathing, brushing the teeth/combing the hair, or rising 
from a chair and it also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated from 0 to 3 and the total score can point from 0 to 24, 
with higher total scores indicating more impairment. The assessments to be performed using 
MG-ADL ( Appendix 1)  do not require any equipment to a ssess MG symptoms and their effects 
on daily activities. The scoring of MG-ADL should be performed by a trained and certified evaluator. 
7.1.2. Quantitative Myasthenia Gravis 
The QMG quantifies disease severity based on impairments of body functions and structures as 
defined by [CONTACT_202051], Disability and Health.
18  
The QMG consists of 13 items ( Appendix 2) that assess ocular, bulba r, and limb function. Out of 
the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a possible score 
from 0-3. The total possible score is 39, wher e higher total scores indicate more severe 
impairments. It is based on quantitative testing of specific muscle groups to assess limb function. 
It requires minimal equipment such as spi[INVESTIGATOR_14007] , mouthpi[INVESTIGATOR_201993], nose clips, 
stopwatch, cups and water for swallowing tests , goniometer, dynamometer , and is based on the 
trained rater‚Äôs examination. The scoring of QMG should be performed by a trained evaluator.  
7.2. Safety 
Safety assessments will consist of monitoring and recording all AEs, pregnancies, suicidality 
assessment (Part A only), safety laboratory testing, measurement of vital signs, ECGs, physical 
examinations; and other tests that are deemed critical to the safety evaluation of the trial in all 
patients who receive at least 1 dose of efgartigimod. As discussed in Section [IP_ADDRESS] , any 
pregnancy that occurs while a patient is enrolled into the trial will also be monitored and reported according to the appropriate regulations. 
The DSMB will evaluate the safety data periodically (see Section 7.2.6). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241095] of the patient. 
Definition of AE: An AE is any untoward medica l occurrence in a clinical trial patient whether 
or not a pharmaceutical product is administered, and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal product or efgartigimod, whether or not considered related to the medicinal product or efgartigimod. 
An AE can also be a new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), if considered clinically relevant by [CONTACT_1275]. 
Abnormal laboratory values, or test results, physical examination findings, and other abnormal 
investigational findings (ie, ECG) should not be reported as AEs unless they are considered clinically significant, eg, require therapy (eg, hematologic abnormality that requires transfusion or hematological stem cell support) or le ad to treatment discontinuation. 
Death is not considered an AE but an outcome. 
MG disease worsening, if considered clinically relevant by [CONTACT_093], can be reported as 
AE, provided that it is supported by a clinically relevant change in total MG-ADL score (as 
compared to SEB). The investigator should contact [CONTACT_202052]. 
Adverse Drug Reaction (ADR): Any untoward and unintended response in a patient to 
efgartigimod, which is related to any dose administered to that patient. 
Definition of Serious AE (SAE): An SAE, ex perience or reaction, is any untoward medical 
occurrence (whether considered to be related to efgartigimod or not) that at any dose: 
x Results in death 
x Is life-threatening (the patient is at a risk of death at the time of the event; it does not 
refer to an event, which hypothetically might have caused death if it was more severe) 
x Requires inpatient hospi[INVESTIGATOR_1081]. 
However, a planned hospi[INVESTIGATOR_201994] 
(Hospi[INVESTIGATOR_2144]/or surgical opera tions planned before a trial are not 
considered SAEs or if the illness or disease, which caused hospi[INVESTIGATOR_059], existed 
before the patient was enrolled in the trial,  provided that it did not deteriorate in an 
unexpected way during the trial. However, the condition for which the surgery is required may be an AE.) 
x Results in persistent or significant disability or incapacity, OR 
x Is a congenital abnormality or birth defect 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 78 x Other: Medically significant events, which do not meet any of the criteria above, but 
may jeopardize the patient and may require medical or surgical intervention to prevent 1 of the other serious outcomes listed in the definition above. Examples of such events are blood dyscrasias (eg, neutropenia or anemia requiring blood transfusion, etc.) or convulsions that do not result in inpatient hospi[INVESTIGATOR_201995] (S[LOCATION_003]Rs) and Unexpected Adverse 
Reactions: Any suspected adverse reaction that is  serious, unexpected, and considered to be 
related to drug exposure is defined as a S[LOCATION_003]R. 
An unexpected AE is any adverse drug event, which is not listed in the current IB or is not listed 
at the specificity or intensity that has been observed. 
Suspected adverse reaction means any AE for which there is a reasonable possibility that the 
drug caused the AE. 
An untoward and unintended post-dosing response to a non-trial drug is, by [CONTACT_108], not a 
S[LOCATION_003]R, but is, however, an AE. 
Each AE is to be evaluated for duration, se verity, seriousness and causal relationship to 
efgartigimod or trial procedures. The action taken with the investigational drug and the outcome 
of the event must also be recorded. Treatment-emergent adverse event (TEAE): Any AE temporally associated with the use of 
efgartigimod, whether considered related to ef gartigimod or not. TEAEs are recorded from the 
start of efgartigimod administration, until completion of the patient‚Äôs last visit.  
Overdose 
For the purposes of this trial, exceeding the dosage requirements specified in this protocol (see 
Section 6.1) represents an overdose. In case of suspected overdose, the patient should be treated 
according to standard medical practice based on the investigator‚Äôs judgment.  
Severity 
All AEs observed will be graded using the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0. The NCI-CTCAE is a descriptive terminology, which can be utilized for AE reporting. A grading (severity) scale is 
provided for each AE term. Grade refers to the severi ty of the AE. If a particular AE‚Äôs severity is 
not specifically graded by [CONTACT_43970], the investigator is to use the general NCI-
CTCAE definitions of Grade [ADDRESS_241096] medical judgment. The 
CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE 
based on the following general guideline: 
x Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated. 
x Grade 2: Moderate; minimal, local or non-i nvasive intervention indicated; limiting 
age--appropriate instrumental activities of daily living (ADL). 
x Grade 3: Severe or medically significan t but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-care ADL. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 79 x Grade 4: Life-threatening consequenc es; urgent intervention indicated. 
x Grade 5: Death related to AE. 
Relationship 
The causal relationship between efgartigimod/trial procedures and the AE has to be characterized 
as unrelated, unlikely, related, possible, and probable. 
x Events can be classified as ‚Äúunrelated‚Äù if there is not a reasonable possibility that 
efgartigimod caused the AE. 
x An ‚Äúunlikely‚Äù relationship suggests that only a remote connection exists between 
efgartigimod and the reported AE. Other conditions, including chronic illness, 
progression or expression of the disease stat e, or reaction to concomitant medication, 
appear to explain the reported AE. 
x A ‚Äúrelated‚Äù relationship suggests that the AE follows a reasonable temporal sequence from administration of efgartigimod, it fo llows a known or expected response pattern 
to efgartigimod and it cannot reasonably be explained by [CONTACT_202053]‚Äôs clinical state.  
x A ‚Äúpossible‚Äù relationship suggests that the association of the AE with efgartigimod is 
unknown; however, the AE is not reasonably supported by [CONTACT_145037]. 
x A ‚Äúprobable‚Äù relationship suggests that a reasonable temporal sequence of the AE with drug administration exists and, in the investigator‚Äôs clinical judgment, it is likely 
that a causal relationship exists between the drug administration and the AE, and 
other conditions (concurrent illness, progre ssion or expression of disease state, or 
concomitant medication reactions) do not appear to explain the AE. 
In final evaluation for reporting, the relationship will be converted into ‚ÄúBinary Determination‚Äù 
as per Council for International Organizati ons of Medical Sciences (CIOMS). Unrelated and 
Unlikely will be clubbed into ‚ÄúUnrelated‚Äù and Related, Possible and Probable will be clubbed 
into ‚ÄúRelated‚Äù for final reporti ng purpose. 
[IP_ADDRESS]. Adverse Events of Special Interest 
An AESI (serious or non-serious, related or not related) is an event of scientific and medical 
concern specific to the sponsor‚Äôs product or program.  
Efgartigimod treatment induces reductions in IgG levels, and there is a potential risk for 
infections associated with the low IgG levels. As such, any infection will be considered AESI in this trial. Further characterizing information will be collected in the eCRF, such as: location of 
infection, relationship to underlying condition, medical history and concomitant medication, reoccurrence of previous infection, previous resc ue therapy, any confirmatory procedure, culture 
or urgent medical intervention. 
[IP_ADDRESS]. Reporting of Adverse Events and Serious Adverse Events 
All AEs that occur during the trial from signature [CONTACT_202097] (either ‚Äúserious‚Äù or ‚Äúnon -serious‚Äù) in the eCRF. The 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 80 investigator should complete all the details requeste d, including dates of onset, time of onset, 
stop date (when applicable), stop time (when applicable), severity, ac tion taken, outcome, and 
relationship to efgartigimod, and to trial procedures . Each event should be recorded separately in 
the eCRF. 
All AEs spontaneously reported by [CONTACT_202054]: ‚Äú Have you had any health problems since th e previous visit or since you were 
last asked?,‚Äù or revealed by [CONTACT_178557]. When 
collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately. 
Any SAE, including death due to any cause, whic h occurs during this trial after signature [CONTACT_170817], whether or not related to efgartigimod, must be reported immediately (within 24 hours of 
the trial site‚Äôs knowle dge of the event). All SAEs will be recorded (within 24 hours) on the paper 
SAE Report Form and the AE form in the eCRF, the investigator or delegated site staff should check that all entered data are consistent. An alert email for the SAE report in the eCRF will then automatically be sent by [CONTACT_109356]‚Äôs designated CRO safety mailbox via the electronic 
data capture (EDC) system. The paper SAE Report Form should be faxed or emailed to the sponsor‚Äôs designated CRO (see the Safety Mailbox/Fax  details on the title page of this protocol). 
The report will contain as much available information concerning the SAE to enable the sponsor 
(or an authorized representative) to file a report, which satisfies regulatory reporting 
requirements. These timelines apply to initial reports of SAEs and to all follow-up reports. 
Criteria for documenting the relationship to efga rtigimod, as well as severity, outcome, and 
action taken will be the same as those previously described. 
The investigator shall report within 24 hours an y SAE (s)he becomes aware of after a patient‚Äôs 
last visit if a causal relationship with the investigational product is suspected. Such a serious 
adverse reaction (SAR) is to be collected and reported as previously described for SAEs. 
All SAEs that are spontaneously reported within [ADDRESS_241097] trial visit are to be 
collected and reported as previously described and all efforts should be made to follow-up until resolution. 
Additional follow-up information should be comple ted and entered on a paper SAE Report Form 
and sent by [CONTACT_6791]/email to the sponsor‚Äôs designated CRO.  
[IP_ADDRESS]. Reporting of Serious Adverse Even ts to Regulatory Authorities and 
Investigators 
The sponsor‚Äôs designee will be responsible for reporting all S[LOCATION_003]Rs, the Analysis of Similar 
Events (AOSE), and any other applicable reports to regulatory authorities, ethics committees, 
and investigators, in accordance with national regulations in the countries where the trial is 
conducted. Relative to the first awareness of the event by/or further provision to the sponsor‚Äôs 
designee, S[LOCATION_003]Rs will be submitted within 7 days for fatal and life-threatening events and 
15 days for other S[LOCATION_003]Rs, un less otherwise required by [CONTACT_2091]. The sponsor‚Äôs 
designee will also prepare an expedited repo rt for other safety issues where applicable. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241098] a copy of all expedited reports to his or her IEC/IRB in 
accordance with national regulations. 
[IP_ADDRESS]. Follow-up of Adverse Events and Serious Adverse Events 
Any AEs observed from signing the ICF to the last study visit will be followed up to resolution, 
until the patient is lost to follow-up, or until the patient withdraws consent. Resolution means that the patient has returned to a baseline state of health or the investigator does not expect any further improvement or worsening of the AE. 
Every effort should be made to follow all (S)AEs considered to be related to efgartigimod or trial 
procedures until an outcome can be reported. If the patient is lost to follow-up, all AEs will be 
categorized based on the investigator‚Äôs last assessment.  
All SAEs that are spontaneously reported after the last study visit are to be collected and reported as previously described (as per Section [IP_ADDRESS]) and will be followed up. During the trial period, 
resolution of SAEs (with dates) should be documented on the SAE page of the eCRF and in the patient‚Äôs medical record to facilitate s ource data verification. If, after follow -up, return to the 
baseline status or stabilization cannot be establis hed, an explanation should be recorded on the 
SAE page of the eCRF. 
All pregnancies reported during the trial should be followed until pregnancy outcome. 
For SAEs, non- serious AEs, and pregnancies, the sponsor‚Äôs designee may follow -up by 
[CONTACT_756], fax, electronic mail, and/or a monitori ng visit to obtain additional case details and 
outcome information (eg, from hospi[INVESTIGATOR_8838], consultant reports, or autopsy 
reports) in order to perform an independent  medical assessment of the reported case. 
[IP_ADDRESS]. Reporting and Follow-up Requirements for Pregnancies 
[IP_ADDRESS].1. Pregnancies in Female Patients 
Urine pregnancy tests will be conducted and analyzed locally at visits as detailed in the General 
Schedule of Assessments for Part A ( Table 1) and for Part B ( Table 2 ). Results will be recorded 
in the eCRF. 
If a patient becomes pregnant after  the administration of efgartigimod  and up to [ADDRESS_241099] infusion, the sponsor and/or sponsor‚Äôs designee should be informed 
immediately (ie, within 24 hours of the trial site‚Äôs knowledge of the event). The following actions will be performed: 
x The patient should immediately be discontinued from trial treatment. 
x The patient should have the planned ED assessments.  
x All planned assessments (see Sections 4.4 and 5.4 ) must be performed unless 
contraindicated by [CONTACT_8663] (harmful to fetus) or unless the patient withdraws informed consent.  
The investigator must update the patient with i nformation currently known about potential risks 
and about available treatment alternatives. Th e pregnancy should be followed up to determine 
outcome, including spontaneous or voluntary termination, details of the birth, and the presence or 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 82 absence of any birth defects, congenital abnormalities, or mater nal and/or newborn 
complications. 
If required by [CONTACT_427], the female participant will be requested to sign a separate 
pregnancy ICF. Full details will be recorded on a paper Pregnancy Report Form and submitted 
via email or fax (see the Safety Mailbox/Fax  details on the title page of this protocol), and 
reporting details will be specified in the trial manual. The investigator will update the Pregnancy Report Form with additional information as soon as the outcome of the pregnancy is known. 
If the outcome of the pregnancy is an SAE, then this must be additionally reported as an SAE on 
the appropriate SAE Report Form. 
[IP_ADDRESS].2. Pregnancies in Female Partners of Male Patients 
Male patients will be instructed through the ICF to immediately inform the investigator if their 
partner becomes pregnant during the trial or up to [ADDRESS_241100] infusion of 
efgartigimod. A Pregnancy Report Form should be completed by [CONTACT_19452] 24 hours 
after learning of the pregnancy and submitted via email or fax (see the Safety Mailbox/Fax 
details on the title page of this protocol). Attempts  should be made to collect and report details of 
the course and outcome of any pregnancy in the partner of a male patient exposed to efgartigimod. 
The pregnant partner will need to sign an ICF to allow for follow-up on her pregnancy. Once the 
ICF has been signed, the investigator will update the Pregnancy Report Form with additional 
information on the course and outcome of the pregnancy. An investigator who is contact[CONTACT_202055], to support an informed decision in cooperation with the 
treating physician and/or obstetrician. 
7.2.2. Clinical Laboratory Evaluations 
In Part A, blood and urine samples for determination of clinical chemistry, hematology and 
urinalysis will be analyzed at a central laboratory. PD and ADA will be analyzed at a specialty 
laboratory as indicated in the Genera l Schedule of Assessments for Part A ( Table 1 ) and 
Appendix 3. Patients need to be fasting for at least 8 hours prior to the sampling for clinical laboratory tests as from SEB up to EoA.  
In Part B, blood and urine samples for determination of clinical chemistry, hematology and urinalysis will be analyzed at local laboratories and results will not be recorded in the eCRF. 
Blood samples for ADA will be analyzed at a sp ecialty laboratory as indicated in the General 
Schedule of Assessments for Part B ( Table 2 ) and Appendix 3.  
Additional safety samples may be collected if clinically indicated at the discretion of the investigator. 
For all patients of childbearing potential, a urine pregnancy test will be conducted and analyzed 
locally at the site (on the urine samples taken for urin alysis, if applicable) at all visits in Part  A 
(Table 1 ) and at visit 1 and 4 of each Treatment Period, at ITPE visits, at EoS/ED and at the 
discretion of the investigator in Part B ( Table 2).  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 83 The estimated total maximum blood volume needed for a patient during Part A of the trial (when 
completing the trial up until the last visit) is between 170 mL for a patient who receives 
1 Treatment Period only and 362 mL for a patient who receives a maximum of 6 Treatment 
Periods. The estimated total maximum blood volume needed for a patient during Part B of the trial (when completing the trial up until the last  visit) is between 24 mL for a patient who 
receives 1 Treatment Period only and 100 mL for  a patient who receives 6 Treatment Periods. 
Clinical laboratory tests will be reviewed for results of potential clinical significance at all time points throughout the trial. The investigator will evaluate any change in laboratory values. If the 
investigator determines a laboratory abnormality to be  clinically significant, it will be considered 
as a laboratory AE; however, if the abnormal laboratory value is consistent with a current 
diagnosis, it may be documented accordingly without being reported as an AE. 
The details of sampling, handling, storage, and tran sportation of the samples will be described in 
the laboratory manual. The actual sample collection date and time must be entered in the 
patient‚Äôs source documents and on the central lab assessment eCRF page.  
Refer to Appendix 4  for the addresses of the laboratories used for sample analyses and storage. 
7.2.3. Vital Signs, Physical Examination, and ECG 
Assessment of vital signs (supi[INVESTIGATOR_9204], heart rate, and body temperature), physical examination and ECG will be performed at the time points indicated in the General Schedule of 
Assessments for Part A ( Table 1 ) and for Part B ( Table 2) (predose at dosing days). 
Supi[INVESTIGATOR_201996] [ADDRESS_241101] on a bed. 
It is recommended that the method used to measure body temperature at SEB is maintained 
throughout the trial for each patient. 
A physical examination will include at a minimum an assessment of general appearance, skin, 
lymph nodes, musculoskeletal/extremities, abdomen, cardiovascular, respi[INVESTIGATOR_696], and 
neurological system.  
Weight will be measured at SEB, at the EoA/ED visit, at visit 1 of Part B, at the EoS/ED visit, 
and can be repeated at any visit when there is an obvious weight change compared to the last 
weight assessment. Patients will be required to remove their shoes and wear light indoor clothing 
for this measurement. 
A 12-lead ECG will be recorded locally as per lo cal regulations in the supi[INVESTIGATOR_201997] [ADDRESS_241102] for a neurological indication, a 
prospective assessment for suicidal ideation and behavior will be included in this clinical trial 
(Part A only). 
This so-called suicidality assessment will be c onducted by [CONTACT_202056], derived from the PHQ-9: 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 84 x "Over the last [ADDRESS_241103]?" 
The patient will be asked this question at each visit and the response documented. Response 
options as per the PHQ-9 are limited to the following: "not at all," "several days," "more than 
half the days" or  "nearly every day."  
This specific question was selected for the reported significant linear relationship between the item [ADDRESS_241104] be reported on the relevant medical history/current medical conditions page of the eCRF. 
Information should be provided on medical and surgical history, and concomitant medical 
conditions specifying those ongoing at SEB. 
7.2.6. Data Safety Monitoring Board (DSMB) 
The sponsor will appoint a DSMB consisting of an independent group of clinical experts, who 
are not participating in the trial. They will be supplemented by [CONTACT_55467]. The 
objective of the DSMB will be to review all safety data (including the overall number of patients 
treated up to that point, rates, and patient-level details). Fixed meetings will be scheduled based 
on the recruitment rate into the trial, and inci dence of (S)AEs. In addition, ad hoc meetings can 
be requested at any time during the trial by [CONTACT_202057]. The DSMB will advise the sponsor concerning continuation, modifi cation or termination of the trial after every 
meeting. 
The composition, objectives, and role and respons ibilities of the independent DSMB will be 
described in a DSMB charter, agreed with the DSMB members and sponsor. The DSMB charter 
will also define and document the content of the safety summaries, and general procedures (including communications). 
7.2.7. Visit Reminder/Subject ID Card 
Patients must be provided with the address and telephone number of the main contact [CONTACT_202058]. The investigator must therefore provide a ‚ÄúVisit 
Reminder/Subject ID Card‚Äù to each patient. In an emergency situation this card serves to inform 
the responsible attending physician that the patient is in a clinical trial and that relevant 
information may be obtained by [CONTACT_202059]. Patients must be instructed to keep 
the card in their possession at all times. 
7.3. Pharmacodynamics 
In Part A, the PD markers (total IgG and IgG subtypes [IgG1, IgG2, IgG3 and IgG4], and 
autoantibodies [anti-AChR antibodies for the AChR-Ab seropositive patients and anti-MuSK 
antibodies for the MuSK-Ab seropositive patients]) will be measured at the time points as 
indicated in Table 1 . Information on the AChR/MuSK-Ab serotype is available from trial 
ARGX-113-1704. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241105] ed in the relevant section of the eCRF. 
7.4. Anti-Drug Antibodies 
Blood samples to assess ADA will be collected predose at the time points as indicated in Table 1 
and Table 2 . At baseline (SEB, TP nB, and TPE nB), confirmatory and titer analysis will be 
performed using a validated ADA assay. Samples having a positive ADA titer will be further 
investigated in a neutralizing ADA assay. The actual date and time of collection of the blood 
sample will be recorded in the relevant section of the eCRF. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 86 8. STATISTICS 
The statistical analyses will be performed by [CONTACT_3211]‚Äôs designated CRO using statistical analysis 
systems SAS¬Æ (SAS Institute, Cary, NC, [LOCATION_002] [US]) version 9.[ADDRESS_241106] operating procedures (SOPs) and work 
instructions of sponsor‚Äôs designated CRO will be used as the default methodology if not 
otherwise specified. 
Any change to the data analysis methods described underneath will be mentioned in the 
statistical analysis plan (SAP). Any additional analysis, and the justification for making the 
change, will be described in the Clinical Trial Report (CTR). Additional exploratory analyses of 
the data will be conducted as deemed appropriate. 
Due to the single-arm, open-label nature of the design, evaluation of all endpoints will be 
essentially descriptive. Endpoints will be summar ized by [CONTACT_3148] (as received in ARGX-113-
1704). 
8.1. Determination of Sample Size 
Not applicable. 
8.2. Analysis Populations 
The analysis population will consist of all patients who rolled over from trial ARGX-113-1704. 
8.3. Patient Disposition, Characteristics and Concomitant Medication 
A tabular presentation of the patient disposition will be provided. It will include the number of 
patients enrolled, completed (by [CONTACT_5265]), as well as the number of early discontinuations 
(including rescued patients), with reasons for discontinuation from trial treatment or trial and 
major protocol deviations. 
A listing will be presented to describe date s of SEB, completion or early discontinuation and the 
reason for early discontinuation, if applicable, for each patient. 
Patient characteristics will be recorded prior to enrollment and will be listed and summarized. 
Overall summaries will include descriptive statistics for continuous measures (number of 
observations, mean, standard deviation, median, minimum and maximum) and for categorical 
measures (sample size, frequency, and percent). Pa tient characteristics include but are not limited 
to age, sex, race, weight, and body mass index (BMI). 
Use of concomitant medication will be summar ized with frequency and percentage. All 
concomitant medications used will be listed.  
8.4. Statistical Methods 
8.4.1. Primary and Secondary Endpoint Analyses 
All endpoints will be summarized in all enrolled pa tients and by [CONTACT_64161].  
Frequency tables will be made for all binary variables, ie, AEs, by [CONTACT_89835].  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 87 Summary statistics will be provided for the c ontinuous endpoints (eg, laboratory values, vital 
signs, ECGs) in terms of absolute values and changes from TP 1B by [CONTACT_202060].  
8.4.2. Tertiary Endpoint Analyses 
The tertiary endpoints will be summarized descriptively.  
Summary statistics will be provided for the cont inuous endpoints (eg, total MD-ADL score, total 
QMG score, levels of total IgG and subtypes, anti-AChR/anti-MuSK antibodies) in terms of 
absolute values, changes from TP 1B or changes from TP nB, by [CONTACT_202061]. 
For levels of total IgG and subtypes and also  anti-AChR/anti-MuSK antibodies, the percentage 
change from TP 1B and from TP nB will also be presented. 
Frequency tables will be made for incidence and prevalence of ADA to efgartigimod. 
8.5. Interim Analyses 
Interim analyses might be performed to support questions for authorities and/or submissions. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 88 9. QUALITY CONTROL AND QUALITY ASSURANCE 
9.1. Investigator‚Äôs Responsibility  
The investigator will comply with the protocol (which has been approved/given favorable 
opi[INVESTIGATOR_44635]), ICH GCP, and applicable regulatory requirements. The investigator is ultimately responsible for the conduct of all aspects of the trial at the trial site and 
verifies by [CONTACT_202062]. The term ‚Äúinvestigator‚Äù 
as used in this protocol as well as in other trial documents, refers to the investigator or authorized 
trial personnel that the investigator has designated to perform certain duties. Sub-investigators or 
other authorized trial personnel are eligible to sign for the investigator, except where the investigator‚Äôs signature [CONTACT_1788].  
9.2. Quality Control of Data 
Quality control will be applied to each stage of data handling. 
The following steps will be taken to ensure  the accuracy, consistency, completeness, and 
reliability of the data: 
x Investigator meetings 
x Central laboratories for clinical laboratory parameters and ECGs 
x Site initiation visit 
x Routine site monitoring 
x Ongoing site communication and training 
x Ongoing oversight by [CONTACT_202063] 
x Data management quality control checks 
x Continuous data acquisition and cleaning 
x Quality control check of the CTR 
x To avoid inter-observer variability, every effort should be made to ensure that the same individual who made the initial baseline determinations completes all safety and 
disease severity evaluations. 
In addition, sponsor and/or sponsor‚Äôs designated CRO Clinical Quality Assurance (CQA) 
Department may conduct periodic audits of the tria l processes, including, but not limited to trial 
site, or site visits, central laboratories, vendors, cl inical database, and final CTR. When audits are 
conducted, access must be authorized for all trial-related documents including medical history and concomitant medication documentation to authorized spon sor‚Äôs representatives and 
regulatory authorities. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 89 9.3. Monitoring 
The sponsor has engaged the services of a CRO to perform all clinical trial monitoring functions 
within this clinical trial. Sponsor‚Äôs designated CR O monitors will work in accordance with SOPs 
of the CRO.  
Monitoring visits must be conducted according to the applicable ICH GCP guidelines to verify 
that, among others, the: 
x Data are authentic, accurate, and complete. 
x Safety and rights of patients are being protected. 
x Trial is conducted in accordance with the c urrently approved protocol, any other trial 
agreements and all applicable regulatory requirements. 
The investigator and the head of the medical instit ution (where applicable) agrees to allow the 
Clinical Trial Monitor direct access to all relevant documents. 
The investigator must ensure provision of reas onable time, space and qualified personnel for 
monitoring visits. The Clinical Trial Monitor will perform an eCRF review and Source Document Verification 
(SDV).  
The Source Documentation Agreement Form describe s the source data for the different data in 
the eCRF. This document should be completed and signed by [CONTACT_202064]‚Äôs trial file. Any data item for which the eCRF 
will serve as the source must be identified, ag reed and documented in the Source Documentation 
Agreement Form. 
Upon completion or premature discontinuation from the trial, the Clinical Trial Monitor will 
conduct site closure activities with the investigator  and site staff as appropriate, in accordance 
with applicable regulations, ICH GCP guidelines and CRO/sponsor procedures. Monitoring details describing strategy (eg, risk-bas ed initiatives in operations and quality such as 
Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on-site monit oring) are provided in the monitoring plan. 
9.4. Data Management 
Data generated within this clinical trial will be handled according to the SOPs of the Data 
Management and Biostatistics departme nts of the sponsor‚Äôs designated CRO.  
Case report forms are provided for each patient in electronic format. It will be transcribed by [CONTACT_202065]. Date must be entered in English and 
guidelines for eCRF completion, including the collection of investigator‚Äôs e -signature, will be 
provided by [CONTACT_2024]. Appropriate training and security measures will be completed with the investigator and all authorized trial site staff prior  to the trial being initiated and any data being 
entered into the system for any trial patient at the site. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 90 The eCRF is essentially considered a data entry form and should not constitute the original (or 
source) medical records unless otherwise specified. Source documents are all documents used by 
[CONTACT_5246][INVESTIGATOR_201998]‚Äôs medical history, that verify the existence of 
the patient, the inclusion an d exclusion criteria, and all records covering the patient‚Äôs 
participation in the trial. They can include laboratory notes, ECG results, memoranda, pharmacy 
dispensing records, patient files, etc. The eCRFs should be completed by [CONTACT_1720] a 
qualified designee from the site as soon as the data are available. 
As a matter of regulation, the investigator is responsible for the accuracy and authenticity of all 
clinical data entered onto eCRFs. Prior to database lock, each completed eCRF must be reviewed 
for accuracy by [CONTACT_093], corrected as necessary and then approved. The investigator‚Äôs 
e-signature [CONTACT_202098] [CONTACT_202066]. The investig ator will be required to electronically sign off 
the eCRF. 
The data will be verified for missing data,  inconsistencies, and for necessary medical 
clarifications. Queries arising from these checks wi ll be flagged to the trial site, and the trial site 
staff will correct data, confirm or clarify data as  appropriate. The CRO will provide the details of 
the review process in a data management plan an d monitoring plan. Any change, including the 
issuing of queries, will be fully audit trailed by [CONTACT_202067], meaning the name [CONTACT_202099], time, and date stamp are recorded , as well as the reason for change. 
Data will also be provided by [CONTACT_185079], such as the results generated by [CONTACT_202068], the Interactive Response Technology (IRT) provider, or centralized ECG reading. These 
data will need to be reconciled with the data recorded in the eCRF before it can be merged with 
the eCRF data into the clinical database. The CRO will provide a data management plan 
detailing this reconciliation. 
Adverse events, concomitant diseases/medical histor y terms will be assigned to a lowest level 
term (LLT) and a preferred term (PT) and will be classified by [CONTACT_202069] (HLT), high level 
group term, and primary system organ class (SOC ) according to the Medical Dictionary for 
Regulatory Activities (MedDRA) thesaurus. 
Prior and concomitant medications will be classifi ed according to active drug substance using the 
World Health Organization Drug Dictionary (W HO-DD). The generic name, the preferred name, 
and the WHO name [CONTACT_202100]-DD thesaurus. 
The Anatomical Therapeutic Chemical (ATC) cl asses will be assigned to the prior and 
concomitant medications. 
9.5. Quality Assurance Audit 
Trial sites, the trial database and trial documentation may be subject to Quality Assurance audit 
during the course of the trial by [CONTACT_4209]‚Äôs designee (CRO or other vendor) on 
behalf of sponsor. In addition, inspections may be conducted by [CONTACT_48699]. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241107] or Independent Ethics Committee 
The investigator will provide the sponsor or designee with documentation of IRB/IEC approval 
of the protocol and informed consent documents before the trial may begin at the trial sites. The investigator will supply documentation t o the sponsor or designee of the required IRB/IEC‚Äôs 
annual renewal of the protocol, and any approvals of revisions to the informed consent document 
or amendments to the protocol. 
The investigator will report promptly to the IRB/IEC, any new information that may adversely 
affect the safety of patients or the conduct of the trial. Similarly, the investigator will submit 
written summaries of the trial status to the IRB/IEC annually, or more freque ntly if requested by 
[CONTACT_1201]/IEC. Upon completion of the trial, the investigator will provide the IRB/IEC with a brief report of the outcome of the trial, if required. 
10.2. Ethical Conduct of the Trial 
This trial will be conducted, and the informed consent will be obtained, according to the ethical principles stated in the Declaration of Helsinki  (2013), the applicable guidelines for GCP, or the 
applicable drug and data protection laws and regulations of the countries where the trial will be 
conducted. 
To comply with the Declaration of Helsinki (2013), argenx is assessing the appropriateness and 
possibility of making the study drug available for clinical study participants post-trial. 
10.3. Patient Information and Informed Consent 
The ICF, will be used to explain the risks and benefits of trial participation to the patient in 
simple terms before the patient rolled over into the tr ial. A separate ICF will be given in case of 
pregnancy of a female partner of male patient. The ICF contains a statement that the consent is 
freely given, that the patient is aware of the risks and benefits of entering the trial, and that the 
patient is free to withdraw from the trial at any time. Written consent must be given by [CONTACT_5363]/or legally acceptable representative, after the receipt of detailed information on the trial. 
All ICFs must be available in the local and verna cular languages required at the site and include 
patient information sheets/brochures that outline the trial procedures. All ICF(s) must be signed 
and dated by [CONTACT_76409] a legally acceptable representative. 
For patients who are unable to read and write, the patient information sheet and ICF(s) should be 
read to the patient in his/her native language in the presence of a legally acceptable 
representative who is literate and not affiliated with the trial. The patient having understood the 
information given to him/her in the presence of a legally acceptable representative will thumbprint the ICF(s) and the same will be countersigned by [CONTACT_202070]. If the patient or legally acceptable representative cannot read, then an impartial 
witness will witness and attest the entire consen t process and will be required to sign the ICF. 
Confirmation of a patient‚Äôs informed consent must also be documented in the patient‚Äôs medical record prior to any testing under this protocol, including SEB tests and assessments. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 92 The investigator is responsible for ensuring that informed consent is obtained from each patient 
or legally acceptable representative and for obtain ing the appropriate signatures and dates on the 
informed consent document prior to the performance of any protocol procedures and prior to the 
administration of efgartigimod. The investigator will provide each patient with a copy of the 
signed and dated ICF(s). 
10.4. Patient Data Protection 
The ICF will incorporate (or, in some cases, be accompanied by a separate document incorporating) wording that complies with re levant data protection and privacy legislation. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241108] Keepi[INVESTIGATOR_201999]‚Äôs responsibility to maintai n essential trial documents (including records and 
documents pertaining to the conduct of this trial and the distribution of IMP, regulatory 
documents, eCRFs, signed patient ICFs, laboratory test results, IMP inventory records, source 
documents, relevant correspondence, AE reports, and all other supporting documentation) as 
required by [CONTACT_202071]. The trial site should plan on 
retaining such documents for approximately [ADDRESS_241109] 2 years after the formal discontinuation of clinical development of 
efgartigimod. The sponsor will notify the principal investigator [INVESTIGATOR_54070]. 
These documents should be retained for a longer period if required by [CONTACT_202072][INVESTIGATOR_307], institution, or private practice in which the trial is being conducted. 
Patient identification codes (patient names and co rresponding trial numbers) will be retained for 
this same period of time. These documents may be transferred to another responsible party, 
acceptable to sponsor, who agrees to abide by [CONTACT_44148]. The investigator is required 
to notify the sponsor (or an authorized representative) in writing prior to changing the location or 
status of any essential clinical trial documents. The investigator must contact [CONTACT_202073]. 
No records should be disposed of without the written approval of argenx BVBA. 
For trials conducted outside the US under a US i nvestigational new drug (IND), the principal 
investigator [INVESTIGATOR_202000]. 
11.2. Direct Access to Source Data/Documents 
The sponsor or designee and auditor may access patient records for the purpose of monitoring 
this trial, auditing, and managing progress details. The investigator must be fully aware that the 
sponsor or designee and auditor can inspect or verify  documents to verify patient chart and eCRF 
records. Such information must be kept confidential and must have locked facilities that allow for this. The investigator will prepare and main tain adequate and accurate source documents to 
record all observations and other pertinent data for each patient enrolled into the trial. 
The investigator is responsible for maintaining source documents. These will be made available 
for inspection by [CONTACT_202074]. The investigator must 
submit a completed eCRF for each patient who receives efgartigimod, regardless of duration. All 
supportive documentation submitted with the eCRF, such as laboratory or hospi[INVESTIGATOR_1097], should be clearly identified with the trial and patient number. Any personal information, including patient name, should be removed or rendered illegible to preserve individual confidentiality. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 94 11.3. Investigator Information 
11.3.1. Investigator Obligations 
The investigator is responsible for ensuring that all trial site personnel, including sub-
investigators, adhere to all applicable regulations and guidelines, including local laws and regulations, regarding the trial, both during and after trial completion. The investigator is 
responsible for informing the IRB/IEC of the progress of the trial and for obtaining annual 
IRB/IEC renewal. The investigator is responsible for informing the IRB/IEC of completion of the trial and will provide the IRB/IEC with a summary of the results of the trial. 
11.3.2. Protocol Signatures 
After reading the protocol, each investigator will  sign the protocol signature [CONTACT_41452] a 
copy of the signed page to the sponsor or representative. By [CONTACT_12142], the investigator 
confirms in writing that he/she has read, understands, and will strictly adhere to the trial protocol 
and will conduct the trial in accordance with ICH Tripartite Guidelines for GCP and applicable 
regulatory requirements. The trial will not be able to start at any site where the investigator has 
not signed the protocol. 
11.3.3. Publication Policy 
All information regarding efgartigimod supplied by [CONTACT_202075] a result of this trial, are considered  confidential and remain the sole property of the 
sponsor. The results of the trial will be reported in a CTR. 
The CTR written in accordance with the ICH E3 Guideline, will be submitted in accordance with 
local regulations. 
Any manuscript, abstract or other publication or presentation of results or information arising in 
connection with the trial must be prepared in conjunction with the sponsor and must be 
submitted to the sponsor for review and comment prior to submission for publication or 
presentation. Trial patient identifiers will not be used in publication of results. 
Authorship will be granted based on scientific input, recruitment efforts, and will be granted 
upon decision of a publication committee. This  committee will include among others the 
coordinating investigator [INVESTIGATOR_11305]. 
The sponsor will register and/or disclose the existence of and the results of clinical trials as 
required by [CONTACT_2371]. 
11.3.4. Financing and Insurance 
The sponsor will fund the trial as outlined in the Clinical Trial Agreement.  
The sponsor will obtain adequate global/local insurance for the trial participants including the 
trial patients for the required duration of time. 
The sponsor maintains an insurance coverage fo r this trial in accordance with the laws and 
regulations of the countries in which the trial is performed. Liability and insurance provisions for 
this trial are specified in the investigator‚Äôs contract. The terms and conditions will apply as  
specified in the policy document. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241110] JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-
controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve . 2013;48(1):76-84. 
2. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol . 2015;14(10):1023-1036. 
3. Gilhus NE. Myasthenia gravis. N Engl J Med . 2016;375(26):2570-2581. 
4. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathies and related neurological disorders. Neuron . 2006;52(1):123-138. 
5. Kaminski HJ. Seronegative myasthenia gravis ‚Äîa vanishing disorder? JAMA . Neurol 
2016;73(9):1055-1056. 
6. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev 
Immunol. 2007;7(9):715-725. 
7. Challa DK, Velmurugan R, Ober RJ, et al.  FcRn: from molecular interactions to 
regulation of IgG pharmacokinetics and functions. Curr Top Microbiol Immunol.  
2014;382:249-272. 
8. Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotech . 2005;23(10):1283-1288. 
9. Patel DA, Puig-Canto A, Challa DK, et al.  Neonatal Fc receptor blockade by [CONTACT_202076] a murine model.  J Immunol . 2011;187(2):1015-1022. 
10. Challa DK, Bussmeyer U, Khan T, et al. Au toantibody depletion ameliorates disease in 
murine experimental autoimmune encephalomyelitis.  MAbs. 2013:5(5): 655-659. 
11. Nowak RJ, Dicapua DB, Zebardast N, et al.  Response of patients with refractory 
myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord . 
2011;4(5):259-266. 
12. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol . 2017;16(12):976-986. 
13. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol . 2009;8(5):475-490. 
14. Liu JF, Wang WX, Xue J, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoa dsorption, and intravenous immunoglobulin 
for the treatment of late-onset myasthenia gravis.  Ther Apher Dial . 2010;14(2):153-160. 
15. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810. 
16. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med . 2016;375(6): 511-522. 
17. Simon GE, Rutter CM, Peterson D, et al. Does response on the PHQ-[ADDRESS_241111] subsequent suicide  attempt or suicide death? Psychiatr Serv . 
2013;64(12): 1195-1202. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 96 18. World Health Organization. International Cla ssification of Functioning, Disability, and 
Health (ICF). 1st edition. World Health Organization website 2001. Available at 
http://www.who.int/classifications/icf/en/. 
19. Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology . 1999;52(7):1487-1489. 
20. Muppi[INVESTIGATOR_121732] S, Wolfe GI, Conaway M, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve . 2011;44(5):727-731. 
21. Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci.  1998:841:769-772. 
22. Katzberg HD, Barnett C, Merkies IS, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve . 2014;49(5):661-665. 
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 97 13. APPENDICES 
APPENDIX 1: Myasthenia Gravis Activities of Daily Living 
 
Source: website MGFA, MG-ADL19,20 
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 98 APPENDIX 2: Quantitative Myasthenia Gravis Score 
 
Source: website MGFA, Quantitative MG score21,22  
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 99 APPENDIX 3: Laboratory Evaluations 
Hematology  Hemoglobin, platelet count, white blood cell (WBC) count with WBC 
differential  
Clinical Chemistry  Creatinine, creatinine clearance, blood urea nitrogen (BUN), glucose, 
glycosylated hemoglobin [HbA1c], alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), total bilirubin, gamma -glutamyl 
transferase (GGT), C -reactive protein (CRP), alkaline phosphatase 
(ALP), lactate dehydrogenase (LDH) , uric acid, albumin, potassium, 
sodium, calcium, lipid panel (total cholesterol, high density lipoprotein 
[HDL], low density lipoprotein [LDL], and triglycerides), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) 
Urin alysis  Color, clarity/appearance, specific gravity, pH, protein, glucose, ketones, 
blood, bilirubin, urobilinogen, nitrite, leukocyte esterase, and 
microscopic examination including red blood cell (RBC) count, WBC, 
cast crystals, bacteria.  
Other  Urine human chorionic gonadotrophin (√ü-HCG) 
Pharmacodynamic (PD) 
markers  Total IgG and subtypes (IgG1, IgG2, IgG3, and IgG4), and AChR -Ab 
(binding) levels in AChR -Ab seropositive patients only and anti- muscle-
specific kinase (MuSK) antibodies in MuSK -Ab seropos itive patients 
only. Information on the AChR/MuSK -Ab serotype (seronegative or 
seropositive) is available from trial ARGX -113-1704. 
Anti -drug antibodies 
(ADA)  Levels of anti -efgartigimod binding and neutralizing antibodies (if 
applicable)  
Note: For Part A, all blood and urine samples will be co llected locally (predose on dos ing days) and analyzed at a 
central or specialty laboratory. For Part B, blood and urine samples for clinical chemistry, hematology, and 
urinalysis will be analyzed locally, while AD A samples will be analyzed at a specialty laboratory. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 100 APPENDIX 4: Administrative Structure 
Clinical Laboratories (Part A only)  
[LOCATION_002]  Covance  
[ADDRESS_241112]  
Indianapolis, IN [ZIP_CODE]  
[LOCATION_002]  
Europe  Covance  
Rue Moise -Marcinhes 7 
CH ‚Äì 1217 Meyrin  
Geneva  
Switzerland 
Japan  Covance Japan Co., Ltd. 
Harumi Triton Square Office Tower Y  
8F,1-8-11, Harumi, Chuo-ku, 
Tokyo 104 -6108  
Japan 
  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 101 Analysis of Pharmacodynamics (PD), Anti -Drug Antibodies (ADA)  
[LOCATION_009]  SGS [LOCATION_009] 
90 Avenue des Hauts de la Chaume BP. 28 
[ZIP_CODE] Saint -Beno√Æt Cedex 
[LOCATION_009] 
Long -Term Storage of Pharmacodynamics (PD), Anti-Drug Antibodies (ADA)  
[LOCATION_013]  Brooks Life Science, BioStorage Technologies GmbH 
Im Leuschnerpark 1b  
[ZIP_CODE] Griesheim  
[LOCATION_013]  
Study Monitoring/Medical Monitoring  
[LOCATION_002]  Syneos Health‚Ñ¢ group company  
including INC Research, LLC, together with INC Research 
[LOCATION_006] Limited  
[ADDRESS_241113]  
Raleigh, North Carolina [ZIP_CODE] -1547 
[LOCATION_002]   
Phone +[PHONE_4343] 
[LOCATION_013]  EastHORN Clinical Service GmbH 
Im Mediapark 6c  
[ZIP_CODE] Cologne  
[LOCATION_013] 
Clinical Trial Supply Management  
Belgium  CSM  
Watson & Crick Hill  
Rue Granbonpr√©  11 
B-1435 Mont-Saint-Guibert 
Belgium 
Data Management and Biostatistics  
Belgium  SGS Life Sciences (SGS LS), a division of SGS Belgium 
NV 
Generaal de Wittelaan 19A b5  
BE ‚Äì 2800 ‚Äì Mechelen 
Belgium 
Drug -Safety Reporting  
[LOCATION_002]  Parexel International  
[ADDRESS_241114]  
Billerica MA [ZIP_CODE]  
[LOCATION_002] 
  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 104 APPENDIX 7: Summary of Changes From Prior Amendments 
Protocol Version 3.1 compared to Protocol Version 3.2 
Changes from Protocol Version 3.1 compared to  Protocol Version 3.2 are summarized below. 
Of note: updates of headers/footers and tables of contents as well as editorial changes regarding 
layout, font, and format are not recorded in this summary. 
Section  Change  Rationale  
Table 2  General 
Schedule of 
Assessments for Part
 B 
 Assessments highlighted in yellow indicate 
assessments ‚Ä¶  
changed to  
Assessments highlighted by [CONTACT_202077] ‚Ä¶  Correction  
Appendix [ADDRESS_241115] symptoms such as cough, 
fever, muscle pain, shortness of breath? 
- If NO: Go to Questions 2 and 3. 
- If YES: 
‚Ä¢ If the patient is not tested for COVID -19:  
The visit will take place after at least [ADDRESS_241116] 
symptoms and only if the patient is symptom free‚Ä¶  
‚Ä¶ 
‚Ä¢ If the patient is tested and found to be COVID -19 
positive:  
The patient can only come to the site once he/she is 
symptom free, and so ‚Ä¶  
changed to  
1. Does the patient have symptoms, such as cough, 
fever, muscle pain, shortness of breath *? 
- If NO: Go to Questions 2 and 3. 
- If YES: 
‚Ä¢ The patient should be tested for COVID -19:  
The Investigator needs to document a positive COVID-
[ADDRESS_241117] as an AESI. The anonymized result needs to be sent to the 
sponsor for filing. If COVID-19 safety 
measures are stopped acco rding to local regulations, 
COVID -19 tests should continue to be performed and 
the results sent to the sponsor. 
*Shortness of breath includes an otherwise unexplained 
deterioration in the patient‚Äôs MG -ADL score for 
breathing. In cases where the MG -ADL score for 
breathing is [ADDRESS_241118] been made to 
allow for COVID -19 testing 
of patients exhibiting 
symptoms of the disease.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241119] for COVID -19‚Ä¶  
‚Ä¶ 
‚Ä¢ If the patient is tested and found to be COVID -19 
positive:  
The patient can only come to the site once he/she has a 
negative test for COVID -19, and so ‚Ä¶  
 
As the COVID-[ADDRESS_241120] patient safety, while still being able to gather additional data. 
Therefore, for the global amendment of the ARGX-113-1705 protocol from version 3.0 to 3.1 an 
addendum has been added to the study detailing  the safety measures and changes to be 
implemented in the current situation. The risk/benefit, safety profile, guidance for site conduct and potential changes in the Schedule of Assessments are detailed in Appendix 8. 
This will be a temporary change to the procedures of the study and will only last as long as the COVID-19 pandemic affects the ability of th e patients to attend their study visits. 
Protocol Version 3.0 compared to Protocol Version 3.1 
Changes from Protocol Version 3.0 compared to  Protocol Version 3.1 are summarized below. 
Of note: updates of headers/footers and tables of contents as well as editorial changes regarding 
layout, font, and format are not recorded in this summary. 
 
An additional part (Part B) was added to ARGX -113-[ADDRESS_241121] access to efgartigimod while it is not yet commercially available or available 
through another patient program. This extension to Part A of the trial will be a maximum of 2 
years and will also enable additional long-term safety and tolerability data to be collected. 
The extension part (Part B) will include fewer assessments to minimize the burden for the 
patients and changes in the SoC are allowed. 
Long-term safety follow-up will be carried out via local lab testing at the discretion of the 
investigator, as well as follow-up of AEs. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 106 In Part A of the trial MG-ADL guidelines need to be followed for re-treatment. In Part B, 
MG-ADL will serve as a guide for re-treatment, but it is up to the investigator to decide when the 
patient will be re-treated. 
Protocol Version 2.0 compared to Protocol Version 3.0 
Changes from Protocol Version 2.0 compared to  Protocol Version 3.0 are summarized below. 
Of note: updates of headers/footers and tables of contents as well as editorial changes regarding 
layout, font, and format are not recorded in this summary. 
Where changes have been made in a few words only these have been highlighted using italics . 
Section  Change  Rationale  
SUMMARY OF 
CHANGES  A summary and table highlighting the differences 
between Part A and Part B of the trial was added. 
The Summary of Changes tables have been moved to 
Appendix 7.  Due to the number of 
changes, and therefore the size of the tables required to describe all the changes made to the protocol, the detailed Summary of Changes tables 
have been moved to 
Appendix 7.
 
SYNOPSIS  
Trial Duration:  The trial duration will be 1 year.  
changed to  
The trial duration will be up to maximum 3 years. The 
trial consists of two parts: Part  A (1 year) and Part B 
(up to maximum [ADDRESS_241122]).
 See summary above.  
SYNOPSIS  
Objectives:  
 
2. TRIAL 
OBJECTIVES  
2.3. Tertiary 
Objectives  Tertiary Objectives : 
‚Ä¶ 
‚Ä¢ To evaluate the immunogenicity of ARGX-113. 
changed to  
Tertiary Objectives : 
Part A only:  
‚Ä¶ 
Part A and B:  
‚Ä¢ To evaluate the immunogenicity of ARGX -113. 
SYNOPSIS  
Methodology:  
DESCRIPTION  This is a 1 -year, single-arm, open- label, multicenter, 
Phase 3 follow -on extension trial of ARGX-113- 1704 
to evaluate the long -term safety and tolerability of 
ARGX -113 in patients with gMG. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 107 Section  Change  Rationale  
 
4.  
INVESTIGATIONAL 
PLAN  
4.1. Summary of Trial 
Design  
Methodology  
DESCRIPTION  A variable number of Treatment Periods consisting of 
4 weekly infu sions of ARGX- 113 (10 mg/kg of body 
weight) infused over a period of 3 weeks will be 
administered to eligible patients on an ‚Äúas needed basis‚Äù on top of their standard of care (SoC) in Treatment Periods.
 
‚Ä¶ 
The Study Entry Baseline (SEB) will be set at the first 
trial visit, while the Baseline of each subsequent 
Treatment Period (TP nB) will be set at Visit 1 of each 
corresponding Treatment Period.  
changed to  
This is a 3 -year (maximum), single-arm, open- label, 
multicenter, Phase 3 follow -on extension trial of 
ARGX -113-1704 to evaluate the long- term safety and 
tolerability of ARGX -113 in patients with gMG. The 
trial consists of two parts: Part  A (1 year) and Part B 
(maximum [ADDRESS_241123]). The additional part (Part B) was added to ARGX
-113- [ADDRESS_241124] access to efgartigimod whil e it is 
not yet commercially available or available through 
another patient program. This extension will also 
enable additional long -term safety and tolerability data 
to be collected.  
A variable number of Treatment Periods consisting of 
4 weekly infusions of ARGX -113 (10 mg/kg of body 
weight) infused over a peri od of 3 weeks will be 
administered to eligible patients on an ‚Äúas needed 
basis‚Äù on top of their standard of care (SoC).  
‚Ä¶ 
The Study Entry Baseline (SEB) will be set at the first 
trial visit, while the Baseline of each subsequent Treatment Period (TP
nB for Part A or TPE nB for Part 
B) will be set at Visit 1 of each corresponding 
Treatment Period.  
SYNOPSIS  
Methodology:  
(RE-)TREATMENT 
 (RE-)TREATMENT 
changed to  
(RE-)TREATMENT (Part A) 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 108 Section  Change  Rationale  
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  
Methodology  
(RE-)TREATMENT 
SYNOPSIS  
Methodology:  
(RE-)TREATMENT 
(Part  A) 
 
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  
Methodology  
(RE-)TREATMENT 
(Part A)  Patients who show a treatment failure to ARGX -[ADDRESS_241125] 50% of the assessments (i.e., TP nV2, TP nV3, 
TPnV4 and the first post-Tre atment Period visit).  
If a patient becomes eligible for (re -)treatment wit h 
ARGX -[ADDRESS_241126] 50% of the assessments (i. e., TP nV2, TP nV3, 
TPnV4 and the first post-Tre atment Period visit).  
If a patient becomes eligible for (re -)treatment with 
ARGX -113 per total MG-ADL score but cannot 
complete the entire Treatment Period within the 
duration of Part A (re -treatment in Part A can start at 
the latest on Day  336) then the patient will be 
transitioned to Part  B after completing the End of Part 
A (EoA) visit. If the patient is not willing or able to 
continue to Part  B then he/she should continue to the 
EoA visit.  
The transition to  Part B can be either at ITPE 0V1 or 
TPE 1V1, depending on the patient‚Äôs status regarding 
the need for (re -)treatment upon transition from Part A. 
The first visit in Part B will always coincide with the 
EoA visit in Part A. The assessments done for the last 
visit in Part  A should not be repeated in Part B. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 109 Section  Change  Rationale  
(RE-)TREATMENT (Part B) 
If the patient feels that his/her condition has 
deteriorated, the Investigator may decide to start a new 
Treatment Period at the time of an Intertreatment 
Period (ITPE) visit or the patient may contact [CONTACT_202078].  
Each patient can start a (new ) Treatment Period with 
ARGX -113 when all the following criteria apply:  
The patient has completed the previous Treatment 
Period (i.e., after Visit 4)*; AND 
The Investigator determines that the patient will benefit 
from re -treatment; AND 
There is at least 1 calendar month (minimum 4 weeks) 
between Treatment Periods (i.e., between TPE nV4 and 
TPE n+1V1). 
*A patient who has had a temporary interruption of 
trial treatment in Part  A may also continue into Part B 
of the trial and receive (re -)treatment if the conditions 
in Section 4.4.3 are met.  
However, patients may not receive (re -)treatment with 
ARGX -113 if, at the time of (re-)treatment, they have 
clinical evidence of bacterial, viral or fungal disease, or 
any other significant disease which could confound the results of the trial or put patients at undue risk.
 
If a patient becomes eligible for (re -)treatment with 
ARGX -[ADDRESS_241127] a clinical benefit from (re -)treatment then the 
patient cannot start a new Treatment Per iod. The 
patient should then con tinue to the EoS visit.  
SYNOPSIS  
Methodology:  
STANDARD OF 
CARE (SoC)  
 
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  Permitted SoC for MG treatment under this protocol 
include ‚Ä¶  
changed  to 
In Part A:  
Permitted SoC for MG treatment under this protocol 
include ‚Ä¶  
In Part B:  
A change of the type or dose/regimen of SoC 
(replacing, adding or removing SoC, or adjustment of See summary above.  
 
Part B allows for freedom of 
changing therapy and there will be no restrictions on the 
type of therapy that can be 
used. This because Part
 B 
will shift to a more real -life 
approach.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241128] OF 
CARE  the SoC dose and/or frequency) is allowed, without 
restrictions, followi ng current medical practice. 
Plasma exchange (PLEX), intravenous 
immunoglobulin (IVIg), immunoadsorption or use of a new type of corticosteroid or  an increased dose of the 
current corticosteroi ds used as stand
-alone therapy or 
in combination is also allowe d in Part B. 
SYNOPSIS  
Methodology:  
TIME BETWEEN 
TREAT MENT 
CYCLES  
 
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  
Methodology  
TIME BETWEEN 
TREATMENT 
CYCLES  TIME BETWEEN TREATMENT CYCLES  
At the end of each Treatment Period, ‚Ä¶ The visit 
frequency in the Intertreatment Period is every 30 days 
(¬± 2 days) after the previous visit. 
changed to  
TIME BETWEEN TREATMENT PERIODS  
At the end of each Treatment Period, ‚Ä¶ For Part A, the 
visit frequency in the Intertreatment Period is every 30 
days (¬± 2 days) after the prev ious visit. For Part B, the 
visit frequency in the Intertreatment Period is every 90 
days (¬±  7 days) after the previous visit. If an ITP visit 
for Part A is scheduled within 14 days of the EoA visit, 
then t he EoA visit should be performed instead. Changed to be consistent 
with ARGX -113- 1704. A 
Treatment Cycle is a 
Treatment Period + follow-up. This section is describing Treatment Periods.
 
 
Since in Part B the dosing 
regimen and visit schedule 
are more in line with a real-life situation with quarterly visits to the treating physician, the frequency of 
the ITP visits has been 
reduced to once every 90 
days. However, should the 
Investigator, together with the patient, deem it necessary the patient can return sooner. 
SYNOPSIS  
Methodology:  
RESCUE THERAPY  
 
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  
Methodology  
RESCUE THERAPY 
 
6.  TRIAL 
TREATMENT  RESCUE THERAPY  
Rescue therapy will be limited to plasma exchange 
(PLEX), intravenous immunoglobulin (IVIg),  
immunoadsorption or use of a new type of 
corticosteroid or an incr eased dose of the current 
corticosteroids used as stand -alone therapy or in 
combination.  
‚Ä¶ 
In situations where the treatments as listed above are 
given under the protocol -defined rescue criteria, 
patients will be discontinued early from trial treatment . 
changed to  
RESCUE THERAPY (Part  A only) 
Rescue therapy will be limited to PLEX, IVIg, 
immunoadsorption or use of a new type of 
corticosteroid or an incr eased dose of the current 
corticosteroids used as stand -alone therapy or in 
combination.  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 111 Section  Change  Rationale  
6.8.  Prior Treatments 
and Concomitant Medications
 
6.8.2.  Rescue Therapy ‚Ä¶ 
In situations where the treatments as listed above are 
given under the protocol -defined rescue criteria, 
patients will be discontinued early from the trial . 
SYNOPSIS  
Methodology:  
EARLY 
DISCONTINUATION 
FROM THE TRIAL 
 
4.  
INVESTIGATIONAL PLAN 
 
4.1. Summary of Trial 
Design  
Methodology  
EARLY 
DISCONTINUATION FROM THE TRIAL Section deleted: 
EARLY DISCONTINUATION FROM THE TRIAL 
Any patient prematurely discontinuing the trial should 
perform the EoS/ED assessments.  In order to reduce the burden 
on the patients, the safety follow
-up period has been 
replaced by [ADDRESS_241129] the trial after a limited safety fol
low-up period. 
 
If warranted further safety 
follow -up can be performed 
by [CONTACT_202079].
 SYNOPSIS  
Methodology:  
EARLY 
DISCONTINUATION 
FROM TRIAL 
TREATMENT  
 
4.  
INVESTIGATIONAL 
PLAN  
4.1. Summary of Trial 
Design  
Methodology  
EARLY 
DISCONTINUATION 
FROM TRIAL TREATMENT
 EARLY DISCONTINUATION FROM TRIAL 
TREATMENT  
Patients who discontinue early from trial treatment 
within a Treatment Period will have to complete the End of Treatment (EoT) assessments and complete the remaining visits in the current Treatment Period according to the General Schedule of Assessments (Table 1). These patients will not receive any further 
administration of ARGX
-113 during the trial and will 
continue to be followed for safety and disease severity 
as per Schedule of Assessments for Patients who Discontinue Early from Trial Treatment (Table 2).  
Patients who discontinue early from trial treatment in 
the 
Intertreatment Period will have to complete the 
EoT assessments and then continue into the Safety and 
Disease Severity Follow -up period as per Table 2. 
changed to  
EARLY DISCONTINUATION  
For patients who discontinue early from trial, the 
assessments will depend on the visit at which it was 
decided that the patient had to disco ntinue (see 
Section  5.4, Figure 1, and Figure 2). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 112 Section  Change  Rationale  
Patients who discontinue early from the trial within a 
Treatment Period should perform the planned 
assessments of the corresponding Treatment Period 
visit. These patients will not receive any further administration of ARGX
-113 during the trial and will 
return for the ED visit one month (30  ¬± 2 days) after 
the last dose administration. An unscheduled visit can 
be organized if deemed necessary by [CONTACT_737]. 
Patients who discontinue early from the trial between 
the last visit of a Treatment Period (TP nV4 or TPE nV4) 
and the next Intertreatment Period visit (ITP nVn or 
ITPE nVn) should perform the ED assessments one 
month (30 ¬± 2 days) after the last dose administration. 
Patients who discontinue early from the trial at the ITP 
(Part A) or ITPE (Part B) visit should perform the ED 
assessments, instead of the ITP nVn (Part A) or 
ITPE nVn (Part B) assessments. 
Patients who discontinue early from the trial after the 
ITP (Part A) or ITPE (Part B) visit should perform the ED assessments.
 
Any patient prematurely discontinuing the trial during 
Part A should perform the EoA/ED assessments according to the General Schedule of Assessments for 
Part
 A (Table 1). Any patient prematurely 
discontinuing the trial during Part B should perform 
the EoS/ED assessments according to the General 
Schedule of Assessments for Part B (Table 2).  
SYNOPSIS  
TEMPORARY 
INTERRUPTION 
FROM TRIAL 
TREATMENT  
 
4.  
INVESTIGATIONAL 
PLAN  
4.1. Summary of Trial 
Design  
Methodology  
TEMPORARY 
INTERRUPTION FROM TRIAL TREATMENT
 A patient who does not need to be discontinued early 
from trial treatment  might still ‚Ä¶  
A schematic of trial design is presented in Figure 1. 
changed to:  
A patient who does not need to be discontinued early 
from the trial  might still ‚Ä¶  
Patients for whom treatment is interrupted will have to 
complete the current Treatment Period and will 
continue the trial as per the General Schedule of Assessments for Part A (Table 1) or for Part B (Table 
2) but without drug administration. A patient who has 
had a temporary interruption of trial treatment in Part A may also continue into Part B of the trial and receive (re
-)treatment if the conditions mentioned above are 
met. 
A schematic of the trial design is presented in Figure 1 
for Part  A and in Figure 2 for Part B. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 113 Section  Change  Rationale  
SYNOPSIS  
Exclusion Criteria  
 
4.  
INVESTIGATIONAL PLAN
 
4.3.  Selection of Trial 
Population  
4.3.2.  Exclusion 
Criteria  1. Patients who discontinued early from trial ARGX-
113-1704 or patients who discontinued early from 
randomized treatment for rescue or pregnancy reasons 
or an (S)AE that might jeopardize the safety of the 
patient in that trial . 
changed to  
1. Patients who d iscontinued early from trial ARGX -
113-1704 or patients who discontinued early from 
randomized treatment for rescue or pregnancy reasons 
or an SAE that is like ly to result in a life-threatening 
situation or pose a serious safety risk . Corrected. This was amended 
in Section 4.4.2 in a previous 
amendment (2.0), but was not 
amended in the exclusion criteria.
 
SYNOPSIS  
Criteria for 
Evaluation:  
 
3. TRIAL 
ENDPOINTS  
3.1. Primary Endpoint 
3.2. Secondary 
Endpoint  
3.3. Tertiary 
Endpoints  Primary Endpoint : 
‚Ä¢ Incidence and severity of AEs, SAEs, vital signs, 
electrocardiogram (ECG) and laboratory assessments 
over 1  year in AChR-Ab seropositive patients. 
Secondary Endpoints:  
‚Ä¢ Incidence and severity of AEs, SAEs, vital signs, 
ECG and laboratory assessments over 1 year in the overall population (AChR
-Ab seropositive patients and 
AChR -Ab seronegative patients). 
‚Ä¢ Incidence and severity of AEs, SAEs, vital signs, 
ECG and laboratory assessments at each Treatment 
Period in AChR -Ab seropositive patients. 
‚Ä¢ Incidence and severity  of AEs, SAEs, vital signs, 
ECG and laboratory assessments at each Treatment 
Period in the overall population (AChR -Ab 
seropositive patients and AChR -Ab seronegative 
patients).  
Tertiary Endpoints  
‚Ä¢ To evaluate the disease severity as assessed by [CONTACT_202080]-ADL score changes compared to SEB and the 
corresponding TP nB in AChR- Ab seropositive patients. 
‚Ä¢ To evaluate the disease severity as assessed by [CONTACT_202080]-ADL score changes compared to SEB and the 
corresponding TP nB in the overall population (AChR-
Ab seropositive and AChR -Ab seronegative patients). 
‚Ä¢ To evaluate the disease severity as assessed by [CONTACT_202081] -Ab seropositive 
patients.  
‚Ä¢ To evaluate the disease severity as assessed by [CONTACT_202082]
 A and Part B 
of the trial.  
 
Corrected to reflect that 
changes from the treatment period baseline of the first 
cycle will be summarized 
(instead of changes from SEB) as patients might start the study with an intertreatment
 period. 
 
‚ÄúTo evaluate the disease 
severity as assessed by‚Äù should not be part of an endpoint definition.
 
 
 
 
For Part B only 
immunogenicity will be 
characterized as a tertiary 
endpoint. Furthermore, only 
safety and tolerability will be 
followed up and no PD markers will be summarized. 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 114 Section  Change  Rationale  
corresponding TPnB in the overall population (AChR-
Ab seropositive and AChR -Ab seronegative patients). 
‚Ä¢ Percentage decrease (compared to SEB and the 
corresponding TPnB) of total IgG level and IgG subtypes in ARGX
-113 (re-)treated patients. 
‚Ä¢ Percentage decrease (compared to SEB and the 
corresponding TPnB) of autoantibodies (anti -AChR 
antibodies and anti -MuSK antibodies) in ARGX- 113 
(re-)treated patients. 
‚Ä¢ Incidence of anti -drug antibodies (ADA) to ARGX -
113 at SEB and at each Treatment Period.  
changed to  
Primary Endpoint : 
‚Ä¢ Incidence and severity of AEs, SAEs, vital signs, 
electrocardiogram (ECG) and laboratory assessments 
over the duration of the trial in AChR -Ab seropositive 
patients.  
Secondary Endpoint:  
‚Ä¢ Incidence and severity of AEs, SAEs, vital signs, 
ECG and laboratory assessments over the duration of 
the trial in the overall population (AChR -Ab 
serop ositive patients and AC hR-Ab seronegative 
patients).  
Tertiary Endpoints:  
Part A only:  
‚Ä¢ Total MG -ADL score changes compared to the 
Treatment Period Baseline of the first cycle (TP 1B) and 
the corresponding TP nB in AChR-Ab seropositive 
patients.  
‚Ä¢ Total MG -ADL score changes compared to TP 1B and 
the corresponding TP nB in the overall population 
(AChR -Ab seropositive and AChR- Ab seronegative 
patients).  
‚Ä¢ Total QMG score changes compared to TP 1B and the 
corresponding TP nB in AChR- Ab seropositive patients. 
‚Ä¢ Total  QMG score changes compared to TP 1B and the 
corresponding TP nB in the overall population (AChR-
Ab seropositive and AChR -Ab seronegative patients). 
‚Ä¢ Percentage decrease (compared to TP 1B and the 
corresponding TP nB) of total IgG level and IgG 
subtypes in AR GX-113 (re-)treated patients. 
‚Ä¢ Percentage decrease (compared to TP 1B and the 
corresponding TP nB) of autoantibod ies (anti-AChR 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 115 Section  Change  Rationale  
antibodies and anti-MuSK antibodies) in ARGX-113 
(re-)treated patients. 
Part A and B:  
‚Ä¢ Incidence and prevalence of anti -drug antibodies 
(ADA) to ARGX -113. 
SYNOPSIS  
Statistical Methods 
and Plan:  
 A Statistical Analysis Plan detailing all statistical 
methods and ana lyses will be issued before the 
database lock. A summary of the plan is described 
below.  
All endpoints will be tested in all enrolled patients and 
by [CONTACT_202083]. All comparisons of 
endpoints between Treatment Periods will be purely descriptive.
 
Summary statistics will be provided for the continuous 
endpoints (e.g., total MG -ADL score, total QMG 
score, levels of total IgG and subtypes, anti -
AChR/anti -MuSK antibodies, laboratory values, vital 
signs, ECG) in terms of absolute values and  changes 
from SEB and changes from Treatment Period 
Baseline (TPB), at each Treatment Period (including Intertreatment
 Period) and available time points. 
Frequency tables will be made for all binary variables, 
i.e., AEs and ADA for all Treatment Periods an d 
overall (including Intertreatment Periods) and available 
time points.  
changed to  
A Statistical Analysis Plan detailing all statistical 
methods and analyses will be issued before any 
database lock. A summary of the plan is described 
below.  
All endpoints w ill be summarized in all enrolled 
patients and by [CONTACT_64161].  
Summary statistics will be provided for the continuous 
endpoints (e.g., total MG -ADL score, total QMG 
score, levels of total IgG and subtypes, anti -
AChR/anti -MuSK antibodies , laboratory values, vital 
signs, ECG) in terms of absolute values, changes from 
TP1B or changes from TP nB, by [CONTACT_202084].  
Frequency tables will be made for all binary variables, 
i.e., AEs and ADA by [CONTACT_89835].  Corrected to ref lect that 
changes from the treatment 
period baseline of the first 
cycle will be summarized 
(instead of changes from 
SEB), as patients might start the study with an intertreatment
 period. 
AEs and ADA will be 
summarized by [CONTACT_5265], not by [CONTACT_11191].
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 116 Section  Change  Rationale  
Table 1  General 
Schedule of 
Assessments  Title:  
Table 1  General Schedule of Assessments  
changed to  
Table 1  General Schedule of Assessments for Part A See summary above.  
Table 1  General 
Schedule of 
Assessments  
End of Study/Early 
Discontinuation  End of Study/Ea rly Discontinuation 
EoS/ED  
changed to  
End of Part A/Early Discontinuation  
EoA/ED  
Table 1  General 
Schedule of 
Assessments  
Trial Day (Visit 
Windows)  Trial Day (Visit Windows):  
(X+8)¬±1/ (X+15)¬±1/ (X+22)¬±1  
changed to  
(X+7)¬±1/ (X+14)¬±1/ (X+21)¬±1  Trial Day (Visit Windows) 
timings were corrected.  
Table 1  General 
Schedule of 
Assessments  
Trial Day (Visit 
Windows)  Trial Day (Visit Windows):  
Y (¬±2)  
changed to  
Y+30 (¬±2)  Clarification added that these 
visits occur 30 days after the previous visit.
 
Table 1  General 
Schedule of 
Assessments  Deleted:  
EoT n There is no End of Treatment 
visit.  
Table 1  General 
Schedule of 
Assessments  Text added:  
Y=previous visit  Y added to footnotes for 
clarification.  
Table 1  General 
Schedule of 
Assessments  
Footnote  EoS/ED=End o f Study/Early Discontinuation; 
changed to  
EoA/ED=End of Part A/Early Discontinuation;  See summary above.  
Table 1  General 
Schedule of 
Assessments  
Footnote  Deleted:  
EoT=End of Treatment  There is no End of Treatment 
visit.  
Table 1  General 
Schedule of 
Assessments  b The intertreatment period visits (ITP nVn) occur every 
30 days after the previous vi sit. The visit denominator 
(‚Äòn‚Äô) will start at 1 at each period. At each ITP nVn, an See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 117 Section  Change  Rationale  
Footnote b evaluation of the need for (re-)treatment should be 
done prior to decide whether assessments listed for ITP
nVn or TP nV1 are to be performed. 
changed to  
b The intertreatment period visits (ITP nVn) occur every 
30 days after the previous  visit (Y). The visit 
denominator (‚Äòn‚Äô) will start at 1 at each period. At each 
ITP nVn, an evaluation of the need for (re- )treatment 
should be done prior to deciding whether the 
assessments listed for ITP nVn or TP nV1 are to be 
performed. If an ITP visit for Part  A is scheduled 
within 14 days of the EoA visit, then this EoA visit 
should be performed ins tead. For patients that 
discontinue at the ITP visit this will then serve as the EoA/ED visit.
 
Table 1  General 
Schedule of 
Assessments  
Footnote c  c  If a patient becomes eligible for (re- )treatment with 
ARGX -113 per total MG-ADL score but cannot 
complete the entire Treatment Period within the trial 
duration, the patient should receive appropriate alternative MG therapy and continue to the EoS visit. 
changed to
 
c  If a patient becomes eligible for (re- )treatment with 
ARGX -113 per total MG-ADL score, but cannot 
complete the entire Treatment Period within Part A of 
the trial (re -treatment in Part A can start at the latest on 
Day 336), then the patient will be transi tioned to Part B 
after completing the EoA visit. If the patient is  not 
willing or able to continue to Part  B then they should 
continue to the EoA visit. The transition to Part B can 
be either ITPE 0V1 or TPE 1V1, depending on the 
patient status regarding the  need for (re-)treatment 
upon transition from Part A. The first visit in Part B 
will always coincide with the EoA visit in Part  A. The 
assessments done for the last visit in Part A should not 
be repeated in Part  B. 
Footnote c was added to the assessment End of Part A. 
Table 1  General 
Schedule of 
Assessments  
Footnote d  d An unscheduled (UNS) visit can be on  request of the 
patient or the Investigator.  
changed to  
d An unscheduled (UNS) visit can occur at the  request 
of the patient or the Investigator.  Use of language corrected. 
Table 1  General 
Schedule of 
Assessments  i Weight will be measured at SEB, at the EoS/ED  visit, 
and when there is an obvious weight change compared 
to the last weight assessment.  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 118 Section  Change  Rationale  
Footnote i changed to 
i Weight will be measured at SEB, at the EoA/ED  visit, 
and when there is an obvious weight change compared 
to the last weight assessment.  
Table 1  General 
Schedule of 
Assessments  
Footnote s  s For patients who discontinue early from trial 
treatment, the assessments will depend on the visit at 
which it was decided that the patient had to discontinue trial treatment (see Section 5.4). Patients who discontinue early from trial treatment within a 
Treatment Period will have to complete the EoT
 
assessments and complete the remaining visits in the 
current Treatment Period according to this Schedule of Assessments. These patients will not receive any further administration of ARGX
-113 during the trial 
and will continue to be followed for safety and disease 
severity as per Schedule of Assessments for Patients 
who Discontinued Early from Trial Treatment (Table 2). Patients who discontinue early from trial treatment in the 
Intertreatment Period will have to complete the 
EoT assessments and then continue into the Safety and 
Disease Severity Follow -up period per Table 2. 
changed to  
s For patients who discontinue early from trial, the 
assessments will depend on the visit at which it was 
decided that the patient had to discontinue (see Section 5.4). Patients who discontinue early from the trial 
within a Treatment Period should perform the planned 
assessments of the corresponding Treatment Period visit. These patients will not receive any furth
er 
administration of ARGX -113 during the trial and will 
return for the ED visit one month (30 ¬± 2 days) after 
the last dose administration. An unscheduled visit can 
be organized if deemed necessary by [CONTACT_737]. 
Patients who discontinue early from the trial between the last visit of a Treatment Period (TP
nV4) and the 
next intertreatment period visit (ITP nVn) should 
perform the ED assessments one month (30 ¬± 2 days) 
after the last dose administration. Patients who 
discontinue early from the trial at the ITP visit should perform the ED assessments, instead of the ITP
nVn 
assessments. Patients who discontinue early from the 
trial after the ITP visit should perform the ED assessments.
 
Footnote s was added to the assessment Early 
Discontinuation.  In order to simplify the safety 
follow -up the different 
scenarios have now been 
linked to the last dose, in order to see what schedule 
needs to be followed for 
further safety follow
-up. 
 
There is no End of Treatment 
visit.  
Table 2:  Schedule of 
Assessments for Table 2 was deleted.  Patients will not be followed 
for safety and disease 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 119 Section  Change  Rationale  
Patients who 
Discontinued Early 
from Trial Treatmenta severity every 30 days. The 
new scenario for early 
discontinuation means that 
patients should perform the ED visit instead (at least [ADDRESS_241130] administration of study drug). 
Figure 1: ARGX -113-
1705 Trial Design  Scenario for early discontinuation added.  
Figure 1: ARGX -113-
1705 Trial Design  Footnotes for ED, EoA, SEB and SoC added  See summary above.  
Title:  
Figure 1:  ARGX-113-1705 Trial Design 
changed to  
Figure 1: ARGX -113-1705 Trial Design for Part A  
EoS 
changed to  
EoA 
Table 2  General 
Schedule of 
Assessments for Part 
B  A new table for the Schedule of Assessments for Part 
B has been added.  
Figure 2: ARGX- 113-
[ADDRESS_241131] of abbreviations updated to include cycle, EoA, 
EoS, ITPEV, TP, TPE, TPE nB and TPEV, and EoT 
removed.  
4.  
INVESTIGATIONAL 
PLAN  
4.2.  Discussion of 
Trial Design  This trial is designed as a 1 -year, single-arm, open-
label, follow -on extension trial of ARGX-113- 1704. 
With the exception of patients who discontinued early 
from trial ARGX-113-1704 or patients who 
discontinued early from  trial treatment for rescue or 
pregnancy reasons or an (S)AE that might jeopardize 
the safety of the patient in that trial, all participants of 
trial ARGX -113- 1704 who reached the EoS visit (Day 
182) are allowed to roll over into this trial.  
The first visi t of trial ARGX-113- [ADDRESS_241132] visit of trial ARGX -113- 1704 for each 
patient.  
changed to  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 120 Section  Change  Rationale  
This trial is designed as a 3-year (maximum), single-
arm, open -label, follow-on extension trial of ARGX -
113-1704. The trial consists of two parts: Part A (1 
year) and Part B (up to maximum [ADDRESS_241133]. The additional part (Part B) was added to ARGX
-113-[ADDRESS_241134] visit of Part A for each patient.  
4.  
INVESTIGATIONAL PLAN
 
4.2.  Discussion of 
Trial Des ign A change of the type or dose/regimen of SoC ‚Ä¶  
‚Ä¶ 
The chosen primary and secondary endpoints in this 
trial are to evaluate the long -term safety and 
tolerability of ARGX -113 over 1 year and at each 
Treatment Period in AChR- Ab seropositive patients 
and in the overall population (AChR- Ab seropositive 
and seronegative patients).  
changed to  
In Part A, a change of the type or dose/regimen of SoC 
‚Ä¶ 
‚Ä¶ 
In Part B, a change of the type or dose/regimen of SoC 
(replacing, adding or removing SoC, or adjustment of See summary above.  
 
Part B allows for freedom of 
changing therapy and there 
will be no restrictions on the type of therapy that can be 
used. This because Part
 B 
will shift to a more re al-life 
approach.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 121 Section  Change  Rationale  
the SoC dose and/or frequency) is allowed, without 
restrictions, following current medical practice.  
PLEX, IVIg, immunoadsorption or use of a new type 
of corticosteroid or an in creased dose of the current 
corticosteroids used as stand -alone therapy or in 
combination is also allowed in Part  B. 
The chosen primary and secondary endpoints in this 
trial are to evaluate the long -term safety and 
tolerability of ARGX -113 over the duration of the 
trial, as w ell as by [CONTACT_5265] , in AChR- Ab seropositive 
patients and in t he overall population (AChR-Ab 
seropositive and seronegative patients).  
4.  
INVESTIGATIONAL PLAN
 
4.4.  Early 
Discontinuation  4.4.  Early Discontinuation  
‚Ä¶ 
4.4.1.  Early Discontinuation from Trial  
‚Ä¶ Patients must be discontinued early from the trial 
and complete the EoS/ED visit if:  
‚Ä¢ They withdraw their cons ent. 
‚Ä¢ The Investigator, after discussion with the sponsor ‚Äôs 
Medical Director, deems it is in the patient‚Äôs best 
interest.  
All patients are free to withdraw consent from 
participation in the trial at any time, for any reason, specified or unspecified, and 
without prejudice to 
further treatment. Prior to actual withdrawal of 
consent, an effort should be  made to perform a final set 
of assessments as per EoS/ED visit in the General Schedule of Assessments (Table 1). Investigators will make and document all efforts made to contact [CONTACT_202006].
 
changed to  
4.4.  Early Discontinuation  
‚Ä¶ 
‚Ä¶ Patients must be discontinued early from the trial if:  
‚Ä¢ They withdraw their consent.  
‚Ä¢ The Investigator, after discussion with the sponsor ‚Äôs 
Medical Director, deems it is in the patient‚Äôs best 
interest.  
‚Ä¢ Patient is pregnant.  
‚Ä¢ Patients receives rescue therapy.  In order to reduce the burden 
on the patients, the safety follow
-up period has been 
replaced by [ADDRESS_241135] 
the trial after a limited safety 
fo
llow-up period. 
 
If warranted further safety 
follow -up can be performed 
by [CONTACT_202085].  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 122 Section  Change  Rationale  
‚Ä¢ Patient develops an SAE that  is likely to result in a 
life-threatening situation or pose a serious safety risk to 
the patie nt. 
‚Ä¢ Prohibited medication is taken (see Section 6.8.1).  
Patients might discontinue early from the trial if:  
‚Ä¢  Patient has clinical evidence of bacterial, viral or 
fungal disease or any other significant disease which could confound the results of the trial or put the patient 
at undue risk. In this situation, decision on whether or 
not to discontinue patients early from trial will depend 
on the evaluation on a case
-by-case basis. Patients 
who, after evaluation of the above situations are not 
discontinued from the trial, may have a temporary 
interruption from trial treatment (see Section 4.4.1). 
For patients who discontinue early from trial, the 
assessments will depend on the visit at which it was decided that the patient had to discontinue (see Section 5.4
). 
Patients who discontinue early from the trial within a 
Treatment Period should perform the planned 
assessments of the corresponding Treatment Period visit. These patients will not receive any further administration of ARGX
-113 during the trial and will 
return for the ED visit one month (30 ¬± 2 days) after 
the last dose administration. An unscheduled visit can be organized if deemed necessary by [CONTACT_737]. 
Patients who discontinue early from the trial between 
the last visit of a Treatment Period (T
PnV4 or TPE nV4) 
and the next Intertreatment Period visit (ITP nVn or 
ITPE nVn) should perform the ED assessments one 
month (30 ¬± 2 days) after the last dose administration. 
Patients who discontinue early from the trial at the ITP 
(Part A) or ITPE (Part B) visit should perform the ED assessments, instead of the ITP
nVn (Part A) or 
ITPE nVn (Part B) assessments. 
Patients who discontinue early from the trial after the 
ITP (Part A) or ITPE (Part B) visit should perform the 
ED assessments.  
Any patient prematurely discontinuing the trial during 
Part A should perform the EoA/ED assessments according to the General Schedule of Assessments for Part
 A (Table 1). Any patient prematurely 
discontinuing the trial during Part B should perform 
the EoS/ ED assessments according to the General 
Schedule of Assessments for Part B (Table 2).  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 123 Section  Change  Rationale  
All patients are free to withdraw consent from 
participation in the trial at any time, for any reason, 
specified or unspecified, and without prejudice to 
further treatmen t. Prior to actual withdrawal of 
consent, an effort should be  made to perform a final set 
of assessments as per the EoA/ED visit in the General 
Schedule of Assessments for Part A (Table 1) or the EoS/ED visit in the General Schedule of Assessments 
for Part
 B (Table 2). Investigators will make and 
document all efforts made to contact [CONTACT_202086].  
4.  
INVESTIGATIONAL PLAN
 
4.4.  Early 
Discontinuation  
4.4.2.  Early 
Discontinuation from Trial 
Treatment Section deleted.  
4.  
INVESTIGATIONAL PLAN
 
4.4.  Early 
Discontinuation  
4.4.3.  Temporary 
Interruption from Trial Treatment
 A patient who does not need to be discontinued early 
from trial treatment  might still have a temporary 
interruption from trial treatment. ‚Ä¶  
Patients for whom treatment is interrupted will have to 
complete the current Treatment Period and will continue the trial as per General Schedule of Assessments (Table 1).
 
changed to  
A patient who does not need to be discontinued early 
from the trial  might still have a temporary interruption 
from trial treatment. ‚Ä¶  
Patients for whom treatment is interrupted will have to 
complete the current Treatment Period and will continue the trial as per
 the General Schedule of 
Assessments for Part A (Table 1) or for Part  B (Table 
2). A patient who has had a temporary interruption of 
trial treatment in Part A may also continue into Part B of the trial and receive (re
-)treatment if the conditions 
mentioned  above are met. 
4.  
INVESTIGATIONAL 
PLAN  
4.4.  Early 
Discontinuation  Patients who miss one, two or three infusions per 
Treatment Period will stay in the trial and will follow 
the assessments as per General Schedule of Assessments (Table 1). These patients may be eligible for further Treatment Periods during the trial.
 
changed to  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 124 Section  Change  Rationale  
4.4.4. Missed Doses Patients who miss one, two or three infusions per 
Treatment Period will stay in the trial and will follow 
the assessments as per the General Schedule of 
Assessments for Part  A (Table 1) or for Part B 
(Table  2). These patients may be eligible for further 
Treatment Periods during the trial. A patient who has 
missed doses in Part A may also continue into Part B of the trial and receive (re
-)treatment if the c onditions 
in Section 4.4.3 are met.  
5.  TRIAL 
PROCEDURES  Patients should be seen for all visits on the designated 
days or as closely as possible to the original planned 
visit schedule. There is a permissible window of ¬±1 day for Treatment Period vis its (Visit 1 to Visit 4), of 
¬±2 days for ITP
nVn, and of ¬±7 days for the EoS visit 
(Day 365). Every effort should be made to schedule 
every visit on the exact day (which is relative to the 
Baseline visit [SEB or TP nB]) within the window as 
described in the General Schedule of Assessments 
(Table 1).  
‚Ä¶ 
The SEB will be set  at the first trial visit, while the 
Baseline of each subsequent Treatment Period ( TP nB) 
will be set at Visit 1 of each corresponding Treatment 
Period.  
‚Ä¶ The MG -ADL scale needs to be performed prior to 
the QMG scale. Acetylcholinesterase inhibitors must 
be halted for at least 12 hours before the QMG 
assessment.  
‚Ä¶ 
As from signature [CONTACT_202101], all 
AEs that occur ‚Ä¶  
Patients who are discontinued early from trial 
treatment, after they have completed the EoT assessments and, if applicable, the
 remaining visits of 
the current Treatment Period, will return every month 
(30 ¬± 2 days) for Follow -up visits until Day 365 as per 
Schedule of Assessments for Patients who 
Discontinued Early from Trial Treatment (Table 2). 
These patients will then continue  in the trial to be 
followed for safety and disease severity.  
changed to  
Patients should be seen for all visits on the designated 
days or as closely as possible to the original planned 
visit schedule. There is a permissible window of ¬±1 
day for Treatment Period vis its (Visit 1 to Visit 4), of 
¬±2 days for ITP nVn (Part A), and of ¬±7 days for the 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 125 Section  Change  Rationale  
ITPE nVn (Part B), EoA visit (Day 365) and EoS visit 
(Day [ADDRESS_241136]). Every effort should be made to schedule every visit on the exact day (which is relative to the Baseline visit [SEB, or TP
nB or TPE nB]) within the window as 
described in the General Schedule of Assessments for 
Part A (Table 1) and for Part B (Table 2). 
‚Ä¶ 
The SEB will be set at the first trial visit, while the 
Baseline of each subsequent Treatment Period ( TP nB or 
TPE nB) will be set at Visit 1 of each corresponding 
Treatment Period.  
‚Ä¶ The MG -ADL scale needs to be performed prior to 
the QMG scale (Part  A) as per Table 1. 
Acetylcholinesterase inhibitors must be halted for at 
least 12 hours before the QMG assess ment (Part A). 
‚Ä¶ 
As from signature [CONTACT_202102], all AEs that occur ‚Ä¶  
5.  TRIAL 
PROCEDURES  
5.2.  Treatment Period ‚Ä¶ A new Treatment Period can only be started if it can 
be completed within the 1 -year trial duration. 
changed to 
5.2.1.  Treatment Period Part A  
‚Ä¶ A new Treatment Period can only be started if it can 
be completed within the 1 -year trial duration of Part A 
of the trial (re -treatment in Part A can start at the latest 
on Day  336). Otherwise the patient can be transit ioned 
to Part B after completing the EoA visit. If the patient 
is not willing or able to continue to Part B, then he/she should continue to the EoA visit.
 
5.  TRIAL 
PROCEDURES  
5.2.  Treatment Period 
5.2.1.  Treatment 
Period Part A  Patients who fail to re spond to ARGX- 113 for three 
consecutive Treatment Periods will be discontinued 
from further treatments with ARGX -113 but will 
remain in the trial to receive appropriate alternative 
MG therapy. ‚Ä¶  
If a patient becomes eligible for (re -)treatment with 
ARGX -113 per total MG-ADL score but cannot 
complete the entire Treatment Period within the trial 
duration, the patient should receive appropriate alternative MG therapy and continue to the EoS visit. 
changed to
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 126 Section  Change  Rationale  
Patients who fail to respond to ARGX-113 for three 
consecutive Treatment Periods will be discontinued from the trial. ‚Ä¶
 
If a patient becomes eligible for (re -)treatment with 
ARGX -113 per total MG-ADL score but cannot 
complete the entire Treatment Period within Part A of 
the trial (re -treatment in Part A ca n start at the latest on 
Day 336) then the patient will be transitioned to Part B 
after completing the EoA visit. If the patient is not 
willing or able to continue to Part B then he/she should 
continue to the EoA visit.  
The transition to Part B can be eith er ITPE 0Vn or 
TPE 1V1, depending on the patient status regarding the 
need for (re -)treatment upon transition from Part A. 
The first visit in Part B will always coincide with the 
EoA visit in Part A. The assessments done for the last visit in Part
 A should not be repeated in Part B. 
5.  TRIAL 
PROCEDURES  
5.2.  Treatment Period 
5.2.2.  Treatment 
Period Part  B Extra section added for Part B:  
5.2.2.  Treatment Period Part B 
A Treatment Period will include assessments in 4 
weekly visits including treatment with ARGX- 113 in 
eligible patients in need for (re -)treatment. A new 
Treatment Period can only be started if it can be 
completed within the trial duration (up to maximum [ADDRESS_241137]).
 
The following assessments will be performed from 
Visit 1 to Visit 4 of each Treatment Period:  
‚Ä¢ Assessments of disease severity (MG -ADL scale). (*) 
‚Ä¢ Weight will be measured at Visit [ADDRESS_241138] weight 
assessment.(*)  
‚Ä¢ Vital signs.(*)  
‚Ä¢ Clinical laboratory tests (local labs), only at Visit 1 
and Visit 4 of each Treatment Period.(*)  
‚Ä¢ Urinalysis, only at Visit 1 and Visit 4 of each 
Treatment Period.( *) 
‚Ä¢ Urine pregnancy test (only for women of childbearing 
potential, see DEFINITION OF TERMS), only at Visit 1 and Visit 4 of each  Treatment Period.(*)
 
‚Ä¢ ADA, only at Visit 1 of each Treatment Period (*)  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 127 Section  Change  Rationale  
‚Ä¢ Administration of ARGX -[ADDRESS_241139] 1 hour following the end of the infusion for safety 
monitoring, based on the patient‚Äôs clinical status.  
‚Ä¢ Review of concomitant medication.  
‚Ä¢ Assess AEs if any.  
(*) These assessments should  be performed prior to 
administration of ARGX -113 (predose). 
At Visit 1 of each Treatment Period, the conditions for 
(re-)treatment will be checked before administration of 
ARGX -113 (see Section 4.1). 
Patients may not receive (re -)treatment with ARGX -
113 i f, at the time of (re- )treatment, they have clinical 
evidence of bacterial, viral or fungal disease, or any 
other significant disease which could confound the 
results of the trial or put patients at undue risk.  
If a patient becomes eligible for (re -)treatm ent with 
ARGX -[ADDRESS_241140] a clinical benefit from re -treatment then the 
patient cannot start a new Treatment Period. The 
patient should then con tinue to the EoS visit.  
A change of the type or dose/regimen of SoC 
(replacing, adding or removing SoC, or adjustment of 
the SoC dose and/or frequency) is allowed, without restrictions, f
ollowing current medical practice. 
5.  TRIAL 
PROCEDURES  
5.3.  Intertreatment 
Period  Intertreatment  Period visits occur every 30 days after 
the previous visit.  
At each ITP nVn, an evaluation of the need for (re-
)treatment should be done. In case the patient is not in 
need of (re -)treatment, assessments for ITP nVn should 
be performed as listed below and per the General 
Schedule of Assessments (Table  1). However, in case 
the eval uation shows that the patient is in need of 
(re-)treatment and is also eligible for (re- )treatment, the 
assessments according to TP nV1 are to be performed 
instead (see Section 5.2).  
The following assessments will be performed:  
changed to  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 128 Section  Change  Rationale  
Intertreatment Period visits occur every 30 days after 
the previous visit in Part A and every 90 days after the 
previous visit in Part B.  
At each ITP nVn (Part A) or ITPE nVn, (Part B) an 
evaluation of the need for (re -)treatment should be 
done. In case the patient is not in need of (re-
)treatment, assessments for ITP nVn (Part A) or 
ITPE nVn (Part B) should be performed as listed below 
and per the General Schedule of Assessments for Part 
A (Table 1) or for Part  B (Table 2). However, in case 
the evaluation shows that the patient  is in need of (re-
)treatment and is also eligible for (re -)treatment, the 
assessments according to TP nV1 (Part A) or TPE nV1 
(Part B) are to be performed instead (see Section 5.2). 
If an ITP visit for Part A is  scheduled within 14 days of 
the EoA visit, then the EoA visit should be performed 
instead.  
The following assessments will be performed in Part 
A: 
5.  TRIAL 
PROCEDURES  
5.3.  Intertreatment 
Period  The following text added:  
The following assessments will be performed in Part 
B: 
‚Ä¢ Assessments of disease severity (MG- ADL scale). 
‚Ä¢ Vital signs.  
‚Ä¢ Urine pregnancy test (only for women of childbearing 
potential, see DEFINITION OF TERMS).  
‚Ä¢ Review of concomitant medication.  
‚Ä¢ Assess AEs, if any.  
5.  TRIAL 
PROCEDURES  
5.4.  End of Treatment Section deleted. There is no End of Treatment 
visit.  
5.  TRIAL 
PROCEDURES  
5.5.  Safety and 
Disease Severity 
Follow -up Period for 
Patients who 
Discontinued Early from Trial Treatment Section deleted.  In order to reduce the burden 
on the patients, the safety 
follow -up period has been 
replaced by 1 safety follow-
up visit.  
5.  TRIAL 
PROCEDURES  5.6.  End of Study and Early Discontinuation (EoS/ED) 
Visit  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 129 Section  Change  Rationale  
5.6.  End of Study and 
Early Discontinuation (EoS/ED) Visit
 In case of early discontinuation from the trial, the same 
assessments as scheduled for EoS (Day 365) must be performed as follows:
 
‚Ä¢ Assessments of disease severity. ‚Ä¶ (*)  
‚Ä¢ ‚Ä¶(*)  
 
(*) Only applicable for patients following Table 1.  
changed to  
5.5.  End of Part A, End of Study and Early 
Discontinuation (EoA/ED or EoS/ED) Visit  
In case of early discontinuation, the same assessments 
as scheduled for EoA (Day  365) or EoS (Day [ADDRESS_241141]) must be performed as 
follows:  
For EoA/ED (Part A):  
‚Ä¢ Assessments of disease severity. ‚Ä¶  
‚Ä¢ ‚Ä¶ 
For EoS/ED (Part B):  
‚Ä¢ Assessments of disease severity (MG -ADL scale) 
should be performed prior to any other  assessments 
except for the weight assessment.  
‚Ä¢ Physical examination.  
‚Ä¢ Weight.  
‚Ä¢ Vital signs.  
‚Ä¢ Clinical laboratory tests (local labs).  
‚Ä¢ Urinalysis.  
‚Ä¢ Urine pregnancy test (only for women of childbearing 
potential, see DEFINITION OF TERMS).  
‚Ä¢ ADA (only in case of ED). 
‚Ä¢ Review of concomitant medication.  
‚Ä¢ Assess AEs, if any.   
Part B allows for freedom of 
changing therapy and there 
will be no restrictions on the type of therapy that can be used and no prohibited medications. This is because Part B will shift to a more real
-life approach. 
6.  TRIAL 
TREATMENT  
6.8.  Prior Treatments 
and Concomitant 
Medications  The following medications or treatments will lead to 
discontinuation from treatment during the trial  as from 
SEB onwards:  
changed to  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 130 Section  Change  Rationale  
6.8.1.  Prohibited 
Medications during the Trial
 The following medications or treatments will lead to 
discontinuation from treatment during Part A of the 
trial as from SEB onwards: 
6.  TRIAL 
TREATMENT  
6.8.  Prior Treatments 
and Concomitant Medications
 
6.8.1.  Prohibited 
Medications during 
the Trial  The following text added:  
In Part B of the trial, a change of the type or 
dose/regimen of SoC (replacing, adding or removing SoC, or adjustment of the SoC dose and/or frequency) is allowed without restrictions, following standard clinical practice.
 
PLEX, IVIg, immunoadsorption or use of a new type 
of corticosteroid or an in creased dose of the current 
corticosteroids used as stan d-alone therapy or in 
combination is also allowed in Part  B. 
6.  TRIAL 
TREATMENT  
6.9.  Medical Care of 
Patients after End of 
Study  Sentence deleted:  
‚Ä¶ The Sponsor will not provide any additional care to 
these patients, neither will ARGX -[ADDRESS_241142] ‚Ä¶ according to the General Schedule of Assessments 
(Table  1). ‚Ä¶  
changed to  
‚Ä¶ according to the General Schedule of Assessments 
for Part A (Table  1) and for Part B (Table 2). ‚Ä¶  See summary above.  
7.  TRIAL 
ASSESSMENTS  
7.1.  Monitoring of 
Disease Severity  Monitoring of disease severity will be assessed using 
MG-ADL and QMG. Both assessments have to be 
performed pre dose on all ARGX- 113 infusion days and 
prior to any other assessment at each visit except for 
the assessment of weight (if applicable) and signing of the ICF at SEB. The MG
-ADL scale needs to be 
performed prior to the QMG scale (Table 1).  
changed to  
Monitoring of disease severity will be assessed using 
MG-ADL (Part A and B) and QMG (Part A only). The 
assessments, where applicable, have to be performed 
predose on all ARGX- 113 infusion days and prior to 
any other assessment at ea ch visit, except for the 
assessment of weight (if applicable) and signing of the 
ICF at SEB. The MG -ADL scale needs to be 
performed prior to the QMG scale in Part  A (Table 1). 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 131 Section  Change  Rationale  
7.  TRIA L 
ASSESSMENTS  
7.1.  Monitoring of 
Disease Severity  
7.1.1.  Myasthenia 
Gravis  Activities of 
Daily Living  ... It evaluates the capacity to perform different 
activities of daily living such as talking, chewing, 
swallowing, breathing, brushing the teeth/combing the 
hair, or arising from the chair and it also assesses 
double vision and eyelid droop.  
changed to  
‚Ä¶It evaluates the capacity to perform different 
activities of daily living such as talking, chewing, 
swallowing, breathing, brushing the teeth/combing the 
hair, or rising from a chair and it also assesses double 
vision and eyelid droop.  Sentence corrected.  
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  Safety assessments will consist of monitoring and 
recording all AEs, pregnancies, suicidality assessment,  
safety laboratory testing, measurement of vital signs, ECGs,
 physical examinations; ‚Ä¶  
changed to  
Safety assessments  will consist of monitoring and 
recording all AEs, pregnancies, suicidality assessment 
(Part  A only), safety laboratory testing, measurement 
of vital signs, ECGs (Part A only), physical 
examinations; ‚Ä¶  See summary above.  
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
[IP_ADDRESS].  Reporting of 
Adverse Events and Serious Adverse Events
 All AEs that occur during the trial from signature [CONTACT_202103] (either ‚Äòserious‚Äô or ‚Äònon -serious‚Äô) in the 
eCRF. ‚Ä¶  
changed to  
All AEs that occur during the trial from signature [CONTACT_202104] ( either ‚Äòserious‚Äô or ‚Äònon -
serious‚Äô) in the eCRF.  
Additional text added:  
All SAEs that are spontaneously reported within [ADDRESS_241143] trial visit are to be collected and 
reported as previously described and all efforts should be made to follow
-up until resolution. In order to comply with 
generally accepted safety pharmacovigilance 
guidelines, this paragraph has 
been added.
 
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
7.2.1.  Adverse Events 
[IP_ADDRESS].  Follow -up of 
Adverse Events and Any AEs observed from signing the ICF to the EoS 
visit will be followed up to resolution, ‚Ä¶  
‚Ä¶ 
All SAEs that are spontaneously reported after the EoS 
visit are to be ‚Ä¶  
changed to  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241144] 
study visit  will be followed up to resolution, ‚Ä¶  
‚Ä¶ 
All SAEs that are spontaneously reported after the last 
study visit are to be ‚Ä¶ 
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
7.2.1.  Adverse Events 
[IP_ADDRESS].  Reporting and 
Follow -up 
Requirements for 
Pregnancies  
[IP_ADDRESS].1.  Pregnancies 
in Female Patients Urine pregnancy tests will be conducted and analyzed 
locally at  all visits as detailed in the General Schedule 
of Assessments (Table 1).  
changed to  
Urine pregnancy tests will be conducted and analyzed 
locally at visits as detailed in the General Schedule of Assessments for Part
 A (Table 1) and for Part B 
(Table  2). Results will be recorded in the eCRF. 
‚Ä¢  The patient should have EoT assessments.  
‚Ä¢  All assessments for EoT (see Sections 4.4.2 and 5.4) 
must be performed unless contraindicated by [CONTACT_8663] ‚Ä¶
 
changed to  
‚Ä¢  The patient should have the planned ED assessments. 
‚Ä¢  All planned assessments (see Sections 4.4.2 and 5.4) 
must be performed unless contraindicated by [CONTACT_8663] ‚Ä¶
 There is no End of Treatment 
visit.  
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
7.2.2.  Clinical 
Laboratory Evaluations
 Blood and urine samples for determination of clinical 
chemistry, hematology, urinalysis, PD, and ADA will be analyzed at a central lab as indicated in the General Schedule of Assessments (Table 1) and Appendix 3. Patients need to be fasting for at least [ADDRESS_241145] 8 
hours prior to the sampling for clinical laboratory tests as from SEB up to EoS.
 
‚Ä¶ 
For all patients of childbearing potential, a urine 
pregnancy test will be conducted and analyzed locally 
at the site (on the urine samples taken for urinalysis) at 
all visits (Table 1).  
The estimated total maximum blood volume needed for 
a patient during the trial (when completing the trial up until the last visit) is between 170 mL for a patient who 
receives 1 Treatment Period only and 362
 mL for a 
patient who receives a maximum of 6 Treatment 
Periods.  See summary above.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241146], which will be 
conducted and analyzed locally, all samples will be analyzed centrally.
 
changed to  
In Part  A blood and urine samples for determination of 
clinical chemistry, hematology and urinalysis will be 
analyzed at a central laboratory. PD and ADA will be analyzed at a specialty labor atory as indicated in the 
General
 Schedule of Assessments for Part A (Table  1) 
and Appendix 3. Patients need  to be fasting for at least 
8 hours prior to the sampling for clinical laboratory 
tests as from SEB up to EoA.  
In Part B, blood and urine samples for determination of 
clinical chemistry, hematology and urinalysis will be 
analyzed at local laboratories and results will not be 
recorded in the eCRF. Blood samples for ADA will be analyzed at a specialty labor atory as indicated in the 
General Schedule of Assessments for Part
 B (Table  2) 
and Appendix 3. 
‚Ä¶ 
For all patients of childbearing potential, a urine 
pregnancy test will be conducted and analyzed locally at the site (on the urine samples taken for urinalysis, if 
applicable) at all visits in Part 
 A (Table 1) and at 
Visit  1 and 4 of eac h Treatment Period, at ITPE visits, 
at EoS/ED and at the discretion of the Investigator in 
Part B (Table 2).  
The estimated total maximum blood volume needed for 
a patient during Part A of the trial (when completing the trial up until the last visit) is between 170 mL for a patient who receives 1 Treatment Period only and 362 
mL for a patient who receives a maximum of 6 
Treatment Periods. The estimated total maximum blood volume needed for a patient during Part B of the trial (when completing the trial up until the last visit) is between 24
 mL for a patient who receives 1 Treatment 
Period only and 100  mL for a patient who receives 6 
Treatment Periods.  
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
7.2.3.  Vital Signs, 
Physical Examination, and ECG
 Assessment of vital signs (supi[INVESTIGATOR_9204], heart 
rate, and body temperature), physical examination and ECG will be performed at the time points indicated in the General Schedule of Assessments (Table 1) (pre
dose at dosing days). 
A 12 -lead ECG will be r ecorded locally as per local 
regulations ‚Ä¶  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 134 Section  Change  Rationale  
changed to 
Assessment of vital signs (supi[INVESTIGATOR_9204], heart 
rate, and body temperature), physical examination and 
ECG (Part  A only) will be performed at the time points 
indicated in the General Schedule of Assessments for 
Part A (Table 1) and for Part B (Table 2) (predose at 
dosing days).  
Weight will be measured at SEB, at the EoS/ED visit, 
and can be repeated ‚Ä¶  
changed to  
Weight will be measured at SEB, at the EoA/ED visit, 
at Visit  1 of Part B, at the EoS/ED visit, and can be 
repeated ‚Ä¶  
A 12 -lead ECG will be recorded locally (only for Part 
A) as per local regulations ‚Ä¶  
7.  TRIAL 
ASSESSMENTS  
7.2.  Safety  
7.2.4.  Suicidality 
Assessment  As is recommended ‚Ä¶suicidal ideation and behavior 
will be included in this clinical trial. 
changed to  
As is recommended ‚Ä¶ suicidal ideation and behavior 
will be included in this clinical trial (Part A only).  
7.  TRIAL 
ASSESSMENTS  
7.3.  
Pharmacodynamics The PD markers (total IgG and IgG subtypes [IgG1, 
IgG2, IgG3 and IgG 4], and ‚Ä¶  
changed to  
In Part A, the PD markers (total IgG and IgG subtypes 
[IgG1, IgG2, IgG3 and IgG4], and ‚Ä¶  
7.  TRIAL 
ASSESSMENTS  
7.4.  Anti -Drug 
Antibodies  Blood samples to assess ADA will be collected 
predose at the time points as indicated in Table 1. At 
Baseline (SEB and TP nB), confirmatory and titer 
analysis ‚Ä¶  
changed to  
Blood samples to assess ADA will be collected 
predose at the time points as indicated in Table 1 and 
Table  2. At Baseline (SEB, TP nB and TPE nB), 
confirmatory and titer analysis ‚Ä¶  
8.  STATISTICS  Wording added:  
Endpoints will be summarized by [CONTACT_3148] (as 
received in ARGX -113-1704). Wording added for 
clarification.  
8.  STATISTICS  A tabular presentation of the patient disposition will be 
provided. It will include the number of patients Wording corrected; statistical 
analysis will be carried out 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 135 Section  Change  Rationale  
8.3.  Patient 
Disposition, 
Characteristics and 
Concomitant Medication
 screened , enrolled, completed (per Treatment Period),  
‚Ä¶ 
‚Ä¶ 
A list of protocol violations will be identified and 
discussed with the Investigator to categorize as major or minor and the same will be reported.
 
‚Ä¶ 
Use of concomitant medication will be summarized by 
[CONTACT_202087]. All 
concomitant medications used will be listed.  
changed to  
A tabular presentation of the patient disposition will be 
provided. It will include the number of patients 
enrolled, completed ( by [CONTACT_5265] ), ‚Ä¶ 
‚Ä¶ 
Use of concomitant medication will be summarized 
with frequency and percentage. All concomitant 
medications used will be listed.  per cycle (Treatment Period + 
Intertreatment  Period) not 
just per Treatment Period. 
The protocol violation 
process is not relevant for the statistics in this section.
 
8.4.  Statistical 
Methods  
8.4.  Statistical 
Methods  
8.4.1.  Primary and 
Secondary Endpoint Analyses
 Frequency tables will be made for all binary variables, 
i.e., AEs, for all available time points, by [CONTACT_202088] (including Intertreatment Period) and overall. 
Summary statistics will be provided for the continuous 
endpoints (e.g., laboratory values, vital signs, ECGs) in terms of absolute values and changes from SEB (for 1-year assessment), and changes from Treatment Period Baseline (TP
1B), at each Treatment Period (including 
Intertreatment  Period),by [CONTACT_202060].  
changed to  
Frequency tables will be made for all binary variables, 
i.e., AEs, by [CONTACT_89835].  
Summary statistics will be provided for the continuous 
endpoints (e.g., laboratory values, vital signs, ECGs) in 
terms of absolute values and changes from TP 1B by 
[CONTACT_202061].  Corrected to reflect that AEs 
are not reported by [CONTACT_202089]. 
8.  STATISTICS  
8.4.  Statistical 
Methods  
8.4.2  Tertiary 
Endpoint Analyses The tertiary endpoints will be analyzed in a descriptive 
manner.  
Summary statistics will be provided for the continuous 
endpoints (e.g., total MD -ADL score, total QMG 
score, levels of total IgG and subtypes, anti -
AChR/anti -MuSK antibodies) in terms of absolute 
values and changes from SEB (for 1-year assessment) Corrected to reflect that 
changes from the treatment period baseline of the first 
cycle will be summarized 
(instead of changes from 
SEB) as patients might start 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 136 Section  Change  Rationale  
and changes from TPB, at each Treatment Period 
(including Intertreatment Period), and available time 
points. For levels of total IgG and subtypes and also 
anti-AChR/anti-MuSK antibodies, the percentage 
change from SEB and from TPB will also be 
presented. Every 30 days‚Äô percent change compared to 
SEB will be calculated.  
Frequency tables will be made for incidence of ADA to 
ARGX -113 every 30 days in patients who are (re-
)treated with ARGX -113, at SEB, at Visits 1 and 4 of 
each Treatment Period, an d at the EoS visit. In 
addition, within each Treatment Period, the proportion 
of patients treated with ARGX -113 that present ADA‚Äôs 
over all time points will be calculated together with 
95% confidence interval (CI) using Clopper -Pearson 
exact method.  
Interim analyses might be performed to support 
questions  for authorities and/or submissions. 
changed to  
The tertiary endpoints will be summarized 
descriptively.  
Summary statistics will be provided for the continuous 
endpoints (e.g., total MD -ADL score, total QMG 
score, levels of total IgG and subtypes, anti-
AChR/anti -MuSK antibodies) in terms of absolute 
values, changes from TP 1B or changes from TP nB, by 
[CONTACT_202061]. For levels of total IgG 
and subtypes and also anti -AChR/anti-MuSK 
antibodies, the percentage change from TP 1B and from 
TPnB will also be presented. 
Frequency tables will be made for incidence and 
prevalence of ADA to ARGX -113. 
8.5.  Interim Analyses  
Interim analyses might be performed to support 
questions for authorities and/or submissions.  the study with an 
intertreatment  period. 
 
ADA will also be 
summarized as is consistent with the literature.
 
 
An extra section has been 
added for interim analyses as 
these do not belong with the 
tertiary endpoints.  
Appendix 3:  
Laboratory Evaluations
 Note: All blood and urine samples will be collected 
locally (pre dose on dosing days) and analyzed 
centrally.  
changed to  
Note: For Part A, all blood and urine samples will be 
collected locally (pre dose on dosing days) and 
analyzed at a central or specialty laboratory. For Part 
B, blood and urine samples for clinical chemistry, 
hematology and urinalysis will be analyzed locally, Given the long time frame of 
the extension and the option 
of unscheduled visits being 
carried out at the request of the Investigator, the more flexible option of working with a local laboratory has been chosen over the central laboratory structure.
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 138 4.1. Summary of Trial 
Design  
ROLL -OVER (serious) adverse event ([S]AE) that might jeopardize 
the safety of the patient in th at trial will not be offered 
the option to roll over into this trial.‚Äù  
changed to  
‚ÄúPatients who discontinued early from trial ARGX -
113-1704 or discontinued early from randomized 
treatment for rescue or pregnancy reasons or for a 
serious adverse event (SAE) that is likely to result in a life
-threatening situation or pose a serious safety risk in 
that trial will not be offered th e option to roll over into 
this trial.‚Äù  serious safety risk in order to 
have the patient discontinued. 
SYNOPSIS  
(RE-)TREATMENT 
4.1. Summary of Trial 
Design  
(RE-)TREATMENT 
 ‚ÄúEach patient may start a (new) Treatment Period with 
ARGX -113 when all the following criteria apply: 
The patient has completed the previous Treatment 
Period; AND‚Äù  
changed to:  
‚ÄúEach patient will start a (new) Treatment Period with 
ARGX -113 when all the following criteria apply: 
The patient has completed the previous Treatment 
Period (i.e. after Visit 4); AND‚Äù  Wording adjusted for 
clarification. 
SYNOPSIS  
(RE-)TREATMENT 
4.1. Summary of Trial 
Design  
(RE-)TREATMENT ‚ÄúPatients who are in need of an additional treatment 
but who are not eligible to receive (re -)treatment for 
reasons listed here will remain in the trial to receive 
appropriate a lternative MG treatment.‚Äù  
changed to:  
‚ÄúPatients who are in need of an additional treatment 
but who are not eligible to receive (re -)treatment for 
reasons listed here will remain in the trial to receive 
appropriate alternative MG treatment see  Appendix 5   
and Appendix 6 .‚Äù Wording adjusted for 
clarification.  
 ‚ÄúPatients who fail to respond to ARGX -113 ...‚Äù  
changed to:  
‚ÄúPatients who show a treatment failure to ARGX -113 
...‚Äù  
SYNOPSIS  
STANDARD of 
CARE (SoC)  
4.1. Summary of Trial 
Design  
STANDARD OF 
CARE (S oC) Addition of the following sentences:  
‚ÄúPermitted SoC for MG treatment under this protocol 
include NSIDs (e.g., azathioprine, methotrexate, 
cyclosporine, tacrolimus, mycophenolate mofetil, and 
cyclophosphamide), s teroids, as well as 
acetylcholinesterase (AChE) inhibitors.‚Äù  Sentences added for extra 
clarification.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 139 ‚ÄúIn case these medications are taken for another 
indication than MG, same  conditions apply.‚Äù  
‚ÄúAdministration of AChE inhibitors must be halted for 
at least 12  hours prior to performing the QMG 
assessment. Following this requirement, this possible 
temporary change in dosing regimen of AChE inhibitors will not be considered as a change in SoC.‚Äù 
SYNOPSIS  
RESCUE THERAPY 
4.1. Summary of Trial 
Design  
RESCUE THERAPY ‚ÄúIf necessary, patients may receive rescue therapy, 
which will be limited to plasma exchange (PLEX), ...‚Äù  
changed to:  
‚ÄúRescue therapy, will be limited to plasma exchange 
(PLEX, ...‚Äù  Wording adjusted to enhance 
clarification.  
 ‚ÄúIn situations where rescue therapy is given, patients 
will be discontinued early from trial treatment.‚Äù  
changed to  
‚ÄúIn situations where the treatments as listed above are 
given under the protocol -defined rescue criteria, 
patients will be discontinued early from trial 
treatment.‚Äù   
SYNOPSIS  
Inclusion Criteria  
4.3.1 Inclusion 
Criteria  Criterion no. 3:  
‚ÄúNote: AChE inhibitors must be held for at least ‚Ä¶ ‚Äù 
changed to  
‚ÄúNote: AChE inhibitors must be halted for at least ‚Ä¶ ‚Äù 
Deletion of the following sentence:  
‚ÄúFollowing this requirement, this possible temporary 
change in dosing regimen of AChE inhibitors will not be considered as a change in SoC.‚Äù
 Administrative  change. 
SYNOPSIS  
Exclusion Criteria 
4.3.2 Exclusion 
Criteria  Criterion no. 5:  
‚ÄúPatients with known autoimmune disease other than 
MG (i.e.,  autoimmune thyroiditis) that ‚Ä¶‚Äù  
changed to  
‚ÄúPatients with known autoimmune disease other than 
MG (for example autoimmune thyroiditis, rheumatoid 
arthritis, ‚Ä¶) that ‚Ä¶‚Äù  Typo/wrong use of ‚Äúi.e.‚Äù was 
corrected, additional example provided.
 
SYNOPSIS  
Exclusion Criteria 
4.3.2 Exclusion 
Criteria  New exclusion criterion added:  
7. ‚ÄúPatients with known medical histo ry of 
hypersensitivity to any of the ingredients of ARGX-
113.‚Äù  Updated in order to align 
with CTP ARGX -113- [ADDRESS_241147] of PMDA.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final 19 Jan 2021
ARGX-113-1705
argenx Confidential 140Table 1 General 
Schedule of 
AssessmentsAssessment ‚ÄúWeight‚Äù
changed to‚ÄúWeig
ht and Height‚ÄùUpdated in order to align 
with ARGX -113- 1705 SAP.
Addition of the following sentence in footnote ‚Äúi‚Äù
‚ÄúHeight will be measured at SEB.‚ÄùAdded for completeness.
‚ÄúdDuring the UNS visit, additional assessments can be 
performed at ‚Ä¶‚Äù
changed to
‚ÄúdDuring the UNS visit, additional assessments as 
indicated in the SoA can be performed at ‚Ä¶‚ÄùAdministrative change.
DEFINITION OF 
TERMSChildbearing potential:
Deletion of the following sentence:
‚ÄúDetermination of FSH levels can be used to confirm 
postmenopausal status in amenorrheic patients not on 
hormonal replacement therapy if the test result is within the postmenopausal range per the central laboratory performed in study ARGX
-113-1704. ‚ÄùCorrection.
4.4.2. Early 
Discontinuation from 
Trial Treatment‚Äú
Patient develops an (S)A E that might jeopardize 
the safety of the patient.‚Äù
changed to:
‚Äú
Patient develops an SAE that is likely to result in a 
life-threatening situation or pose a serious safety risk.‚ÄùChange of wording to clarify 
that there needs to be a 
serious safety risk in order to 
have the patient discontinued.
4.5. Protocol 
Deviations‚ÄúThe Investigator should not implement any deviation 
from, or changes of the protocol without agreement by [CONTACT_202090]/Independent 
Ethics Committee (IRB/IEC), except ‚Ä¶‚Äù
changed to‚ÄúThe Investigator should not implement any deviation 
from, or changes of the protocol without agreement by [CONTACT_202090]/Independent 
Ethics Committee (IRB/IEC) of an amendment from the IRB/IEC and Regulatory Authority as per local regulation, except ...‚ÄùAdministrative change.
4.7. End of Trial 
DefinitionThe following was added:
‚Äú4.7. End of Trial DefinitionEnd of trial is defined as last patient last visit.‚ÄùAdded for completeness (was 
missing in the previous version).
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final 19 Jan 2021
ARGX-113-1705
argenx Confidential 1415.1. Informed Consent 
and Roll -Over Visit‚Äú
Weight‚Äù
changed to
‚Äú
Weight and height‚Äù
6.8. Prior Treatments
and Concomitant 
MedicationsAddition of the following sentence:
‚ÄúVaccines (except for live/live -attenuated vaccines) 
will be allowed during the trial when administered at 
least 48 hours pre -infusion or 48 hours postinfusion of 
IMP.‚ÄùFor patient safety, allowing 
for vaccines to be 
administered according to common clinical practice and to reduce the risk of confusing vaccination
-related 
adverse events (such as fever) 
with IMP -infusion related 
adverse events.
6.8.1. Prohibited 
Medications during the Trial‚ÄúThe following medications or treatments will not be 
permitted as from signing the ICF during the trial:‚Äù
changed to‚ÄúThe following medications or treatments will lead to 
discontinuation from treatment during the trial as from 
SEB onwards:‚ÄùWording updated f or 
clarification.
6.8.1. Prohibited 
Medications during the Trial‚Äúan increase of the dose/frequency of SoC, even if used 
for indications other than MG‚Äù
changed to
‚Äúa change in the type or an increase of the 
dose/frequency of SoC, even  if used for indications 
other than MG‚ÄùClarify that patients are not to 
start treatment with a new SoC
‚ÄúVaccines‚Äù
changed to
‚ÄúLive/live -attenuated vaccines‚ÄùFor patient safety, allowing 
for vaccines to be administered according to common clinical practice and to reduce the 
risk of 
confusing vaccination -related 
adverse events (such as fever) 
with IMP -infusion related 
adverse events.
‚ÄúRescue therapy‚Äù
changed to‚ÄúRescue therapy when used in patients who meet the 
criteria to be rescued‚ÄùWording added for 
clarification.
Additional bullet:
‚Äú
Use of PLEX or immunoadsorption more than 
once during the study period‚Äù
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241148] sentence (‚ÄúIf necessary, patients may receive 
rescue therapy if their gMG deteriorates.‚Äù) deleted.  To align with the 
corresponding section in the Synopsis, Section 4.1, and Section 6.8.1.
 
 ‚ÄúIn situations where rescue therapy is given, patients 
will be discontinued early from trial treatment.‚Äù  
changed to  
‚ÄúIn situations where the treatments as listed above are 
given under the protocol -defined rescue criteria, 
patients will be discontinued early from the trial 
treatment.‚Äù   
6.11. Handling Missed 
Doses of Investigational Medicinal Product ‚ÄúIn case a dose needs to be delayed for more than 5 
days, ‚Ä¶‚Äù  
changed to  
‚ÄúIn case a dose needs to be d elayed for more than 3 
days, ‚Ä¶‚Äù  Correction.  
7.1.2. Quantitative 
Myasthenia Gravis End of section, one but last sentence:  
‚Äú‚Ä¶dynamometer, and is based on physician‚Äôs 
examination.‚Äù  
changed to  
‚Äú‚Ä¶dynamometer, and is based on the trained rater‚Äôs 
examination.‚Äù  Updated because the rater 
needs to be a trained person, 
but not necessarily a physician.
 
[IP_ADDRESS]. Adverse 
Events of Special Interest
 New section added:  
‚ÄúAn AESI (serious or non -serious, related or not 
related) is an event of s cientific and medical concern 
specific to the sponsor‚Äôs product or program.  
ARGX -113 treatment induces reductions in IgG levels, 
and there is a potential risk for infections associated 
with the low IgG levels. As such, any infection will be considered AESI in this trial. Further characterizing 
information will be collected in the eCRF, such as: 
location of infection, relationship to underlying condition, medical history and concomitant medication, reoccurrence of previous infection, previous rescue therapy, any confirmatory procedure, 
culture or urgent medical intervention.‚Äù
 Since the mechanism of 
action of ARGX -[ADDRESS_241149].
 
[IP_ADDRESS]. Follow -up of 
Adverse Events and 
Serious Adverse Events
 Second paragraph:  
‚ÄúEvery effort should be made to follow all AEs ‚Ä¶‚Äù  
changed to  
‚ÄúEvery effort should be made to follow all (S)AEs ‚Ä¶‚Äù  Table deleted and text 
updated to clarify that all 
SAEs are to be followed- up 
until resolution.  
 Sentence referring to Table 3 and Table 3 deleted   
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 143 [IP_ADDRESS].1 Pregnancies 
in Female Patients The following sentence has been added:  
‚ÄúIf required by [CONTACT_427], the female participant 
will be requested to sign a separate pregnancy ICF.‚Äù  Added for completeness.  
7.2.2. Clinical 
Laboratory 
Evaluations  ‚ÄúRefer to Appendix 4  for the addresses of the 
laboratories used for sample analyses.‚Äù  
changed to  
‚ÄúRefer to Appendix 4  for the addresses of the 
laboratories used for sample analyses and storage.‚Äù  Updated in order to align 
with CTP ARGX -113- 1705 
The Netherlands -specific 
version 1.2.  
7.3. 
Pharmacodynamics ‚Äú(PD)‚Äù was added to the section title.  Added for completen ess. 
7.4. Anti -Drug 
Antibodies  ‚Äú(ADA)‚Äù was added to the section title.   
10.2. Ethical Conduct 
of the Trial  The paragraph: ‚ÄúThis trial will be conducted and the 
informed consent will be obtained according to the 
ethical principles stated in the Declaration of Helsinki (2008), the applicable guidelines for GCP, or the applicable drug and data protection laws and regulations of the countries where the trial will be conducted.‚Äù
 
was updated to:  
‚ÄúThis trial will be conducted and the informed consent 
will be obtained according to the ethical principles stated in the Declaration of Helsinki (2013), the applicable guidelines for GCP, or the applicable drug 
and data protection laws and regulations of the 
countries where the trial will be conducted.
 
To comply with the Declaration of Helsinki (2013), 
argenx is assessing the appropriateness and possibility of making the study drug available for clinical study participants post
-trial.‚Äù  Updated in order to align 
with CTP ARGX -113- [ADDRESS_241150] sentence:  
‚ÄúIt is the Investigator‚Äôs responsibility to maintain 
essential trial documents (including regulatory 
documents, eCRFs, si gned patient ICFs, source 
documents, ‚Ä¶‚Äù  
changed to  
‚ÄúIt is the Investigator‚Äôs responsibility to maintain 
essential trial documents (including records and 
documents pertaining to the conduct of this trial and the distribution of IMP, regulatory documents, eCRFs, signed patient ICFs, laboratory test results, IMP 
inventory records, source documents, ‚Ä¶‚Äù
 Updated to avoid duplication 
of information.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241151] paragraph:  
‚ÄúThe Sponsor will notify the Principal Investigator [INVESTIGATOR_202001].‚Äù   
11.1. Data Handling 
and Record Keepi[INVESTIGATOR_202002] ("The [LOCATION_002] (US) Food and 
Drug Administration (FDA) regulations ‚Ä¶ the Principal Investigator [INVESTIGATOR_54070].‚Äù) deleted.
 Updated to avoid duplication 
of information. 
Appendix 3
 Laboratory 
Evaluations  Other:  
‚Äúfollicle -stimulating hormone (FSH) test‚Äù deleted  Correction (FSH test does not 
need to be redone in this trial).
 
Appendix 4
 Administrative Structure
 Clinical Laboratories:  
‚ÄúAsia  
Covance Asia  
Pte Ltd1  International Business Park 
#01-01 The Synergy 
Singapore 609917‚Äù  
deleted  This Covance Lab is not 
involved anymore in the trial 
since Korea is dropped from 
country mix.  
 ‚ÄúAnalysis of Pharmacokinetics -Pharmacodynamics 
(PK-PD), Anti-Drug Antibodies (ADA)‚Äù  
changed to  
‚ÄúAnalysis of Pharmacodynamics (PD), Anti -Drug 
Antibodies (ADA)‚Äù  Correction (PK is not 
performed in this trial).  
 Addition of the following:  
‚ÄúLong -Term Storage of Pharmacodynamics (PD), 
Anti-Drug Antibodies (ADA) 
Brooks Life Science, Biostorage  Technologies GmbH 
Im Leuschnerpark 1b  
[ZIP_CODE] Griesheim  
[LOCATION_013]‚Äù  Updated in order to align 
with CTP ARGX -113- 1705 
The Netherlands -specific 
version 1.2.  
Appendix 5  Decision 
Tree for re -Treatment 
(Part A)  Figure added.  Added for clarification.  
Appendix 6  Decision 
Tree for re -Treatment 
(Part B)  Figure added.   
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 145 APPENDIX 8: Temporary Changes to Study Procedures in ARGX-113-[ADDRESS_241152] patient safety, while still being able to gather additional data.  
The risk/benefit, safety profile, guidance for site conduct in terms of visits and assessments, as 
well as data entry, and potential changes in th e Schedule of Assessments are included below. 
Safety of Efgartigimod: Mechanism of Action , Pharmacodynamics and Risk/Benefit in  
Patient Safety 
Efgartigimod administration results in a targe ted reduction in levels of all IgG subtypes. 
However, and more importantly, it does not impact levels of other immunoglobulin isotypes, 
such as IgA and IgM. Other elements of the immune system are not impacted by [CONTACT_202040]. 
Efgartigimod induces a targeted reduction of Ig G levels, without impacting IgG production. The 
maximum mean reduction in total IgG is approximately 70%; therefore, residual IgG and other 
immunoglobulin levels remain consta nt during treatment. It is therefore anticipated that patients 
can mount an immune response. In support of this, experiments in FcRn knockout animals and in 
animals treated with FcRn antagonist demonstrated that a specific immune response was 
obtained following an antigen trigger, albeit with reduced (antigen-specific) IgG titers. 
Additionally, after ceasing efga rtigimod treatment, IgG recycling returns and total IgG levels 
increase and return to baseline levels within a few weeks. 
Looking at administration in humans, efgartigimod treatment at doses ‚â•10 mg/kg have been 
administered to more than 120 healthy volunteers  and patients with generalized myasthenia 
gravis (gMG), immune thrombocytopenia, and pemphigus in studies carried out prior to phase [ADDRESS_241153] not identified any increased risk of 
infection. 
 
ADAPT/ADAPT+: Pre-existing Safety Measures  and Changes to Be Implemented in the 
Current Situation 
The phase 3 ADAPT study implements multiple layers of safety measures and reporting. 
Efgartigimod is administered in treatment cycles, in which 4-weekly infusions are followed by 
[CONTACT_202091]. Therefore, during the 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241154] (AESI) and is subject to structured safety reporting with standardized questions in the eCRF. 
The current COVID-19 situation warrants new measures to be introduced for patient safety. 
These measures will allow patients to be evaluated remotely if/when quarantine is imposed. For example, any remaining visits in an interrupted Treatment Period, may be performed remotely, in 
cases where the patient is not allowed or cannot physically visit the site. These measures respect 
both patient safety and local guidance, as well as  allowing basic safety data to be collected. 
The assessments identified for telephone assessment visits are highlighted with the use of bold 
italics in the existing Schedu le of Assessments for Part A in Table 1  and for Part B in Table 2. 
Guidance on the execution of these visits and assessments is given below. 
By [CONTACT_1541] a structured back-up plan, we aim to mitigate the risks of the COVID-19 pandemic, 
while still respecting both patient safety and co llection of safety data and remaining compliant 
with GCP. 
 Visits with the possibility of remote assessment by [CONTACT_756]: 
TPxV2, TPE xV2, TP xV3, TPE xV3, TP xV4, TPE xV4, ITP xVx, ITPE xVx, EoA, EoS, ED, and 
UNS. See the Schedule of Assessments for Part A (Table 1) and for Part B ( Table 2 ). 
Treatment Period visits will be replaced by  [CONTACT_202041]-19 situation when the Treatment Period is considered interrupted.   Mandatory physical visits: 
Initiating a new Treatment Period can only be done when the patient is physically on site.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241155] the following COVID-19 
assessments:  
1. Does the patient have symptoms, such as cough, fever, muscle pain, shortness of breath *? 
- If NO: Go to Questions 2 and 3. 
- If YES: 
‚Ä¢ The patient should b e tested for COVID-19:  
The investigator needs to document a positive COVID-[ADDRESS_241156] as an AESI. The anonymized 
result needs to be sent to the sponsor for filing. If COVID-19 safety measures are stopped 
according to local regulations, COVID-19 tests should continue to be performed and the 
results sent to the sponsor. 
*Shortness of breath includes an otherwise une xplained deterioration in the patient‚Äôs MG -
ADL score for breathing. In cases where the MG-ADL score for breathing is [ADDRESS_241157] to be interrupted. A new treatment 
cycle may be initiated later. Remaining visits in the Treatment Period can be performed 
as telephone assessment visits.  
‚Ä¢ If the patient is tested and found to be COVID -19 negative:  
The patient can come to the next visit as sche duled. Follow-up of the patient should be done 
according to the protocol (decision to be take n if treatment can be given or is to be 
postponed). 
‚Ä¢ If the patient is tested and found to be COVID -19 positive:  
The patient can only come to the site once he/she has a negative test for COVID-19, and so 
the planned visit may need to be rescheduled or replaced by a telephone assessment visit. If the patient was in a treatment cycle, the treatment will have to be interrupted. A new 
treatment cycle may be initiated later. The remaining visits in th e Treatment Period can be 
replaced by [CONTACT_202042].  
 
2. The patient has no Corona-like symptoms and is not aware of any contact [CONTACT_202046]/she may have had 
with someone who tested positive for COVID-19:  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 148 ‚Ä¢ The visit can proceed as planned. If the patient cannot physically come to the clinic due to the 
local COVID-[ADDRESS_241158] with someone who tested 
positive for Corona virus: 
‚Ä¢ If the contact [INVESTIGATOR_30647] 14 days or longer before the study visit => the visit can go ahead as planned. 
If the patient cannot physically come to the clinic due to the local COVID-19 situation, the visit can be replaced by a telephone assessment visit. 
‚Ä¢ If the contact [CONTACT_202043] 14 days before the study visit => the visit needs to be rescheduled at 
least [ADDRESS_241159] occurred or be replaced by a telephone assessment visit. 
 
How to: Information related to study procedures and data collection 
The assessments deemed suitable for telephone consultation are: 
x Re-consenting where warranted, MG-ADL, Adverse Event and Concomitant 
Medication questioning.  
Since QMG needs quantification by [CONTACT_202044] n, using specific equipment, such as a 
dynamometer and spi[INVESTIGATOR_14007], this assessment is not deemed suitable for telephone assessment.  
Telephone consultation will allow safety data to be  collected and to check on the patient‚Äôs well -
being, while the derived MG-ADL score may give an indication of the need for another treatment 
with efgartigimod. 
Re-consenting with the updated ICF, or cons ent to Part B of the ADAPT+ study can be done 
remotely in view of the COVID-19 situation.  
Options for consent might entail: 
x physical signature [CONTACT_3265] [CONTACT_202045] a phone call 
with the patient, then having the signed document sent back to the site. 
x phone call with the patient, asking for email confirmation to corroborate verbal consent. 
x organize a conference call or video call tog ether with the patient and impartial 
witness, where needed. 
x if no phone call or video call is possible, email documented consent. 
Depending on regional requirements the options can be limited, after consultation with the relevant IRB/IEC and/or regulatory authority. 
Data collected during a telephone assessment visit can be entered into the e-CRF pages of the 
corresponding ‚Äúmissed‚Äù visit. Enter the date of th e phone call as the ‚Äúdate of visit‚Äù and enter the 
data obtained in the applicable CRF pages. For th e assessments that are not performed, answer 
‚Äúno‚Äù to the question if the assessment was made in the respective forms. Add ‚ÄúCOVID -19 
telephone‚Äù in the comment section of the CRF.  
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  [ADDRESS_241160] the patient, inactiva te the full study visit in the CRF and confirm the 
missing visit in the comm ents section as ‚ÄúCOVID -19.‚Äù 
Other than conducting telephone assessments, there may be other changes in the current practice 
on site. Halting spi[INVESTIGATOR_201991]-19 patients may be required, or only allowing use of a 
dedicated spi[INVESTIGATOR_201992] (for contamination reasons).  There can be a temporary halt in performing this assessment, or conducting a partial assessment is also permitted. 
In order to give a clear overview of protocol deviations related to the specific COVID-[ADDRESS_241161] been created to which any missed visit or assessment can be attributed.  
 
APPENDIX 9: Contraceptive and Barrier Guidance 
Definitions 
Woman of childbearing potential 
A woman is considered to be of childbearing potential unless she is either:  
a. Postmenopausal: A postmenopausal state is defined by [CONTACT_202092] 1 year without an alternative medical cause with a follicle-
stimulating hormone (FSH) measurement of >40 IU/L. A historical pretreatment FSH measurement of >40 IU/L is accepted as proof of a postmenopausal state for women on hormone replacement therapy 
b. Surgically sterilized: Women who have had a documented permanent 
sterilization procedure (ie, hysterectomy , bilateral salpi[INVESTIGATOR_1656], or bilateral 
oophorectomy) 
Contraception Guidance 
Female Contraception for Women of Childbearing Potential 
Women of childbearing potential must use a highly effective or acceptable method of 
contraception which should be maintained at minimum until [ADDRESS_241162] dose of IMP. 
The following methods are considered highly effective methods of contraception: 
1. Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation 
 Oral 
 Intravaginal 
 Transdermal 
2. Progestogen-only hormonal contraception associated with inhibition of ovulation 
 Oral 
 Injectable 
 Implantable 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)
Clinical Trial Protocol Version 4.0, Final  19 Jan 2021 
ARGX-113-1705 
 
argenx Confidential 150 3. Intrauterine device (IUD) 
4. Intrauterine hormone-releasing system (IUS) 
5. Bilateral tubal occlusion 
6. Vasectomized partner 
7. Sexual abstinence 
The following methods are considered acceptable methods of contraception: 
1. Progestogen-only oral hormonal contraception in which inhibition of ovulation is 
not the primary mode of action 
a. Oral 
b. Injectable 
c. Implantable 
2. Male or female condom with or without spermicide 
3. Cap, diaphragm, or sponge with spermicide 
Male Contraception 
An acceptable method of contraception is a condom. 
 
6\VWHP 9HUVLRQ  6WDWXV $SSURYHG 'RFXPHQW ,' 9970)